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ABStRAct
Multiple sclerosis is a disabling inflammatory and neurodegenerative disorder that 
predominantly affects young adults. There is a great need for biomarkers, which could 
elucidate pathology as well as provide prognosis of disease progression and therapy 
response in Multiple sclerosis. Rapidly evolving, technology driven applications such as 
mass spectrometry based proteomics are currently being developed for this purpose. 
In this review, we will outline the current status of the field and detail a number of the 
bottlenecks as well as future prospects of this type of biomarker research.
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1. IntROdUctIOn
Multiple sclerosis is an inflammatory and neurodegenerative disease of the central 
nervous system (CNS), with a complex and incompletely understood aetiology. The 
disease appears to evolve/occur in individuals that are genetically susceptible to the 
disease, but only those who are exposed to certain unknown environmental triggers 
develop the disease. It is believed that the disease process has an early phase with 
increased migration of auto-reactive lymphocytes across the blood-brain barrier (BBB) 
into the CNS (1). One of the major adverse effects that can be observed in multiple 
sclerosis patients is damage to the myelin sheath that enwraps axons, and is physi-
ologically needed to increase the speed of signal transmission. This process culminates 
in the hallmark of the disease; the formation of the sclerotic lesions from which the 
disease gets its name. Other cells affected besides the myelin-forming oligodendro-
cytes are neurons with their axons. One of the main issues in multiple sclerosis is the 
heterogeneity of the disease, as observed by the different patterns of plaque formation 
in patients (2) and the variability of clinical symptoms in patients. The majority of pa-
tients (80-85%) have the relapsing remitting subtype of the disease, in which relapses 
are followed by periods of remission. Around two thirds of these patients eventually 
enter a secondary, progressive phase of the disease. In 10-20% of multiple sclerosis 
patients the disease is progressive from onset (3).
In recent years new techniques have become available for analysis of biological 
samples in search of potential biomarkers for diseases such as cancer, Alzheimer’s 
disease and also multiple sclerosis. These biomarkers can be useful in a number of 
different ways, like for example prognosis, monitoring of disease progression and early 
detection of diseases, which is of specific importance in multiple sclerosis as early 
detection and subsequent early treatment retards disease development (4). Additional 
purposes include detection of new possible therapy targets, monitoring of response 
to certain therapies as well as increasing our understanding of disease pathology (5). 
In this review we will discuss available mass spectrometry-based proteomics tech-
nologies, sample selection considerations and future prospects for multiple sclerosis 
research.
2. BIOlOgIcAl SAMPlES
2.1. Blood
Blood is a promising body fluid for biomarker discovery because of its easy collection 
and the presence of brain specific proteins and peptides produced in the CNS. These 
may reflect pathological changes occurring within the brain and spinal cord (6). In blood 
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TNF-α and CCL2 have been suggested to be indicators of inflammatory responses in 
primary progressive multiple sclerosis (7), whereas kallikreins has been linked to the 
secondary progressive stage of multiple sclerosis (8). Blood is a rich source of disease 
related proteins due to its large dynamic range (> 1015) (9). Since it is located distantly 
from CNS, the detection of disease related proteins may be complicated by dilution 
and fast clearance of proteins by the liver and kidneys. Additionally metabolic changes 
may occur and there is also the possibility that highly abundant proteins like albumin 
in blood may mask detection of low abundant proteins, therefore making detection 
difficult (10, 11). In addition, proteases may be effective during the travel from the CNS 
to the blood stream that may truncate proteins of interest and even more make the 
exercise to find reliable and clinical relevant markers a challenge.
2.2. Urine
Urine is another interesting body fluid that attracts attention because of its non-invasive 
collection method. Past studies have reported neopterin and nitric oxide metabolites 
as marker of disease activity in multiple sclerosis (12). The possibility of detecting 
interesting protein biomarkers in urine is limited by metabolic variations observed in 
urine, relatively low protein content overwhelmed by a few high abundant proteins 
(for example albumin and tamm-horsefall protein (13)), high salt concentration and 
presence of relatively high levels of low molecular proteins. Based on these difficul-
ties Thongboonkerd and co-workers concluded that urine may not the best choice 
especially for proteomics based biomarker research for CNS disorders (14). However 
the proteolytic cleavage into low molecular weight products can also be related to 
protease activity that could be partly disease specific (15).
2.3. cerebrospinal fluid
While blood and urine are easily obtainable, the key endorsement of cerebrospinal 
fluid (CSF) as a body fluid for biomarker detection of CNS disorders is its direct connec-
tion and close proximity to the CNS. However, its collection is obviously more invasive 
and elaborate than the collection of blood.
As a consequence of fluid transports in the CNS, most of CNS-disease related pro-
teins are likely to diffuse into the CSF. Therefore CSF is able to reflect directly the on-
going pathological conditions in the brain (16). This fluid is partly produced in choroid 
plexus of the brain at a rate of 500 ml/day and very rich in brain specific proteins. 
Normally, the concentration of protein in CSF (0.2-0.5g/l) is far lower than in serum 
(60-80g/l) (17), mainly because of the vastly lower concentrations of highly abundant 
blood proteins that could mask detection of low abundant proteins by sophisticated 
techniques. Together this makes CSF an interesting body fluid for biomarker research 
for CNS disorders.
15
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2.4. cnS tissue
Post-mortem brain tissue, and in particular brain lesions, allow for the possibility to 
detect changes caused by the pathology of multiple sclerosis at possible sites of the 
disease activity. These lesions are a combination of demyelination and inflammation 
occurring in different parts of CNS. Histological patterns of active demyelinating 
lesions vary from patient to patient (18). Lesion tissue obtained post-mortem from 
multiple sclerosis patients has been shown to have differences in RNA expression 
compared to normal appearing white matter (19). Consequently, if differences exist on 
a transcriptomics level, then effector molecules like proteins and metabolites might 
also be differentially abundant at the site of disease activity. Active multiple sclerosis 
lesions could be of great interest to approach disease in a targeted manner using an 
efficient technique called laser capture microdissection. This technique does not alter 
or damage the morphology and chemistry of the tissue and the surrounding cells. Using 
this type of method Han et al. have reported increased protein C inhibitor protein and 
tissue factors in chronic active multiple sclerosis lesions (20). Availability of this kind of 
material is limited, so it is difficult to obtain sufficient numbers of samples to perform 
meaningful statistics on detected biomarkers. Therefore biobanking of brain tissue ma-
terial is, along a good description of the obtained material, essential. The Netherlands 
Brain Bank (www.nin.knaw.nl) is a nice example of brain tissue banking. Additionally, 
tissue is an interesting biological option for validation of biomarkers detected in other 
types of biological samples (Figure 1).
Figure 1. Staining of brain tissue for the protein clusterin. In several studies on CSF, clusterin has 
been shown to be elevated in multiple sclerosis patients. Histochemical staining of human normal 
white matter brain sections for clusterin of active (a) and inactive (b) lesions shows an increased 
abundance of clusterin in active lesions, validating the implication of clusterin in the disease (Pic-
ture taken from the dissertation of Marcel Stoop, “Cerebrospinal Fluid Proteomics of Multiple Scle-
rosis Patients”).
2.5. Animal models
Animal models may be a good alternative and a more experimentally accessible road 
to investigate tissue for multiple sclerosis. However, the translation of results observed 
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in the animal model to the human situation can be quite difficult. Experimental auto-
immune encephalomyelitis (EAE) mimics the CNS inflammation observed in multiple 
sclerosis to a certain extent. EAE can be induced in a number of different animals, 
such as marmoset monkeys and rodents. Rodent EAE is a well-studied model which 
has helped scientists to understand underlying biology of CNS inflammation, and 
has shown the importance in testing of therapeutic approaches to multiple sclerosis 
immunology and pathology in animal models (21). However, therapeutic success and 
detection of biomarkers in EAE cannot be directly translated to humans because of the 
phylogenetic distance between rodents and humans. In contrast, a non-human primate 
EAE model such as the marmoset monkey, which is phylogenetically closer to humans, 
has more similarities at molecular and functional level with our nervous system and 
immune response (22, 23), and could potentially be more efficient and beneficial in 
pre-clinical trials and investigation (24).
3. PRE-AnAlytIcAl FActORS
The proteome can be affected by several pre-analytical factors prior to measurement, 
resulting in inaccuracies in the data. These factors include sample collection and sample 
storage. Sample collection according to a strict, standardized protocol is essential for 
preventing unnatural variation in the proteome of the samples (25). Adherence to such 
a protocol would make future proteomics studies and the exchange of samples be-
tween laboratories, for potential biomarker validation studies, easier. The importance 
of sample storage conditions for biomarker research for multiple sclerosis is perhaps 
best illustrated by the identification of an N-terminal cleavage product of cystatin C in 
CSF of multiple sclerosis patients by Surface-Enhanced Laser Desorption/Ionization 
(SELDI) mass spectrometry as a potential biomarker (26), which was later shown to be 
an artefact caused by sample storage at −20°C instead of −80°C (27). This example 
illustrates both the necessity of storing both case and control samples under the same 
conditions as well as the limits of −20°C storage of biological samples. Additional is-
sues arise when the samples are subjected to multiple freeze/thaw cycles or are not 
centrifuged correctly (28), so essentially biological samples should be aliquoted and 
centrifuged before storage and all samples should be stored at −80°C.
Another factor that should be controlled rigorously when performing CSF pro-
teomics experiments is blood contamination. Protein concentrations in blood are 
400-600 fold higher in blood than in CSF, so any contamination of CSF samples by 
blood, due to traumatic CSF tap, will invariably skew the protein abundances in CSF 
tremendously, leading to erroneous measurements (29). Essentially, any CSF sample 
in which blood-specific proteins such as haemoglobin or apolipoprotein B-100 can be 
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identified by mass spectrometry should be excluded from CSF proteomics studies (30). 
Individual sample selection is also a topic that should be considered carefully before 
commencing a proteomics experiment. Although overall proteome differences due to 
gender and age do not appear to be extensive, several proteins are exceptions to this 
observation. Thus, these proteins should be evaluated with great care, in the context of 
age and gender of the selected samples, if these prove to be significantly differentially 
abundant between case and control groups (31).
4. “OMIcS” StRAtEgIES
The complexity that surrounds the aetiology and pathology of multiple sclerosis sug-
gests that effects of disease processes will not just be present at a single biological 
level. Indeed, even a genetic component, potentially precluding biological effects, as 
evidenced in genetic isolates, has been shown to be present in multiple sclerosis (32). 
Thus, all “omics” disciplines (genomics, proteomics, metabolomics and all variants 
thereof) are of potential interest in multiple sclerosis research. Specific genetic varia-
tions influence susceptibility for the disease (33) but environmental factors are also of 
great influence in multiple sclerosis disease evolution (34). Transcriptomics, located 
one step downstream from genomics, uses microarrays to analyze RNA expression 
profiles to provide valuable insights on mechanisms of damage, repair and regenera-
tion (35). With these techniques post-mortem brain tissue can be compared on RNA 
expression levels to detect gene expression differences between acute, chronic active 
and chronic inactive lesions (36). Even closer to the active disease processes than DNA 
and RNA are proteins and metabolites. These molecules are probably more directly 
involved in the acute pathological issues in multiple sclerosis and therefore interesting 
as biomarkers. Metabolomics biomarker studies are, to date, limited in number, due to 
technical difficulties regarding metabolite stability, metabolite identification and the 
potential introduction of sample variation due to collection and preparation (37). Pro-
teomics, the study of the function as well as the primary structure of proteins, allows 
for the large scale study of protein profiles in complex biological samples, typically in 
an unbiased fashion (38). Currently, it is anticipated that a future merger of proteomics 
with cell biology will yield a better understanding of regulation of cellular processes, 
both in healthy and diseased states (39).
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5. PROtEOMIcS-BASEd BIOMARkER RESEARcH
Mass spectrometry (MS) is the core technique in proteomics. Hence, the evolution of 
mass spectrometry techniques towards high resolution and more high through-put 
machinery has been essential for the advancement of the field. Current MS instru-
ments such as Fourier transform ion cyclotron resonance, Orbitrap and quadrupole 
time-of-flight mass spectrometers have greatly enhanced the quality of proteomics 
data. Flexibility on either side of the mass spectrometer, in the form of different modes 
for ionization, sample separation and data analysis, enables the adaptation of differ-
Sample collecon /storage
Sample preparaon
Measurement
Stascs
Biological evaluaon
Validaon
Clinical tesng
-Biobanking
-Uniform treatment
-Targeted vs. untargeted approach
-Reproducibility
-Accuracy (high resoluon MS)
-Sensivity (chromatography advances)
-Power (sufficient number of samples)
-Stringent candidate selecon criteria
-Biological relevance
-Bioinformacs pathway analysis
-SRM
-Immunoassay
Figure 2. Flow chart for an extended proteomics experiment. The process starts with the collec-
tion of well annotated samples and continues on through the bioinformatics stage. Validation of 
biomarkers and the relation of biomarkers to biological and pathological relevance are especially 
important as these factors determine the value of the reported biomarker. For all stages of the ex-
periment some key considerations are highlighted. The last stage, clinical testing, is often problem-
atic, as it is difficult to trans- late biomarkers to clinical practice.
Definition: Selected reaction monitoring (SRM) is defined as a targeted MS technique for the detec-
tion and accurate quantification of a predetermined set of proteins in a complex background. In a 
SRM-MS assay, one or two signature proteotypic peptides which are unique to the protein of interest 
are selected to represent the protein. Proteotypic peptides are the peptides that uniquely identify 
each protein and are consistently observed when a sample mixture is examined by a (tandem) mass 
spectrometer. In an SRM experiment, a predefined precursor ion and one of its fragments are se-
lected by the two mass filters of a triple quadrupole mass spectrometer and monitored over time for 
precise quantification. This is an instrument which has a capability to selectively isolate precursor 
ions corresponding to the m/z of the signature peptides and to selectively monitor peptide-specific 
fragment ions. SRM assays do not require the generation of high affinity antibodies, and yet have 
lower limit of detection to pg/ml protein concentrations.
19
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ent experimental designs based on the mass spectrometry core of the analysis. After 
sample selection a typical proteomics experiment consists of four distinct stages: 
sample pre-treatment, protein or peptide separation, protein of peptide identification, 
and a bioinformatics-supported data analysis stage (Figure 2).
5.1. Sample pre-treatment
Sample pre-treatment and the separation of peptides or proteins in a sample are 
interchangeable components of a proteomics experiment. In some approaches one 
precedes the other while in other strategies it is the other way around. Decisions on 
sample preparation include the choice to either digest the proteins enzymatically or 
not to digest and whether to analyze the naturally occurring peptides and proteins. 
Whereas both approaches have merits, the majority of approaches contain an enzy-
matic digestion of proteins, typically by trypsin.
A second available choice is the option to utilize stable isotope labels to quantify 
differences or to pursue label-free approaches. Potential tags that can be included 
to quantify differences between cases and controls are isobaric tags for relative abun-
dance and quantitation (ITRAQ), isotope coded affinity tags (ICAT) and 18O labelling. 
Using these techniques quantification of peptides can be achieved based on the in-
tensity ratio of heavy and light forms of the labelled peptides. Label-free quantitation 
either employs spectral counts or peak areas for quantitative measures. Whereas the 
stable isotope labels complicate the sample pre-treatment procedures, they do not 
necessarily result in better quantitative data (40).
5.2. Protein or peptide separation
Protein or peptide separation is not always essential when performing proteomics 
experiments on biological samples. Studies without separation strategies have yielded 
a number of potential CSF markers for differences between multiple sclerosis and 
controls (41) as well as significant differential protein abundances between different 
multiple sclerosis disease types (42). However, given the complexity of biological 
samples, fractionation of the contents does allow for a more in-depth analysis of the 
proteome. Proteins in a sample can be separated by a number of different methods, 
such as 2-dimensional gel electrophoresis (2-DGE), liquid chromatography (LC) or “pro-
tein chips” (43). 2-DGE separates proteins according to charge and size in two discrete 
steps, but this technique is limited due to the relatively high labour intensity of the 
technique and troubled by co-migration issues. The online application of nanoscale 
LC techniques offers an increased potential to detect low abundant proteins, but like 
2-DGE this technology is also relatively time consuming (44). Additionally, quantita-
tive analysis using online coupled LC and MS is less straightforward as 2-DGE, but the 
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reproducibility and the ease of comparing relatively large numbers of samples is more 
developed in LC based techniques.
Protein chip arrays, used in combination with SELDI mass spectrometry, fractionate 
and enrich subpopulations of proteins from complex mixtures on the chip surface. 
Although SELDI has been applied to the analysis of potential biomarkers, there remain 
reproducibility, sensitivity, and protein sequencing concerns regarding this technique 
(30).
5.3. Protein identification
One of the key elements in proteomics is protein identification. This is typically done by 
one of two methods: database searching and de novo sequencing. Database searching 
employs algorithms to match the experimental fragmentation spectra to known amino 
acid sequences in a database, which subsequently gives a score related to a statistical 
probability of a correct identification. De novo sequencing, i.e. sequencing without the 
assistance of a linear database aims to identify peptides which are not present in a 
database (45). By using the experimental tandem mass spectrometry data a sequence 
can be proposed by using the information of fragments of the peptides observed. A 
combination of database searching and de novo sequencing is a powerful method to 
increase the number of identified peptides in a proteomics setting (46), which is one of 
the key goals to proteomics in the near future as, currently, many potentially biologi-
cally interesting peptide peaks in this type of research remain unidentified.
5.4. Bioinformatics-supported data analysis
Data analysis has long been one of the bottlenecks of proteomics research (47). Only 
very recently software applications that allow for the analysis of large numbers of 
complex liquid chromatography mass spectrometry (LC-MS) runs have become avail-
able. These advances will allow for more in-depth analysis of biological samples due 
to the separation of the components of the sample which will allow for detection, and 
comparison between sample groups, of lower abundant proteins (48).
6. REcEnt MUltIPlE SclEROSIS cSF PROtEOMIcS dEVElOPMEntS
Besides proteomics analysis of CSF peptides (49) and proteins (50-59) that differenti-
ate between multiple sclerosis patients and controls, recently some other potential 
biomarker avenues have been explored. One of the key events in multiple sclerosis 
disease development is the patients’ conversion from a clinically isolated syndrome 
of demyelination to clinically definite multiple sclerosis. Two recent studies have 
analyzed CSF samples with proteomics techniques to investigate this conversion and 
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identified a number of proteins, like for example chitinase 3-like protein 1 and fetuin-
A, whose abundances were altered in patients that converted to clinically definite 
multiple sclerosis (60, 61). These findings could be very intriguing stepping stones 
in the investigations of multiple sclerosis disease evolution. Secondly, another recent 
study has reported on the effects of Natalizumab treatment in a cohort of multiple 
sclerosis patients. A small number of proteins were found to be decreased after six 
months of treatment, but after twelve months of treatment this effect could no longer 
be observed (62). Finally, an interesting approach was taken by Obermeier et al., who 
matched transcriptome immunoglobulin data to CSF immunoglobulin proteome data 
to identify specific immunoglobulin sequences relating to multiple sclerosis pathology, 
which could, due to the known involvement of immunoglobulins in inflammatory dis-
orders, be a very promising avenue for biomarker research for multiple sclerosis (63).
7. BOttlEnEckS
Although the proteomics field is rapidly developing and new advances in technology 
and analysis software are reported in quick succession, several bottlenecks for the ap-
plication of proteomics to clinical applications remain. Until recently one of the major 
bottlenecks was the lack of advanced analysis software options for large datasets of 
LC-MS experiments. Especially retention time alignment has long remained a difficult 
issue, as retention times can vary between runs. For meaningful comparison between 
the samples these small differences in retention time need to be corrected, and this is 
typically done by advanced software options, which have become available in recent 
years (64). However, this was not the only bottleneck for proteomics applications in 
biomarker research. Additional, still remaining, issues are the techniques’ bias towards 
high abundant proteins, the lack of validation of found biomarkers, the perception of 
limited reproducibility of mass spectrometry-based proteomics research and the lack 
of clear, well-defined bioinformatics analysis options to relate the mass spectrometry 
data to the underlying biology. The proteomics field is rapidly developing and new 
advances in technology and analysis software are reported in quick succession, several 
bottlenecks for the application of proteomics to clinical applications remain. Until re-
cently one of the major bottlenecks was the lack of advanced analysis software options 
for large datasets of LC-MS experiments. Especially retention time alignment has long 
remained a difficult issue, as retention times can vary between runs. For meaningful 
comparison between the samples these small differences in retention time need to be 
corrected, and this is typically done by advanced software options, which have become 
available in recent years. However, this was not the only bottleneck for proteomics ap-
plications in biomarker research. Additional, still remaining, issues are the techniques’ 
Chapter 1/1.1
22
bias towards high abundant proteins, the lack of validation of found biomarkers, the 
perception of limited reproducibility of mass spectrometry-based proteomics research 
and the lack of clear, well-defined bioinformatics analysis options to relate the mass 
spectrometry data to the underlying biology.
7.1. Protein enrichment or depletion
The large dynamic range of proteins in biological samples is one of the major obstacles 
in clinical proteomics. As high throughput sample fractionation techniques are limited 
in capacity, additional steps are often required to detect and quantify the lower abun-
dant proteins (65). Two main options exist to enable the detection of these proteins; 
depletion of high abundant proteins and specific enrichment of a group of target 
proteins.
Depletion of high abundant proteins increases the dynamic range of the measure-
ment for the remaining proteins (66). Commercial products have been developed 
for depletion of up to 20 high abundant proteins from biological samples with high 
reproducibility. However, one of the main problems with depletion techniques is the 
specificity of the depletion procedure. Several high abundant proteins, like albumin for 
example, are transport proteins to which many other proteins can attach. By removing 
albumin from the complex mixture, the proteins that albumin binds to, are co-depleted, 
which affects the remaining, depleted sample with regards to its content (67). So, while 
the removal of the high abundant proteins is reproducible, the side effects of this 
procedure may be quite variable.
One of the alternatives to protein depletion is targeted enrichment, which is a 
straightforward fractionation strategy for the detection of low abundant proteins 
(68). Using targeted enrichment strategies specific sub-proteomes can be isolated 
from complex samples which greatly enhances the capacity for the detection of low 
abundant proteins. Affinity to azide resins and immobilized metal ions can be ex-
ploited to enrich for post translational modifications, such as glycosylation (69) and 
phosphorylation (70), respectively. Post translational modifications are known to play 
a major role in pathophysiological processes, and consequently specific enrichment of 
these modifications is of significant interest for elucidation of disease pathology. There 
are a large number of affinity capture approaches, as any epitope or functional group 
one can raise an antibody to, or can design a chemical coupling to, like active sites of 
enzymes, can be captured (71).
Due to the influential inflammatory component of multiple sclerosis affinity enrich-
ment of immunoglobulins would be an interesting avenue to explore. In lung carcinoma 
it has recently been shown that patients have different amino acid sequences in the 
complementarity determining regions of IgG compared to controls (46). This would 
be of considerable interest for multiple sclerosis, because immunoglobulins have 
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been widely reported to be involved, and multiple sclerosis-specific complementarity 
determining regions could be very intriguing biomarkers. However, all these targeted 
enrichment strategies are limited by their lack of high throughput and by the fact that 
researchers need to already have defined a target proteome before analysis commences 
and consequently can only study a part of the total proteome in a given experiment.
7.2. Biomarker validation
One of the key components of a biomarker study is the validation phase. Unfortu-
nately this part of the biomarker pipeline has also long been one of the bottlenecks 
of biomarker research (72). Immunoassays and antibodies allow for analysis of small 
numbers of proteins, but the lack of commercially available reagents, combined with 
high costs, lengthy production and purification times, have rendered the large majority 
of biomarker candidates untestable. MS-based quantification methods, SRM (Figure 3) 
in particular, are interesting alternatives to immunoassays due to their independence 
on antibodies and the possibility of rapid and cost-efficient development (73, 74). This 
targeted MS technique is not burdened by Bonferroni correction requiring multiple 
testing issues, which are potentially problematic in other MS methods. Additionally, 
in contrast to immunoassays, SRM techniques offer good multiplexing capabilities, 
enabling researchers to simultaneously quantify numerous peptides in parallel. SRM 
quantification uses stable isotope labelled peptides as internal standards, which must 
be synthesized for all candidate markers to ensure the best possible results. One pos-
Figure 3. Schematic of a SRM measurement. In SRM measurements complex (digested) biological 
samples can be quantitatively measured by using the quadrupoles (Q1, Q2 and Q3). In the first 
quadrupole the target (the parent mass) is selected. Only molecules of that mass are allowed to en-
ter the second quadrupole, in which this molecule is fragmented in specific parts. Then in the third 
quadrupole one of the fragments is selected, and only this fragment is permitted to reach the detec-
tor where it is measured. The sensitivity of the measurements can be increased by fractionation of 
the biological samples before entry into the first quadrupole, for example by liquid chromatography 
gradient. By programming the machinery for multiple parent masses, these SRM measurements can 
be multiplexed and a relatively large number of targets can be quantified in a single experiment, 
provided that for all targets an internal standard is present in the sample. For accurate quantitative 
measurements multiple transition states (multiple fragment masses) are preferred, as this increases 
the accuracy of the measurements significantly.
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sible drawback of SRM for peptide quantification is the limited concentration range 
in which reliable quantification in complex, unfractionated biological samples can be 
performed. Sample fractionation, followed by SRM quantification is possible with low 
CV’s in biological samples, but this substantially decreases the high sample through-
put, which is one of the main strengths of SRM protein quantification (75). However, 
the high reproducibility across laboratories and instrument platforms as reported by 
Addona et al. is a very strong selling point for SRM protein quantification (76) that 
should foster greater acceptance by the clinical community of this type of technology 
for validation of candidate biomarkers. And while it seems unlikely that immunoassays 
will be replaced by MS-based protein quantification in the near future, even though 
both methods are similar with regards to sensitivity, SRM-based approaches, coupled 
with expected developments in MS instrumentation with regards to specificity and 
detection limits, might facilitate the alleviation of one of the big existing bottlenecks 
in biomarker studies.
7.3. Reproducibility
To understand accurate protein dynamics, a highly reproducible proteomics analytical 
method is required (77). As proteomics studies often include extensive sample pre-
treatment procedures, this required reproducibility is not merely limited to the mass 
spectrometry method but extends to every single part of the process from sample col-
lection to data analysis. Currently published proteomics biomarker studies for multiple 
sclerosis show only limited overlap between them, but this is not necessarily due to a 
lack of reproducibility, but rather due to differences in approach and clinical starting 
material. Different sample pre-treatment methods and different mass spectrometry 
tools are of great influence to the end results in these types of studies, which must be 
accounted for when assessing these data. The fact that different mass spectrometry 
techniques have confirmed protein differences of patients compared to controls on 
multiple occasions is quite promising and to be expected based on the current assess-
ment of proteomics reproducibility in the scientific community (78-80). In fact, the 
sample pre-treatment and clinical parameters of the sample appear to be of greater 
influence on reproducibility than the mass spectrometry methods. Therefore, it appears 
that two factors are essential for enhanced reproducibility of biomarker studies. The 
first is adherence of researchers to a consensus on sampling, storage and biobanking 
of biological samples (25), as this would limit variations in samples and reproducibility 
issues prior to commencement of the proteomics study. This would also allow easier 
exchange of samples between institutes to increase sample sizes in proteomics stud-
ies, which would allow for more advanced statistical analysis, and consequently better 
defined results. Secondly, a standard has recently been proposed for reporting on pro-
teomics studies (81). Reporting proteomics studies according to the recommendations 
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proposed by Mischak et al. would increase the quality standards and scientific validity 
of these reports and could power significant progress in clinical medicine.
7.4. Bioinformatics
Processing and management of acquired mass spectrometry data is one of the major 
bottlenecks in proteomics studies. Due to the fact that data is generated in large quan-
tities, extraction of the meaningful knowledge from the results presents especially 
large challenges (82). After resolving one of the major bottlenecks in the application of 
biocomputing to proteomics data by development of a standardized universal output 
format for mass spectrometry data (83), two major issues remain. The first issue is the 
use of a large number of different databases, which includes publicly available well 
maintained libraries as well as home-made derivates consisting of sub-populations 
of these libraries, for peptide and protein identification by proteomics researchers. 
Although the plethora of available databases perhaps increases the chance of iden-
tification of peptides from MS/MS spectra, chances of reproduction of the results by 
other laboratories are decreased and results become complex and confusing due to 
the lack of insight in the contents of these databases. A major step forward in this area 
would be the systematic use of an up-to-date, well maintained database accessible by 
all researchers and laboratories. The second, more complex issue is the development 
of standard approaches to discern relevant biological networks and pathways from 
proteomics data. This is an essential step for the application of proteomics techniques 
on biological issues and should be given high priority, as these developments are still 
lagging behind.
8. FUtURE PERSPEctIVES
Mass spectrometry-based proteomics is a research field that has depended largely on 
developments in instrumentation during its recent period of rapid growth. Only very 
recently developments in analysis software, sample pre-treatment applications and 
biological sample availability have begun to catch up. The increasing interest of life 
sciences in proteomics still stands to gain significantly from improving those specific 
areas further.
Aberrant cleavage of proteins combined with the biological activity of many pep-
tides in body fluids in normal and diseased states, makes analysis of endogenous 
peptides and small molecules an interesting alternative to trypsin-digested proteome. 
Analysis of endogenous peptides, a research field labelled peptidomics (84), could be 
an interesting addition to tryptically digested proteins for detection of biomarkers, 
which has already been shown to be applicable to multiple sclerosis CSF studies (49).
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Proteomics is only one of the “omics” disciplines, and while it is a key part of Sys-
tems Biology due the effector role that proteins play in biological processes and the 
fact that proteins are very rich in information, the other “omics” are also of great value 
for biomarker studies. Integration of data from multiple disciplines, like for example 
fusion of metabolomics and proteomics data as shown by Blanchet et al. in an EAE 
model for multiple sclerosis (85), is a new approach to combine a larger part of Systems 
Biology in a single analysis. Additionally, mRNA expression profiles and protein expres-
sion profiles contribute to a more refined description of biological systems due to the 
fact that they appear to be largely complementary (86). So combining the different 
“omics” fields in experiments from the same biological system would seem to increase 
our understanding of complex biological processes.
Adherence to the recommendations and protocols for sampling, sample storage and 
reporting on proteomics biomarker studies (25, 81) should also be very beneficial for 
the advancement of proteomics in clinical settings. The standardized sampling and 
storage will allow for collaboration between research groups without variation in the 
results due to differences in sample handling prior to the mass spectrometry measure-
ments. The main advantage here will be the possibility to create larger sample sets 
which would allow for more advanced analysis and consequently more reliable results. 
Additionally the reporting standards for proteomics studies will be greatly beneficial 
for the reproducibility of the results and the ability of outsiders to compare between 
proteomics studies. In particular the characterization of the samples, which would 
also allow for better matching between cases and controls (87), and the details on the 
bioinformatics analysis are of great import in this area (82).
Finally, the introduction of new instrumentation and instrument application remains 
a strong force in the advancement of proteomics for biomarker research. Recently mass 
cytometry, a combination of mass spectrometry and flow cytometry, was introduced 
as an elegant option for the analysis of target analytes in single cells (88). Using this 
technique, mass spectrometry can be elevated from a level in which a group of cells, 
isolated by laser capture microdissection for example, are examined, to a level where 
mass spectrometry examines every cell as an independent “test tube” (89). Isolation 
and mass spectrometry analysis of T lymphocytes at the initiation of immune responses 
using mass cytometry would of great interest for multiple sclerosis, as lymphocyte 
migration to the central nervous system is one of the key events in the disease.
9. cOnclUdIng REMARkS
Biomarkers for disease diagnosis, monitoring of disease progression, monitoring of the 
effects of treatment and disease prognosis are urgently needed for complex disorders 
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such as multiple sclerosis. Despite the fact that mass spectrometry based techniques 
are limited by a variety of factors, like for example the large dynamic range of proteins 
in biological samples, new developments are rapidly emerging to take proteomics to 
the next level. By standardizing critical elements of proteomics studies in the area of 
sample collection, sample storage, sample documentation and data analysis, combined 
with the constantly growing progress in the field, proteomics can potentially evolve to 
a level of genuine clinical proteomics in the near future.
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Multiple sclerosis (MScl) is a chronic, autoimmune, inflammatory neurological disease 
of the central nervous system (CNS) (1). MScl attacks the myelinated axons in the CNS, 
and destroys the myelin and the axons to different degrees (2, 3). It has a lifetime 
prevalence of 1 per 1000 individuals in the western world (4). It is twice as common in 
women as in men, and people of Northern European descent happen to be at the high-
est threat for MScl (1, 2, 5). The MScl is diagnosed on the basis of clinical findings and 
supporting evidence from additional tests, such as magnetic resonance imaging (MRI) 
of the brain and testing for oligoclonal bands in cerebrospinal fluid (CSF). MScl usually 
presents in adults of 20 to 45 years age. Sometimes, MScl presents in childhood or 
late middle age (5). The cause of MScl is not known, but it seems to involve a combina-
tion of genetic susceptibility and a nongenetic trigger, for example a virus, change 
in metabolism, environmental factors, which all together result in a self-sustaining 
autoimmune disorder that leads to recurrent immune attacks on the CNS (5). No single 
diagnostic test exists for MScl (1). Diagnosis is based on the evidence of (a) at least 
two different lesions (plaques or scars) in the white matter of the CNS; (b) At least two 
different episodes during the disease course; and (c) chronic inflammation of the CNS, 
which is determined by analysis of the CSF. This is in the absence of an alternative 
explanation for the clinical signs or symptoms. A general diagnosis of MScl is allowed 
in the presence of one or more of these criteria, which may be refined according to the 
subsequent course of the disease.
tyPES OF MScl
The MScl patients can be categorized into four major groups based on the course of the 
disease (1) (Figure 1):
(A) Relapsing remitting (RR) MScl
This is the most common form. It affects about 85% of MScl patients. Most people 
with this type of MScl first experience symptoms in their early 20s. It is noticeable by 
flare-ups (relapses) of symptoms followed by periods of remission, when symptoms 
improve or disappear. The patterns of nerves affected, severity of attacks, degree of 
recovery, and time between relapses varies from person to person. Eventually, most 
people having RR MScl will enter a secondary progressive phase of MScl.
(B) Secondary progressive MScl
This type of MScl may develop in some patients with RR MScl. The disease course 
continues to worsen with or without periods of remission or leveling off of symptom 
severity.
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(c) Primary progressive (PP) MScl
It affects approximately 10-20% of MScl patients. In PP MScl, symptoms continually 
worsen from the time of diagnosis. There are no well-defined attacks, and there is a 
little or no recovery. There are several aspects of PP MScl that differentiates it from 
other types of MScl, such as 1) at the time of diagnosis people with PP MScl are usually 
older than an average age of 40; 2) This type of MScl usually leads to disability earlier 
than RR MScl; 3) Roughly equal numbers of men and women develop PP MScl. Whereas 
in other types of MScl, women outnumber men by three to one.
(d) Progressive-relapsing MScl
This is a rare form of MScl. It affects less than 5% of patients. From the start it is pro-
gressive with intermittent flare-ups of worsening symptoms along the way.
Variation in clinical course reflects the complexity in MScl pathophysiology. Cat-
egorization of MScl is important to help with the prediction of disease severity and 
response to the treatment.
cHIldHOOd-OnSEt OF MScl
MScl that onset before the age of 18 is defined as childhood MScl. Nearly, 3-5% of 
all individuals with MScl experience disease onset before the age of 16 (6, 7). It is 
increasingly recognized and represents 2-5% of the total MScl cases (7). This disorder 
was previously known as early onset MScl. Once diagnosed, almost all children are 
considered to have RR MScl, with most symptoms of MScl similar to those seen in 
adults. Children experience 2-3 times more frequent relapses than adults with early 
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Figure 1. MScl classification. Graphical representation of four types of disease courses. All the 
graphs display level of disability over time.
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onset (8). Generally, children with MScl have a higher relapse rate and reach permanent 
disability at a younger age than adult-onset MScl. In children, progression of motor 
disability as measured by an expanded disability status scale (EDSS) takes longer than 
in adults (9). Secondly, childhood onset MScl patients have a higher T2 lesion (part 
of conventional MRI technology) burden than adult MScl patients, which supports 
the conclusion that MScl in children is more inflammatory (10). Diagnosing of MScl in 
children is more challenging than in adults due to the frequency of other childhood 
disorders with similar symptoms and characteristics. The main challenge is to exclude 
other CNS disorders that could mimic MScl, and to distinguish between MScl and 
various temporary demyelinating syndromes that can occur in children. Some of these 
patients are reclassified as MScl based on the nature of the clinical events, laboratory 
findings, and subsequent MRI changes. While the risk of developing MScl following an 
episode of acute disseminated encephalomyelitis (ADEM) in childhood is <10%, the 
risk following an episode of clinically isolated syndrome (CIS) has been shown to be 
between 26% to 62% in several recent studies using the international study group 
criteria (11, 12).
Early and correct diagnosis of childhood onset MScl is essential for immediate treat-
ment to diminish ongoing neuro-inflammation and irreversible neurodegeneration (13) 
and still remains an understudied topic.
MScl PREgnAncy (A nAtURAl dISEASE MOdIFIER)
MScl affects women in their pregnancy years. In this respect, the first large prospec-
tive study of natural history in pregnant women with MScl was PRIMS (pregnancy in 
multiple sclerosis) study (14). This study clarified the possible influence of pregnancy 
and delivery on the clinical course of MScl (14, 15). The study showed reduction in the 
relapse rate during pregnancy, as compared to the year before pregnancy, especially 
marked in the third trimester, and a significant increase in the relapse rate in the first 
trimester after postpartum (Figure 2).
Several other studies also confirmed the same (16). It is interesting to note that the 
decrease in relapse rate during pregnancy is more pronounced than the effect obtained 
with any disease modifying treatment (15). It seems that pregnancy has a protective 
effect on the disease activity, which is also reproduced in the experimental autoim-
mune encephalomyelitis (EAE) model in guinea pig, rats and rabbits (17, 18). During 
pregnancy high placental and maternal production of sex hormones is known and these 
are the most intensive biological features (Figure 3). It is also shown that oestrogen and 
progesterone can suppress EAE (19). Pregnancy is also characterized by major immu-
nological changes that recedes with delivery. In this regard, a shift from cell mediated 
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Thy1 responses to enhanced humoral immunity and a Th2 profile is also noted during 
pregnancy (20) (Figure 3). The fetal placental unit secretes cytokines, such as IL10, that 
down regulates the production of maternal factors mediating cellular immunity. On the 
contrary, delivery might be associated with reversal of this cytokine balance-similar, in 
some respects, to the process of graft rejection (20). Further, there are systemic changes 
that have a direct impact on the activity of the disease process in MScl (21).
A better understanding of the biological mechanisms underlying these pregnancies 
related changes in disease activity could usefully illuminate ideas on the pathogenesis 
and may even suggest new treatment strategies. For this purpose body fluids such as 
urine can be studied as a marker of disease activity (22).
dISEASE-MOdIFyIng tHERAPIES (nAtAlIzUMAB)
Currently, no Food and Drug Administration Agency (FDA) approved treatment exists for 
MScl patients. Disease-modifying agents, shortens the duration of acute exacerbations, 
decreases their frequency, and gives symptomatic relief (5) thus maintaining func-
tion and improving the quality of life (24). There are eight FDA-approved therapeutic 
agents, which can decrease the disease activity and progression in RR MScl patients. 
Natalizumab (Tysabri) is one of these therapeutic agents.
In MScl patients, the formation of inflammatory lesions may contain lymphocytes 
(T cells, B cells and NK cells) and monocytes, that gain access to the brain parenchyma 
from the circulation by first adhering to vascular endothelial cells (25, 26).
Natalizumab is an effective drug for the treatment of RR MScl. It is a recombinant 
humanized immunoglobulin (IgG4) monoclonal antibody that is produced from mam-
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Figure 2.  Figure shows the rate of relapses per women per year for each three month period before, 
during and after pregnancy. Reproduced with permission; Brain (2004); 127:1353-1360.
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Figure 3. Pregnancy and MScl. (A) MScl relapse rate decreases during the third trimester (arrow) and 
increases in postpartum period (arrow).
(B) Immunomodulatory properties of raised steroid hormones might be a cause for beneficial effects 
of pregnancy. They reach a peak during the third trimester of pregnancy (arrow) therefore overlap 
with the strongest decrease in relapse rate.
(C) Immunological processes occur both locally at the feto-maternal interface and to a smaller ex-
tent systemically. Although a systemic Th2-like shift is evident starting in the second trimester and 
lasting until pre-parturition.
(D) The advantageous effects of pregnancy in MScl may not be restricted to variation of the maternal 
immune system, but could in part also reflect effects on the maternal CNS, either by increasing resil-
ience to immune-mediated attacks or by stimulating endogenous repair mechanisms. (Reproduced 
with permission, J Reprod Immunol. (2013); 97:140-6, see reference (23).
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malian cells. It is the first in a class of agents named selective adhesion molecule 
inhibitors. Natalizumab binds to the 4 subunit of α4β1 (CD49d; VLA4) and α4β 7 
integrins expressed on the surface of leukocytes (except neutrophils), and it inhibits 
the α4 mediated adhesion of leukocytes to their counter receptors (2) (Figure 4). In 
MScl patients, Natalizumab treatment is associated with a reduced migratory capacity 
of immune cells and a prolonged decrease in lymphocyte counts in the CSF (27, 28). 
Natalizumab markedly reduces the attack rate in patients with MScl and significantly 
improves all measures of severity (29). Like the beta interferon and glatiramer acetate, 
Natalizumab’s precise mechanism of action in MScl patients has not been completely 
defined. Treatment with Natalizumab might have different side effects that require 
monitoring. Adverse effects must be recognized and identified.
With respect to the above, the effect of Natalizumab in MScl patients before and 
after treatment should be evaluated. Therapy biomarkers can state whether it is suc-
cessful and functional or not.
nEUROBIOlOgy
Neurons are cells that transmit information to other nerve cells, muscle, or gland 
cells. They have a cell body, an axon, and dendrites. Small cellular processes called 
dendrites receive the input. A longer process called an axon, or nerve fiber, carries the 
information away from the cell in the form of bioelectric signals, often called impulses. 
It allows the neuron to communicate with other neurons and with cells outside the 
nervous system. Neurons and their axonal and dendritic processes embedded in a glial 
network provide additional structure and function. The brain contains at least ten times 
Figure 4.  Figure shows blockade of lymphocytic diapedesis by natalizumab in MScl.
(A) Alpha 4 integrin binds to vascular cell adhesion molecule 1 (VCAM1) on inflamed brain endothe-
lium. This interaction provides lymphocytes entree to the CNS.
(B) Natalizumab blocks binding of lymphocytes to VCAM on inflamed brain endothelium, therefore 
preventing lymphocyte access into the CNS. (Reproduced with permission; J. Cell Biol. (2012) 199: 
413–416)
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more glia (also known as glial cells or, neuroglia) than neurons. Glia contributes to the 
cellular architecture of CNS. It is the non-neuronal cells that maintain homeostasis, 
form myelin, and provide support and protection for neurons in the brain and periph-
eral nervous system. They are of four types: 1) Astrocytes (star-shaped cells), these are 
commonly found between neurons and blood vessels. They provide architecture for 
neurons and define anatomical boundaries and also act as a source of growth factors 
and cytokines; 2) Oligodendrocytes, these resemble astrocytes but are smaller and 
have fewer processes. They form in rows along myelinated axons, and they synthesize 
and maintain the myelin sheath; 3) Microglia, are small cells and have fewer processes 
than other types of neuroglia, they are scattered throughout the CNS, where they help 
support neurons and phagocytize bacterial cells and cellular debris; 4) Ependyma, form 
the inner lining of the central canal that extends downward through the spinal cord, 
these cells also cover the specialized capillaries called choroid plexuses associated 
with the ventricles of the brain. Here they help to regulate the composition of CSF.
MScl PAtHOlOgIcAl FEAtURES
MScl pathology is characterized by inflammation, demyelination (with limited remy-
elination), axonal injury and astrocytic scar formation. Although MScl is classically 
considered as white matter disease (31, 32), the recent methodological approach also 
point to strong contribution of cortical gray matter damage. The pathology of grey mat-
ter lesions varies from white matter lesions. The cortical lesions (at autopsy) are less in-
flammatory, with less macrophage, lymphocyte infiltration and decreased complement 
activation (33) as compared to the white matter lesions. However, cortical inflammation 
can be an important feature also in early MScl stages (32). A detailed evaluation of the 
white matter pathology shows four different lesion patterns (34), all of them harboring 
macrophages, T cells and some B cells.
MScl IMMUnOlOgy
B cells and autoantibodies in the pathology of MScl
MScl is characterized by increased permeability of blood-brain barrier (BBB); this 
allows immune cells such as macrophages, T and B cells, to infiltrate into the CNS. 
According to the traditional view of MScl pathophysiology, CD4+ T helper cells react 
with myelin components and trigger an inflammatory cascade in the CNS that results 
in demyelination and axonal loss. However, there are several studies that suggest the 
involvement of B cells and autoantibodies in the pathology of this disease (35-38).
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A clarification for this shift of focus (39) towards B cells in the pathogenesis of MScl 
comprises: (a) An intrathecal immunoglobulin (Ig) synthesis with the oligoclonal Ig 
band in the CSF; (b) The clonal expansion of B cells in the CSF. Clonal expansion of 
B cell populations in the lesion is indicated by the antibody spectrum characterized 
fluid or in the tissue itself. Some data suggest that the process is driven by specific 
antigens itself. Relatively less is known about the antigen specificity of B lymphocytes 
and plasma cells in MScl lesions;
(c) In the meninges of some patients with a progressive disease course, presence 
of follicle-like aggregates is observed. Presence of B cells, plasma cells and excess Ig 
both in brain lesion and CSF of patients with MScl also provides a basis for treatments 
directed against B cells. Four possible mechanisms for B cells associated MScl patho-
physiology are described such as: (a) antigen presentation, (b) antibody production, (c) 
cytokine regulation and (d) the formation of new lymphoid structure in the meninges. 
B cells express a number of surface receptors at different phases of their develop-
ment, for example CD19, CD20, CD40, CD22 and BAFF-R. In MScl, certain stages of B 
cells maturation may be crucial for determining the pathogenicity activity of B cells. 
B cells have pro-inflammatory as well as anti-inflammatory functions. Previous stud-
ies, conducting clinical trials with rituximab and ocrelizumab, monoclonal antibodies 
which deplete cells of the CD20 positive B cell lineage, show that the pro-inflammatory 
features of B cells dominate in most of the MScl patients. Still, as those antibodies 
spare long-lived plasma cells (which lack CD20) and therefore should hardly remove 
the amount of circulating Ig, their effect on autoantibodies is more complex and sug-
gests that the depletion of B cells is beneficial in a manner independent of Ig (40).
Immunoglobulin g (Igg)
IgG play a role in MScl courses in at least a subset of patients. This is suggested by 
some evidences, for instance: (a) Oligoclonal antibody response generated by a limited 
repertoire of activated B cells, a diagnostic finding in the CSF (36). The increased level 
of IgG in the CSF represents an intrathecal antibody synthesis, which is related with 
oligoclonal banding and it also indicates that an immunological process is active in 
the CNS. Oligoclonal bands are shown to found in >95% of patients with clinically 
definite disease (41); (b) Therapeutic success of plasma exchange in a proportion of 
MScl patients (42); (c) The demonstration of demyelinating and axopathic IgG in MScl 
patient serum (43), and (d) The Ig deposition and complement activation in a subset of 
MScl patients (34).
In B-cell immune responses, IgG play several important roles, first by inserting on 
the surface membrane, they act as a receptor, bind to specific antigens and transmits 
activation signals that start the immune response. Furthermore, in secreted soluble 
form they function as antibodies, binding and assigning antigen for destruction by 
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macrophages or proteases (via complement), thus exerting effector functions of the 
immune response.
In both situations, Igs use the variable (V) segment. The Ig V region and correspond-
ing antigenic epitope fit together no less tightly than the key and its lock. The V region 
of the Ig is formed in the course of B cell differentiation through a complex series of 
diverse events. The step in naïve B cell development includes recombination of germ-
line genes, addition of non-germline (N) encoded elements, and somatic mutation to 
improve further the fit (affinity) of Ig after an encounter with the actual antigen.
Typical monomeric Ig is made up of two light and two heavy chains interconnected 
by disulphide bonds. Binding sites, each formed by the V regions of adjacent light and 
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Figure 5. the Igg molecule (a) comprises two of each type of light (IgL) and heavy (IgH) chain. These 
are covalently joined by disulphide bonds (shown as S–S) between cysteine residues. The variable 
domains (V) of the heavy chain (VH) and the light chain (VL) contribute to the binding site of the anti-
body molecule. The variable regions of the IgH and IgL chains, contains framework regions (FR1, FR2 
and FR3) and three hypervariable or complementarity-determining regions (CDRs; CDR1, CDR2 and 
CDR3). CDRs determine the recognition and binding site to the antigen, in the three-dimensional 
structure. Figure (b and c) shows variability in V regions of the IgH and IgL chains. The degree of 
variability, at each different position is, graphically shown for the entire V region of IgH (b) and IgL 
chain (c). The three arms of hypervaribility CDR1, 2 and 3 residue position numbers are shown on 
the X axis.
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heavy chains. The Ig V regions are thus the structural basis for antibody diversity. Ig V 
regions are composed of framework segments with genetically conserved sequences 
and interspersed hypervariable region (sequences specific for each individual specific 
Ig). They combine to form the molecular surface of an antigen-binding site. Structural 
genes for the Ig V region fall into three sets: variable (V), diversity (D) and joining seg-
ments clustered on the chromosome as linearly arranged gene segments. Each group 
contains a large number of individual genes and human heavy chain has hundreds of V, 
dozens of D and several J genes (44) (Figure 5).
nEEd FOR MScl BIOMARkERS In BOdy FlUIdS
MScl has pathophysiological complexities; it is a heterogeneous disease with respect 
to clinical symptoms, neuroradiological findings and treatment responses. MScl is 
normally diagnosed only after repeated bouts, that is, only after some time following 
disease onset. A golden standard for the diagnosis of MScl is inadequate. However, 
the diagnosis of MScl relies on a combination of clinical features with imaging and 
CSF abnormalities (oligoclonal Ig bands). These later changes can be counted among 
immunological biomarkers, but they are not specific for MScl. In terms of disease 
management, early diagnosis and appropriate and timely therapeutic intervention are 
crucial factors in establishing favorable outcomes. Thus, there is an urgent requirement 
for easily accessible biomarkers. Mass spectrometry-based proteomics approach has 
developed as a powerful method that has the potential to accelerate MScl biomarker 
discovery in body fluids.
OUtlInE OF tHE tHESIS
This thesis focuses on five topics in MScl: 1) two major subtypes, 2) early-onset, 3) 
involvement of pathogenic IgG (auto) antibodies (humoral immune response,) 4) effect 
of disease modifying therapy (Natalizumab), and 5) pregnancy.
The goal of the study on two different MScl subgroups (RR and PP MScl), was to 
differentiate and to identify bioclinical markers by comparing CSF proteins. For child-
hood-onset MScl study, our aim was to improve diagnosis. The main goal in this study 
was to find CSF protein markers expressed during first event of CNS demyelination that 
can help to distinguish children with MScl from children with monophasic ADS. The 
aim of our study on humoral immune response in CSF was to perform the clonal char-
acterization of the CSF IgG antibody repertoire and to find common characteristics of 
the antigen binding sites exclusively among RR MScl patients. Further, we monitored 
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the effects of Natalizumab drug treatment on RR MScl. This was to study potential 
CSF markers that are relevant for CNS pathology and identify the protein markers for 
effects of the therapy. The main objective of our study on pregnancy in MScl was to 
identify biological mechanism of the decreased activity of disease during pregnancy. 
To this we performed a longitudinal study in RR MScl patients at 28-30 weeks during 
pregnancy and at 4-8 weeks after delivery. To quantify and identify disease associated 
proteins different types of high resolution mass spectrometer was applied on samples 
from MScl patients. Overall, the thesis here emphasized the identification of biomark-
ers related to MScl and to improve further understanding of the disease.
This thesis can be divided into six parts:
chapter 1.1 outlines the current research scenario of the MScl and a detailed num-
ber of bottlenecks as well as a future prospect of mass spectrometry based proteomics 
biomarker research.
chapter 1.2 describes the general characteristics of MScl.
In chapter 2 we report the CSF proteomic profile of two different MScl types, PP and 
RR MScl. In this chapter, we set out to identify the proteins that differentiate between 
the two disease types using quantitative MALDI-FT-MS mass spectrometry.
chapter 3 deals with the childhood onset MScl and monophasic ADS. In this chapter 
we describe the results of a nano scale liquid chromatography coupled online to high 
resolution mass spectrometer (LC-MS) based trypsin profiling study for quantification 
and identification of proteins in CSF samples of the children with MScl.
In chapter 4 we have investigated clonality of CSF IgG using LC-MS. The aim of 
this work is to detect specific proteomic profiles of CDR (in CSF IgG) present in MScl 
patients but absent in controls.
In chapter 5 we describe the results of a LC-MS tryptic profiling study on RR MScl 
patient’s CSF before and after one year of Natalizumab treatment. The differentially 
expressed proteins were confirmed by SRM and ELISA measurements.
In chapter 6 we describe the result of urinary proteome analysis of pregnant women 
(during third trimester and at first postpartum period) with MScl using LC-MS. We de-
scribes the identification of protein that are related to pregnancy and proteins that 
change significantly different in MScl compared to normal pregnancy.
In chapter 7 the finding of the studies are summarized and discussed with the 
indication for future directions.
Chapter 1/1.2
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ABStRAct
Based on clinical representation of disease symptoms multiple sclerosis (MScl) pa-
tients can be divided into two major subtypes; relapsing remitting (RR) MScl (85-90%) 
and primary progressive (PP) MScl (10-15%). Proteomics analysis of cerebrospinal fluid 
(CSF) has detected a number of proteins that were elevated in MScl patients. Here we 
specifically aimed to differentiate between the PP and RR subtypes of MScl by compar-
ing CSF proteins. CSF samples (n=31) were handled according to the same protocol 
for quantitative mass spectrometry measurements we reported previously. In the com-
parison of PP MScl versus RR MScl we observed a number of differentially abundant 
proteins, such as protein jagged-1 and vitamin D-binding protein. Protein jagged-1 was 
over three times less abundant in PP MScl compared to RR MScl. Vitamin D-binding 
protein was only detected in the RR MScl samples. These two proteins were validated 
by independent techniques (western blot and ELISA) as differentially abundant in the 
comparison between both MScl types. The main finding of this comparative study is the 
observation that the proteome profiles of CSF in PP and RR MScl patients overlap to a 
large extent. Still, a number of differences could be observed. Protein jagged-1 is a li-
gand for multiple Notch receptors and involved in the mediation of Notch signaling. It is 
suggested in literature that the Notch pathway is involved in the remyelination of MScl 
lesions. Aberration of normal homeostasis of Vitamin D, of which approximately 90% is 
bound to vitamin D-binding protein, has been widely implicated in MScl for some years 
now. Vitamin D directly and indirectly regulates the differentiation, activation of CD4+ 
T-lymphocytes and can prevent the development of autoimmune processes, and so it 
may be involved in neuroprotective elements in MScl.
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IntROdUctIOn
Multiple sclerosis (MScl) can be divided into two major subtypes based on clinical 
representation of disease symptoms in the patients (1). Between 85-90% of patients 
can be classified as having the relapsing remitting (RR) MScl subtype, in which disease 
relapses are followed by periods of remission, and 10-15% of all MScl patients are 
diagnosed with the primary progressive (PP) subtype (2). Even within a single large 
Dutch MScl pedigree of 26 patients with similar genetic background, the percentage of 
patients with a PP phenotype remained 15% (3).
By definition, in PPMScl progression is characterized by a progressive course without 
relapses or remissions from the onset of the disease (4). PP patients tend to have lower 
inflammatory lesional activity, for which no immunological or genetic explanation has 
been identified yet. The scarce comparative neuropathological studies show a large 
overlap in lesional pathology, but indicate less inflammatory activity for PP, with still 
substantial axonal damage (5). The general picture is that relapse onset and PP forms 
share substantial characteristics. In other words, it has remained a challenge to identify 
the biological parameters that determine a PP disease course.
Although proteomics analysis of active multiple sclerosis lesions may be a straight-
forward approach to study the processes involved in MScl pathways (6), this is very 
difficult to perform in living individuals. In most cases the pathology of the disease 
can only be investigated in post-mortem material, which quite frequently represents 
the end-stage of the disease. The study of CSF taken during disease appears a good 
alternative. CSF is in close contact with the CNS parenchyma and collects the products 
of the inflammatory and neurodegenerative processes of MScl activity.
Proteomics analysis of CSF has detected a number of proteins that were elevated 
in MScl patients (7, 8). Additionally, differentially abundant proteins identified by 
proteomics, such as apolipoprotein A1 (9) and chromogranin A (10) were validated by 
other techniques. Other studies added additional data on elevated immunoglobulin 
expression in MScl CSF, as well as increased levels of apolipoprotein E (11, 12). Yet 
in all currently reported proteomics CSF studies of MScl patients either only a single 
subtype of MScl patients or a combined group of all subtypes of MScl was studied, 
whilst the differences between the subtypes of MScl remained unexplored. Because RR 
MScl and PP MScl are very different in terms of disease course and disease progression, 
this also has therapeutic consequences. Hence, there are probably also differences 
on a biological and pathological level, which could, if determined, be very useful for 
elucidation of the biology and pathology of both disease types.
In the current study we specifically aimed to differentiate between the MScl patients 
and healthy controls and between both subtypes of MScl by comparing CSF proteins 
and peptides. Subsequently, the identified biomarker proteins and peptides were 
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discussed in relation to the different pathological processes observed in RR MScl and 
PP MScl.
MEtHOdS
Ethics statement
The Medical Ethical Committee, de commissie medisch ethische vraagstukken, of the 
Erasmus University Medical Centre in Rotterdam, The Netherlands, approved the study 
protocol and patients gave written consent. The approval numbers for this study are 
200.721/2001/75 and 2006/188.
Patient selection
The CSF samples of MScl patients, divided into two groups, RR MScl (13) and PP MScl 
(14), were collected from untreated patients undergoing routine diagnostic procedures 
by an experienced neurologist (RQH), and matched for presence or absence of oligoclo-
nal bands. The healthy control CSF samples were taken from patients receiving spinal 
anesthesia prior to non-neurological minor surgical interventions, such as knee and 
hip replacements, groin rupture and Achilles tendon rupture. All samples were handled 
in exactly the same way after sampling, using a procedure that has been previously 
reported (12). In brief, immediately after sampling, the CSF samples were centrifuged 
to discard cells and cellular elements and the total protein concentration and albumin 
concentrations were determined. The number of oligoclonal bands and the intrathecal 
cell count were also reported. The remaining volume of the samples was aliquoted and 
stored at −80°C, where they remained until sample preparation for this study. No extra 
freeze-thaw cycles were allowed.
Sample preparation, measurement and analysis
The CSF samples were handled according to the same protocol for quantitative 
MALDI-FT-ICR MS measurements we reported previously (12), which consists of a 
blinded experiment in which the samples were digested by trypsin and subsequently 
measured by MALDI-FT-ICR (APEX IV Qe 9.6 Tesla MALDI-FT-ICR mass spectrometer 
(Bruker Daltonics, USA)). After calibration by means of omnipresent albumin peaks, an 
analysis matrix is generated. A univariate analysis, in which a p-value was determined 
for every peak position, was used for statistical analysis, in which two groups were 
compared at a time, for a total of three individual comparisons between the groups. 
The differentially abundant peaks (p < 0.01) in the comparisons were considered for 
identification purposes. The fold increase of every identified peptide with p < 0.01 in 
the comparisons was determined to confirm differential abundance between groups. 
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Assessment of the statistical background, by means of permutation of a series of 50 
scramblings of the samples for each comparison, was used to define a cut-off number 
for the determination of statistically significant differences between groups. In this 
permutation procedure all samples are randomly assigned a new group number, scram-
bling the sample group compositions, prior to performing the univariate analysis to 
determine the p-values for each peak position. By this method the number of peaks 
that is assigned a p-value below 0.01 by chance is determined. Iterative repetition 
of this procedure allows for a statistically relevant mean with standard deviation that 
could be taken as a realistic background value for this not normally distributed data.
The differentially abundant peptides were identified by nano-LC-ESI-Orbitrap MS. 
These measurements were carried out on a Ultimate 3000 nano LC system (Dionex, 
Germering, Germany) online coupled to a hybrid linear ion trap / Orbitrap MS (LTQ 
Orbitrap XL; Thermo Fisher Scientific, Germany). Five µL digest were loaded on to a C18 
trap column (C18 PepMap, 300µm ID x 5mm, 5µm particle size, 100 Å pore size; Dionex, 
The Netherlands) and desalted for 10 minutes using a flow rate of 20 µL /min 0.1% 
TFA. Then the trap column was switched online with the analytical column (PepMap 
C18, 75 µm ID x 150 mm, 3 µm particle and 100 Å pore size; Dionex, The Netherlands) 
and peptides were eluted with following binary gradient: 0% - 25% solvent B in 120 
min and 25% - 50% solvent B in further 60 minutes, where solvent A consist of 2% 
acetonitrile and 0.1% formic in water and solvent B consists of 80% acetonitrile and 
0.08% formic acid in water. Column flow rate was set to 300 nL/min. For MS detection 
a data dependent acquisition method was used: high resolution survey scan from 400 
– 1800 Th. was performed in the Orbitrap (value of target of automatic gain control AGC 
106, resolution 30,000 at 400 m/z; lock mass was set to 445.120025 u (protonated 
(Si(CH3)2O)6) (15)). Based on this survey scan the 5 most intensive ions were con-
secutively isolated (AGC target set to 104 ions) and fragmented by collision-activated 
dissociation (CAD) applying 35% normalized collision energy in the linear ion trap. 
After precursors were selected for MS/MS, they were excluded for further MS/MS 
spectra for 3 minutes. The MS/MS identifications were obtained using in the Bioworks 
3.2 (peak picking by Extract_msn, default settings) software package (Thermo Fisher 
Scientific, Germany), and its’ SEQUEST feature, using minimum XC scores of 1.8, 2.2 and 
3.75 for reliable identification of single, double and triple charged ions respectively in 
the UniProt-database (version 56.0, human taxonomy (20069 entries)). Carboxymeth-
ylation of Cysteine (+57.021 u) as fixed and oxidation of Methionine (+15.996 u) as 
variable modifications and tryptic cleavage were considered. The number of allowed 
missed cleavages was 2, the mass tolerance for precursor ions was 10 ppm and for 
fragment ions 0.5 Da. The cut-off for mass differences with the theoretical mass of the 
identified peptides was set at 2 ppm.
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Contamination of CSF by serum of plasma is a possible issue in CSF peptide profil-
ing, because if one or more of the samples is contaminated by serum or plasma, the 
comparison of CSF peptide profiles is inevitably skewed by the higher total protein 
concentrations in serum or plasma (16). To prevent inclusion of contaminated CSF 
samples in this study, the CSF samples were checked for specific blood contamination. 
If a hemoglobin peptide could be identified by nanoLC-ESI-Orbitrap (C18 column) with 
sufficiently high confidence score or if the mass peak 1274.7255 (part of hemoglobin 
gamma) has a signal to noise of 4 or higher in MALDI-FT-ICR measurements, the sample 
was discarded from further analysis due to plasma/serum contamination. Another 
blood specific protein, apolipoprotein B100 was checked in the same way as possible 
blood contamination.
Immuno-assays for validation of differentially abundant proteins
For two proteins, for which we found differentially abundant peptides, we performed 
validation experiments. This was done by commercially available ELISA (for vitamin 
D-binding protein) and by western blot (for protein jagged-1), using a validation cohort 
of patients consisting of 10 RR MScl and 10 PP MScl samples. The samples of the vali-
dation cohort were demographically and clinically comparable to the original cohort 
of patients (average EDSS RR MScl group (standard deviation in brackets): 2.5 (0.8), 
average EDSS PP MScl group 2.8 (1.0), and the disease duration, presence/absence 
of oligoclonal IgG bands and male female ratio were all similar to the original cohort 
(no p-values below 0.05) using a t-test to compare the groups). Additionally we also 
measured the original samples using this ELISA and western blot. For the first protein, 
vitamin D-binding protein, we performed a commercially available ELISA (Immundiag-
nostik, Germany) according to the manufacturer’s specifications. For the second protein 
that was differentially abundant between the both MScl types, jagged-1, we performed 
a two-step western blot using goat anti-jagged1 antibodies (primary antibody) and 
anti-goat antibodies (secondary antibody) (Sigma Aldrich, United States). Protein trans-
fer was checked by Ponceau staining. Quantitative assessment of the gel bands after 
photoluminescence was performed using Image J (freely available at www.rsb.info.nih.
gov/ij).
RESUltS
clinical information
In total 34 CSF samples were used for mass spectrometry analysis, while twenty of 
these samples and twenty additional samples were used for validation experiments. 
All samples analyzed by mass spectrometry were tested as being negative for serum/
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plasma contamination by MALDI-FT-ICR measurements. However, in three samples we 
were able to identify hemoglobin peptides with sufficiently high XC scores for confi-
dent identification using nano LC-ESI-Orbitrap measurements. These three samples, 2 
PP MScl and 1 RR MScl, were subsequently excluded from further analysis. The analysis 
matrix, which was used to profile the differences in peptide profile between the three 
groups, consisted therefore of 31 CSF samples (Table 1).
Peak detection and data analysis
After the MALDI-FT-ICR spectra were loaded into PeptrixTM software package, they 
were each tagged with a group number (1, 2 and 3 for PP MScl, RR MScl and controls 
respectively). Calibrating using five omnipresent albumin peaks was followed by gen-
eration of an analysis matrix with the intensity of all peaks of every sample recorded 
for all detected peaks. Using the Wilcoxon-Mann-Whitney test to compare the groups 
pair-wise, the comparison between both MScl types resulted in 15 peak masses with p-
values below 0.01. By scrambling the sample groups the number of background peaks 
was determined at 17, so the number of differentially abundant peptide peaks in the 
comparison of the two MScl types is around the level of the number of background 
peaks, indicating that the difference between these two groups appears to be nonexis-
tent or at least at background level. However, the proteins that were identified with low 
p-values in this comparison were of substantial interest in a MScl context.
A total of 43 peptide peaks with a p-value below 0.01 were observed for the com-
parison of PP MScl versus the controls. The comparison of RR MScl versus the controls 
had 41 peak masses with p-values lower than 0.01. Seventeen of the peak masses with 
p < 0.01 were present in both comparisons.
table 1. cSF sample information: The concentrations, age, Expanded Disability Status Scale (EDSS) 
score and disease duration values are averages with standard deviation in brackets. None of the 
variables in these tables differed significantly between the groups (all t-tests showed p-values 
higher than 0.05).
PP MScl RR MScl controls
Number of samples 10 11 10
Protein concentration (g/L) 0.398 (0.118) 0.391 (0.135) 0.386 (0.110)
Albumin concentration (g/L) 0.254 (0.104) 0.228 (0.082) 0.205 (0.090)
Age 48.1 (9.0) 43.9 (14.1) 51.1 (13.7)
EDSS 3.2 (0.8) 2.8 (0.9) -
Disease duration (years) 3.4 (1.3) 2.6 (1.5) -
Male/Female ratio
(% females in group)
6 / 4 (40%) 6 / 5 (45%) 8 / 2 (20%)
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Identification
Identification of the differentially abundant peptides was performed by measuring 
all samples using the nanoLC-ESI-Orbitrap. Due to the prefractionating by nanoLC far 
more peak masses and identifications are generated by ESI-Orbitrap than there are 
peak masses in the analysis matrix generated by quantitative MALDI-FT-ICR. Although 
many of the identified peptides do not correspond to peak masses in the analysis 
matrix, we were able to identify a number of differentially abundant peptides for all 
three comparisons (full list, including charge states and sequence coverage. Of the 
43 differentially abundant peptide masses that were observed using MALDI-FT-ICR 
mass spectrometry in the comparison of PP MScl versus the controls we were able to 
identify 29 peptides. These peptides included several peptides of Ig gamma-1 and Ig 
kappa. Another differentially abundant peptide was identified as a part apolipoprotein 
D, which has previously been shown to be elevated intrathecally in MScl patients (17). 
In the comparison of RR MScl versus controls we were able to identify 24 of the 41 
differentially abundant peptide masses, which, as was the case with the comparison of 
PP MScl versus the controls, also included several peptides of Ig gamma-1 and Ig kappa 
as well as apolipoprotein D. In fact, of the 24 peptides identified in this comparison, 14 
were also identified in the comparison of PP MScl versus the controls, indicating that 
the differences of the two MScl types compared to the controls are remarkably similar. 
Additional proteins with low p-values in the comparisons of both MScl types with the 
controls include StAR-related lipid transfer protein 4 (2.551 fold increase in PP MScl 
compared to controls and 2.837 fold increase in RR MScl compared to controls), LON 
peptidase N-terminal domain and RING finger protein (2.847 fold increase in PP MScl 
and 2.212 fold increase in RR MScl), and ryanodine receptor 1 (2.129 fold increase in 
PP MScl and 1.877 fold increase in RR MScl).
PP MScl versus RR MScl
The comparison of PP MScl versus RR MScl showed a limited number of differentially 
abundant peptide peaks. Of these peaks 7 were identified, the most notable being 
protein jagged-1 (Table 2). This particular protein was over three times less abundant 
in PP MScl compared to RR MScl. Another interesting differentially abundant protein 
is vitamin D-binding protein, which was not detected by mass spectrometry in the PP 
MScl samples but was detected in the RR MScl samples. Other proteins, such as serine/
threonine kinase NLK and sodium leak channel non-selective protein were more abun-
dant in PP MScl than in RR MScl, although for the latter protein the difference was small 
(1.18 fold increase).
Because our main interest was focused on the differences between the two MScl 
types we selected two differentially abundant proteins from that comparison for 
validation purposes using 10 PP MScl and 10 RR MScl samples measured by mass 
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spectrometry and an additional 10 PP MScl and 10 RR MScl samples from independent 
patients. Validation by ELISA showed that the concentration of vitamin D-binding 
protein was significantly lower (t-test, p < 0.05) in the PP MScl group compared to the 
RR MScl group in the samples also measured by MALDI-FT-ICR MS (Table 3). A similar 
result was observed in the new, clinically and demographically comparable validation 
samples (Table 4). After western blotting, quantitative assessment of the gel bands 
showed that protein jagged-1 was indeed less abundant in PP MScl than in RR MScl. A 
t-test on the photoluminescence readout values of the original sample set showed a 
p-value below 0.05 when comparing the RR and PP MScl samples (Table 3). The same 
comparison in the validation samples also showed a p-value below 0.05), indicating 
a significant differential abundance of jagged-1 in the two MScl types (Table 4). In 
order to place the identified proteins in a biological context, they were uploaded to 
the Ingenuity Pathways Analysis service (Ingenuity Systems) for to network analysis. 
Six of the seven differentially abundant proteins were placed in a network relating to 
neurological disease (Figure 1).
table 3. the results of the validation experiments in the original sample set. By ELISA measure-
ment vitamin D binding protein is more abundant in RR MScl than in PP MScl in the original sample 
set (p = 0.017), based on the average (+/− standard deviation) concentrations in CSF. Protein jag-
ged-1 (western blot) is more abundant in RR MScl than in PP MScl in the original sample set (p = 
0.019), based on the averages (+/− standard deviation) in photoluminescence readout.
Original sample set PP MScl RR MScl
p-value
(t-test)
Average Standard
deviation
Average Standard
deviation
Vitamin Dbinding protein concentration in 
pg/ml - (ELISA)
13716 5881 19594 3938 0.017
Protein jagged-1 photoluminescence 
readout (western blot)
8304 3553 16640 9563 0.019
table 4. the results of the validation experiments in the validation sample set. By ELISA measure-
ment vitamin D binding protein is more abundant in RR MScl than in PP MScl in the demographically 
and clinically comparable validation sample set (p = 0.032), based on the average (+/− standard 
deviation) concentrations in CSF. Protein jagged-1 (western blot) is more abundant in RR MScl than 
in PP MScl in the validation sample set (p = 0.041), based on the averages (+/− standard deviation) 
in photoluminescence readout.
Validation sample set PP MScl RR MScl
p-value 
(t-test)
Average Standard 
deviation
Average Standard 
deviation
Vitamin D-binding protein concentration in 
pg/ml ELISA)
15411 6186 23125 8458 0.032
Protein jagged-1 photoluminescence 
readout (western blot)
9462 3867 19868 14393 0.041
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dIScUSSIOn
The main finding of this comparative study is the observation that the proteome profiles 
of CSF in PP vs RR MScl patients overlap to a large extent. This is in line with the lack of 
clear-cut differences between the two major clinical MScl sub-groups, at genetic, im-
munological and neuropathological levels. Interestingly, our approach using sensitive 
state-of the art mass spectrometry techniques, led to the identification of a few distinct 
CSF proteins, some of them with biological functions that appear of direct interest 
for MScl pathology. Two of these proteins were validated by other techniques as well 
as in a validation sample set. The lack of statistical power, due to the low number of 
biological samples available for this study, led to a less than ideal statistical analysis, 
meaning that the reported p-values may not be directly associated to disease pathol-
ogy. However, the reported unvalidated proteins are of significant biological interest, 
Figure 1. Six of the seven differentially abundant proteins (in red) identified in the comparison of 
the two MScl disease types (PP and RR) fit into a network related to neurological disease.
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and among these are several immunoglobulin proteins, which have been previously 
reported to be elevated in CSF of MScl patients (18, 19).
The number of peaks with low p-values in the comparison of the two MScl types 
is lower than the number of background peaks, so this is a strong indication that, 
even though there may be peptides and proteins that are differentially abundant in 
the comparison, overall the difference between the two disease types appears to 
be undetectable by means of the univariate analysis. One of the peptides of protein 
jagged-1 is over three times less abundant in PP MScl and also is observed with a 
lower incidence in this group (Table 2). Protein jagged-1 is a ligand for multiple Notch 
receptors and involved in the mediation of Notch signaling, which influences neuronal 
function and development (20). The Notch signaling pathway has long been known to 
influence cell fate in the developing nervous system. Jagged-1 has been found to be 
highly expressed in hypertrophic astrocytes within and around active MScl plaques 
lacking remyelination, while, in contrast, there was negligible jagged-1 expression in 
remyelinated lesions suggesting involvement of the Notch pathway in remyelination 
in MScl (21). Later, linkage equilibrium screening implicated a number of genes, in-
cluding the jagged-1 gene, as susceptibility genes for MScl in a large contingent of 
Europeans (22). It has also been suggested that jagged-1 has therapeutic potential in 
the treatment of CD8+ T cell mediated diseases, due to its ability to deliver indirect 
negative signals into CD8+ T cells in vivo (23). Additionally, animal models have shown 
that elevated expression of Notch and jagged-1 expression does not appear to be a 
limiting factor in remyelination, but the animal model study reports that there were no 
quantitative differences in Notch1 expressing cells in slow and rapidly remyelinating 
lesions, indicating that Notch–Jagged signaling is not a rate-limiting determinant of 
remyelination in rodent models of demyelination (24). Additionally immunohistochem-
istry experiments have shown that constituents of the Notch pathway are expressed in 
remyelination in an animal model of T-cell- and antibody-mediated CNS demyelination 
(25). However, network studies based on the quantitative expression levels of 20 genes 
in over one hundred individuals identify jagged-1 as a new therapeutic target whose 
differential behavior in the MScl network was not modified by immunomodulatory 
therapy, illustrating how network analysis can predict therapeutic targets for immune 
intervention and identifying the immunomodulatory properties of jagged-1, making it 
a new therapeutic target for MScl and other autoimmune diseases (26).
The identified peptide of vitamin D-binding protein is not observed in any of 
the PP MScl samples, but small peaks of this peptide are detected in 6/11 RR MScl 
samples. Impaired vitamin D homeostasis has been widely implicated in MScl for some 
years now (27-29). This vitamin directly and indirectly regulates the differentiation, 
activation of CD4+ T-lymphocytes and can prevent the development of autoimmune 
processes (30, 31), and so it may be involved MScl. Considering that the geographic 
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incidence of MScl indicates an increase in MScl with a decrease in sunlight exposure, 
that vitamin D is produced in the skin by solar or UV irradiation and that high serum 
levels of 25-hydroxyvitamin D have been reported to correlate with a reduced risk of 
MScl, a protective role of vitamin D has been suggested (32). More than 99% of 25-hy-
droxyvitamin D, the principle circulating metabolite of vitamin D is bound to proteins, 
of which approximately 90% is bound to vitamin D-binding protein (33, 34). Recently, 
a CSF proteomics study showed that serum levels of vitamin D-binding protein were 
decreased significantly in RR MScl patients compared to other neurological disorders 
(35). While our results do not indicate a differential abundance difference between 
the MScl subtypes and the controls, the two disease types did vary significantly in CSF 
levels of vitamin D-binding protein, with RR MScl showing a higher abundance. Since a 
neuroprotective function has been suggested for vitamin D, it may be that in PP MScl 
this neuroprotective pathway is at least partially deficient, resulting in a significantly 
more disabling disease manifestation. However, it should not be forgotten that vitamin 
D-binding protein has pleiotropic functions, beyond vitamin D metabolism. It can 
significantly enhance the chemotactic response to complement fragment C5a (36), and 
there are substantial stimulatory effects on macrophages (37). In light of the increas-
ingly recognized role of innate immunity in the progressive phase of MS pathogenesis 
(38), vitamin D-binding protein appears an interesting candidate mediator.
The identification of a peptide of beta-2-microglobulin as differentially abundant 
in the comparison between both MScl types is somewhat misleading. Another seven 
peptides of this protein were identified among the peak masses in the analysis matrix 
that had high p-values in the comparison of PP and RR MScl, so it is very likely that 
the low p-value of the peptide of beta-2-microglobulin reflects high abundant protein 
variations, suggesting this low p-value is most likely a false positive. In contrast, the 
other proteins that are differentially abundant in this comparison were either identified 
by the single peptide listed in Table 2 or by multiple peptides that had low p-values.
The identification of peptides of albumin and serotransferrin stands out in the 
tables of the differentially abundant peptides and proteins. While the identifications 
are essentially correct it must be noted that only 2.4% of the identified albumin pep-
tides and 4.8% of the identified serotransferrin peptides had p-values below 0.01, 
which means that the values for the peptides of these two particular proteins are most 
likely due to other reasons than large abundance differences in these two proteins. In 
comparison, most of the other differentially abundant proteins that we identified were 
found by a small number of peptides with a low p-value or a single peptide with a low 
p-value. For these proteins we did not observe any other peptides with non-significant 
p-values, with the exception of bromodomain adjacent to zinc finger domain protein 1A 
and Rho GTPase-activating protein 18-like. For both of these proteins another peptide 
was identified with high p-value, indicating these proteins were likely not differentially 
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abundant. The peptides with low p-values of these proteins were also characterized 
by a low fold increase, making them less interesting for independent immunoassay 
follow-up.
Because of the healthy state of the CSF control group, no intrathecal inflammatory 
response was to be expected in this group. Therefore the very clear difference in immu-
noglobulin abundance in the comparison with the both MScl types can be explained. 
In the two comparisons of both MScl types with the control group, several proteins 
are present in both comparisons, for example Ig gamma-1 chain C region and apo-
lipoprotein D. Apolipoproteins have been previously implicated in MScl. Proteomics 
studies have shown apolipoprotein E abundances to be elevated in CSF of MScl pa-
tients compared to controls (9, 12). In the central nervous system apolipoprotein D is 
a lipocalin that is mainly expressed in glia, but also in neurons. This protein has been 
repeatedly implicated in MScl, and it has been shown that it has a neuroprotective ef-
fect in a number of neurodegenerative diseases by controlling the level of peroxidated 
lipids, which coincides with glial activation in mouse models of encephalitis (39). A 
previous proteomics study showed increased levels of apolipoprotein D in patients 
with a clinically isolated syndrome of demyelination, indicating that abundance levels 
of this protein are highest in MScl patients at the time of their first exacerbation (10, 
17). Another potentially interesting protein found to be differentially elevated in the 
comparisons of both MScl types with the controls is ryanodine receptor 1. This receptor 
is involved in the maintenance of the calcium-equilibrium in brain tissue. The release 
of toxic levels of positively charged calcium ions may, due to the deleterious effects 
of excitotoxicity, represent a key mechanism of axonal degeneration in disorders such 
as MScl (40).
In conclusion, the CSF peptide profile of the control samples differed from both 
MScl types, with, not unexpectedly, proteins related to immune response showing the 
highest fold increase in abundance in the MScl types compared to the controls. Even 
though the CSF peptide profiles measured by MALDI-FT-ICR of PP MScl and RR MScl 
were quite similar, still a few differences could be observed, most notably regarding the 
molecules confirmed by immunoassay, protein jagged-1 and vitamin D-binding protein.
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ABStRAct
Objective: Identification of CSF biomarkers for multiple sclerosis (MScl) in children 
with an initial acquired CNS demyelinating syndrome (ADS).
Methods: CSF was collected from a cohort of 39 children with initial ADS, of them 18 
were diagnosed with MScl and 21 had a monophasic disease course. Proteomic analy-
sis of trypsinised CSF (20 µl) was performed by nano liquid chromatography Orbitrap 
mass spectrometry. Univariate statistical analysis was used to identify differentially 
abundant proteins between childhood-onset MScl and monophasic ADS.
Results: A total of 2260 peptides corresponding with 318 proteins were identified 
in the total set of samples. Of these 2260 peptides, 88 were identified as most distinc-
tive between MScl and ADS. 53 peptides, corresponding to 14 proteins, had higher 
abundance in children with MScl as compared to monophasic ADS. Twelve out of these 
14 proteins were linked to neuronal functions and structures such as synapses, axons 
and CNS proteases (example: neurofascin, carboxypeptidase E, brevican core protein, 
and contactin-2). The other two were functionally related to immune function. The 35 
peptides identified with decreased abundance in children with MScl corresponded to 
seven proteins. Six of them linked to innate immune function (example: haptoglobin, 
haptoglobin-related protein, c4b-binding protein alpha chain and monocyte differen-
tiation antigen CD14) and one to cellular adhesion (protein diaphanous homolog 1).
conclusion: At first onset of ADS, CSF of children diagnosed with MScl showed 
increased abundance of CNS grey matter related proteins, whereas CSF of children 
with a monophasic disease course showed increased abundance of innate immunity 
related proteins.
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IntROdUctIOn
A few percent of all multiple sclerosis (MScl) patients experience their first event in 
childhood (1, 2). In children, such a first acquired demyelinating syndrome (ADS) can 
present with a spectrum of clinical features including optic neuritis (ON), transverse 
myelitis (TM), acute disseminated encephalomyelitis (ADEM), neuromyelitis optica 
(NMO), and other clinically monofocal or polyfocal symptoms (3, 4). In most children 
with monophasic ADS, the disease course remains monophasic. However, a significant 
part of these children will subsequently be diagnosed with MScl (5, 6). In this group, 
the time between the initial monophasic ADS, and the second MScl defining attack was 
typically <2 years (5).
Current diagnosis of MScl uses the combination of clinical features, cerebrospinal 
fluid (CSF) findings such as positive oligoclonal bands (OCB), and magnetic resonance 
imaging (MRI) criteria for dissemination in time and space (1, 5, 7). These factor are 
insufficient to predict the disease course at first event. The availability of a biomarker 
that helps to differentiate between children with monophasic ADS, and those subse-
quently diagnosed with MScl is needed. Moreover, identification of CSF proteins that 
are associated with childhood onset MScl can provide further insight into the disease 
pathophysiology. So far, only one study was published that compared CSF in MScl (n=8) 
patients with monophasic ADS (n=11) in children. Zooming in on neuronal peptides 
and non-myelin proteins in CSF, this study suggested for disturbed axoglial biology 
during early MScl (8) event. Involvement of central nervous system (CNS) gray matter 
components (which relates to neuronal cell bodies, dendrites, axons, oligodendrocytes 
and synapses) has also been shown in early MScl initiation in one other study that was 
performed in adults (>18 yrs.) clinically isolated syndrome (CIS) and established MScl 
patients(9).
In the present study, we have investigated CSF, a body fluid that reflects ongoing 
CNS pathology (10) in a fully unbiased manner. Samples were analyzed by high resolu-
tion, and sensitive nano-liquid chromatography Orbitrap mass spectrometry (LC-MS) 
(11). Our aim was to find CSF protein markers expressed during first event of CNS 
demyelination that can help to distinguish children with monophasic ADS (n=21) from 
children with MScl (n=18).
MAtERIAlS And MEtHOdS
Patients
Children (<18 years old), who were diagnosed with either monophasic ADS or MScl 
were identified by the Dutch Study Group for Pediatric MScl, which includes 13 major 
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pediatric neurology centers in The Netherlands as described earlier(12). Diagnosis (12) 
of pediatric MScl patients was made in case they had a second demyelinating attack of 
the CNS and/or MRI evidence of a new lesion at least one month after onset (1). Initial 
phenotypes of participants were defined by clinical history and physical examination. 
This study included 41 participants; 22 children diagnosed with monophasic ADS, and 
19 children diagnosed with clinically defined MScl. After collection, all CSF samples 
included in this study were immediately centrifuged at 3000g to remove cell debris, 
subsequently coded, frozen and stored at −80°C until analysis. An aliquot was subse-
quently used for routine CSF diagnostics. The remaining volume of the samples was 
aliquoted and stored at −80°C. The study was approved by the Clinical Research Ethics 
Board of the Erasmus University. Written informed consent was obtained from family 
of patients.
Sample preparation and lc-MS measurements
CSF samples (20 µL) were digested using an in-solution trypsin digestion protocol 
followed as previously described (13). Samples prepared were analyzed by LC-MS/
MS using an Ultimate 3000 nano RSLC system (Thermo Fischer Scientific, Germering, 
Germany) online coupled to a hybrid linear ion trap / Orbitrap mass spectrometer (LTQ 
Orbitrap XL; Thermo Fisher Scientific, Bremen, Germany). Five microliter of each tryptic 
digest were loaded onto a C18 trap column (C18 PepMap, 300 µm ID x 5 mm, 5 µm 
particle size, 100 Å pore size; Thermo Fisher Scientific, The Netherlands) and desalted 
for 10 minutes using 0.1% TFA in water at a flow rate of 20 µL/min. The trap column 
was switched online with the 50 cm long analytical column (PepMap C18, 75 µm ID × 
500 mm, 2 µm particle and 100 Å pore size; Dionex, Amsterdam, The Netherlands) and 
peptides were eluted with the following binary gradient: 3% - 25% eluent B for 120 
min and 25% - 50% eluent B for a further 60 min, where eluent A consisted of 0.1% 
formic acid in ultrapure water and eluent B consisted of 80% acetonitrile and 0.08% 
formic acid in water. The column flow rate was set to 250 nL/min (oven temperature: 
40°C). For electro-spray ionization (ESI), metal-coated nano ESI emitters (New Objec-
tive, Woburn, MA, USA) were used and a spray voltage of 1.5 kV was applied. For MS/
MS analysis a data dependent acquisition method was used: a high resolution survey 
scan from 400 – 1800 m/z was performed in the Orbitrap (automatic gain control (AGC) 
106, resolution 30,000 at 400 m/z; lock mass set to 445.120025 m/z(14). Based on this 
survey scan the 5 most intense ions were consecutively isolated (AGC target set to 104 
ions) and fragmented by collision-activated dissociation (CAD) applying 35% normal-
ized collision energy in the linear ion trap. Precursor masses within a tolerance range of 
+/− 5 ppm that were selected once for MS/MS were excluded for MS/MS fragmentation 
for 3 minutes (dynamic exclusion).
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Protein identification and quantification
MS/MS spectra were extracted and converted into mgf files using extract_msn (part 
of Xcalibur version 2.0.7, Thermo Fisher Scientific Inc. Amsterdam, The Netherlands). 
Sequencing of the fragmentation spectra was conducted by a Mascot MS/MS database 
search (version 2.3.01, Matrix Science Inc., London, UK) against the human subset of the 
uniprot database (20,253 Homo sapiens entries; version: June 1st 2013). The following 
search parameters were applied: a maximum of two missed cleavages, tryptic cleavage, 
oxidation as a variable modification of methionine (+ 15.995 u) and carbamidomethyl-
ation as a fixed modification of cysteine (+ 57.021 u). Further peptide mass tolerance 
was set to 10 ppm and fragment mass tolerance to 0.5 u. To estimate the false dis-
covery rate (FDR), a decoy database search was conducted. Next, peptide and protein 
probabilities were determined by using Scaffold (version 3.6.3, Proteome Software Inc., 
Portland, OR) and finally the identification result was filtered by a protein and peptide 
threshold probabilities of minimal 95% and a protein ought to be identified by at least 
2 peptides. Peptide FDR was 0.2% and protein FDR was 3.4% (corresponds with 95% 
probability). LC-MS data were analyzed using the Progenesis LC-MS software package 
(11) (version 3.6, Nonlinear Dynamics Ltd, Newcastle - upon - Tyne, United Kingdom). 
Individual runs were aligned with each other in this software by at least 200 vectors 
using the automated alignment option to compensate for variations of retention times. 
Subsequently, peak picking and integration of peak areas were performed and peaks 
(features) with +2 and +8 and at least 2 isotopes were selected. Identification results 
(as described before) were imported and assigned to the corresponding peaks (2260 
peaks identified). Subsequently, the result data were exported in excel format and 
further normalized abundance (computed by Progenesis) used for further statistics.
Statistical analysis
The Wilcoxon test (unpaired, two tailed) was used to analyze the differences in the 
abundance of peptides between MScl, and monophasic ADS with p<0.01 being consid-
ered statistically significant. Relative quantitative differences of peptide abundances 
between MScl and monophasic ADS samples were calculated as log2 ratio between 
median abundances of both groups. A set of significantly distinct peptides and proteins 
was determined by applying following criteria: (a) peptides that had at least 1.5 fold 
difference in expression at a p-value < 0.01; (b) protein identified by at least 2 peptides, 
and (c) at least 40% differentially expressed peptides (p<0.01) per protein, whereby 
peptides of a given protein were required to have representation in the same direction 
(increased or decreased abundance in MScl). In the above dataset we also excluded 
those proteins that had only 1 peptide differentially identified out of total two.
To verify these findings and to determine the statistical background level, we 
performed a permutation analysis on the entire dataset (2260 peptides) between 
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MScl (n=18) and monophasic ADS (n=21) sample groups included with the above 
mentioned criteria. Whereby, we determined the statistical background level on a set 
of significantly distinct peptides. The random permutation test, on the dataset with 
randomized sample group assignment, was repeated 1000 times through which, the 
resulting thresholds were saved.
For all calculations and graphics, we used the R software package (R version 3.0.2, 
http://www.R-project.org) (15). For other calculations and graphics, SPSS 15.0 (SPSS, 
Chicago, IL, USA) and Microsoft Excel 2010 were used.
RESUltS
Patient characteristics
We have analyzed 18 MScl and 21 monophasic ADS patients. One MScl and one mono-
phasic ADS patients were excluded because of <200 required alignment vectors found 
during Progenesis LC-MS analysis. From 18 patients diagnosed with MScl, 5 had ON, 
2 had TM, 3 had clinical monofocal, and 8 had clinical polyfocal symptoms as their 
first symptoms of onset. From the remaining 21 patients with monophasic ADS, 2 had 
experienced ON, 2 had TM, 8 had clinical polyfocal and 9 had ADEM. No significant 
differences were observed between the two groups in terms of gender, CSF levels of 
total protein, albumin, albumin CSF/serum quotient, leukocyte and IgG concentration. 
The mean age at onset of children diagnosed with MScl (14.17 ± 1.5) was found to 
be significantly higher in comparison to monophasic ADS (6.89 ± 4.9), reflecting the 
epidemiology of these phenotypes. In addition, CSF elevated IgG index and positive 
oligoclonal bands (OCB) were more frequently present in children with MScl (p ≤ 0.01). 
Patient characteristics are given in table 1.
Identification of proteins that discriminates MScl from monophasic AdS
We have detected 50,119 peptide precursors from Progenesis label-free analysis LC-MS 
experiment from all trypsin digested protein in CSF samples. A Mascot database search 
in the human subset of the Uniprot database resulted into 2260 unique peptides that 
corresponded with 318 proteins. The total protein concentrations of digested peptide 
samples quantified (integrated UV area at 214 nm) during LC–MS measurements did 
not show any significant difference (p = 0.54) between CSF samples of children with 
MScl and monophasic ADS group. To check technical variability, at regular interval we 
measured 12 reference samples (pooled CSF samples from all patients). Here, also 
the total protein concentrations of digested peptide samples quantified (integrated 
UV area at 214 nm) during LC – MS measurements between Reference group 1 (n=6) 
and 2 (n=6) did not show any difference (Reference group 1 (n=6) =382.94 ± 153.28; 
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versus Reference group 2 (n=6), 429.34± 661.90, p=0.3). In addition, a number of 
MS/MS fragmentation spectra also did not show any significant difference between 
samples of children with MScl and monophasic ADS. In particular, the measured MS/
MS fragmentation spectra for MScl, and monophasic ADS samples were 16796 ± SD 
1795 and 16971 ± 1153 (p=0.72) respectively. Moreover, the database identified MS/
MS spectra for MScl and monophasic ADS samples were 1607 ± 280 and 1626 ± 256 
(p=0.83) respectively.
Comparing abundance of identified peptides (n=2260) from CSF samples of children 
with MScl and monophasic ADS patients and using the stringent criteria as described in 
statistical analysis, we found a total of 88 differentially abundant peptides. Of these 88 
peptides, 53 were significantly increased (table 2) and 35 decreased in CSF samples of 
table 1. clinical characteristics and routine cSF findings of children with multiple sclerosis (at 
disease onset) and the monophasic acquired demyelinating syndrome. Data are presented as the 
mean ± SD or median and range of patients. In case of missing data, the number of patients with 
available data is indicated between parentheses.
Monophasic AdS (n=21) MScl (n=18) p-value2)
Mean ± Sd Median Range Mean ± Sd Median Range Monophasic 
AdS vs MS
Age at onset, 
years
6.89 ± 4.91
(n = 21)
5.81 1.14 - 17.11 14.17 ± 1.50
(n = 18)
14.29 11.14 - 16.21 p<0.01
Sex, % 
females
71.4 N/A N/A 61.1 N/A N/A N.S.
Protein g/l 0.36 ± 0.21
(n = 21)
0.3 0.18 - 1.15 0.33 ± 0.14
(n = 17)
0.32 0.19 - 0.75 N.S.
Albumin g/l 0.23 ± 0.20
(n = 11)
0.16 0.11 - 0.79 0.18 ± 0.07
(n = 14)
0.17 0.08 - 0.36 N.S.
leukocytes 
x10/6
37.12 ± 34.91
(n = 20)
28.5 1 - 118 20.98 ± 25.68
(n=17)
13 1.0-87 N.S.
Igg g/l 0.05 ± 0.07
(n = 11)
0.03 0.01 - 0.27 0.05 ± 0.03
(n = 13)
0.05 0.03 - 0.12 N.S.
Igg index 0.61 ± 0.10
(n = 12)
0.58 0.5 - 0.79 1.36 ± 0.72
(n = 17)
1 0.67 - 3 p<0.01
Elevated Igg 
index1), n (%)
2 (16.7) N/A N/A 16 (94.1) N/A N/A p<0.01
Positive OcB, 
n (%)
2 (12.5)
(n = 16)
N/A N/A 14 (87.5)
(n = 16)
N/A N/A p<0.01
Relapsing 
disease, n (%)
0 (0) N/A N/A 18 (100) N/A N/A p<0.01
1) IgG index considered elevated 0.68 or higher (6) 2) p value was calculated by Mann-Whitney test, 
and p<0.01 was considered significant.
Abbreviations used: AdS, monophasic acquired demyelinating syndrome; d, Days; MScl, multiple 
sclerosis; n/A, not applicable; n.S., not significant; OcB, oligoclonal bands.
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table 2. Identification of proteins differentially expressed in cSF of pediatric multiple sclerosis 
patients (n=18) as compared to monophasic acquired demyelinating syndrome (n=21). The table 
shows 21 proteins, from which 14 were identified with increased and 7 with decreased abundance 
in MScl. The table includes the direction of difference in MScl, name of the protein, p-value and 
fold expression difference. All proteins given in the table were identified with at least two unique 
peptides, differentially abundant peptides (p<0.01) had at least 1.5 fold difference in expression 
(median) between groups; For the same protein, 40 percent of identified peptides were differen-
tially expressed with the expression in the same direction (i.e. either higher or lower abundant in 
MScl) of the same protein.
trend 
in 
MScla)
description Sig./totalb) Fold change
Average
(Min-Max)c
p-valued)
Average (Min-Max)
In
cr
ea
se
d 
ab
un
da
nc
e 
in
 M
Sc
l
Amyloid-like protein 2 2/2 3.8 (2 - 5.5) 0.006 (0.003 - 0.008)
Neurofascin 3/3 2.5 (2.1 - 3) 0.002 (0.001 - 0.002)
Carboxypeptidase E 2/3 2.4 (2.1 - 2.6) 0.0004 (0.0002 - 0.0005)
Neuronal growth regulator 1 2/3 2.3 (2.1 - 2.5) 0.0008 (0.0008 - 0.0009)
Contactin-2 4/9 2.3 (1.5 - 3.2) 0.002 (0.0005 - 0.003)
Amyloid beta A4 protein 6/11 2.2 (1.8 - 2.6) 0.002 (0.00003 - 0.008)
Brevican core protein 5/7 2.1 (1.7 - 2.6) 0.002 (0.0001 - 0.005)
Disintegrin and metalloproteinase 
domain-containing protein 22
2/2 1.9 (1.7 - 2.1) 0.0004 (0.0001 - 0.0006)
Tyrosine-protein phosphatase non-
receptor type substrate 1
3/4 1.9 (1.5 - 2.1) 0.003 (0.001 - 0.006)
Dickkopf-related protein 3 6/11 1.8 (1.6 - 2) 0.002 (0.00004 - 0.006)
Neuronal cell adhesion molecule 9/18 1.8 (1.6 - 2.1) 0.004 (0.001 - 0.009)
Ig kappa chain V-III region POM 2/2 1.8 (1.7 - 1.8) 0.002 (0.0009 - 0.003)
Ig gamma-1 chain C region 5/11 1.7 (1.5 - 1.8) 0.0016 (0.0002 - 0.005)
Kallikrein-6 4/7 1.7 (1.5 - 1.9) 0.001 (0.0006 - 0.004)
d
ec
re
as
ed
 a
bu
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Apolipoprotein B-100 7/17 661 (3.5 - 3930) 0.0026 (0.00002 - 0.01)
C4b-binding protein alpha chain 2/4 8.1 (2.9 - 13.4) 0.008 (0.007 - 0.008)
Haptoglobin 18/29 3.7 (2 - 12.1) 0.002 (0.00004 - 0.01)
Haptoglobin-related protein 2/4 3.3 (3.1 - 3.5) 0.0002 (0.00001 - 0.0005)
Leucine-rich alpha-2-glycoprotein 2/3 2.6 (2.3 - 3) 0.008 (0.007 - 0.009)
Monocyte differentiation antigen 
CD14
3/3 1.9 (1.8 - 2) 0.006 (0.004 - 0.009)
Protein diaphanous homolog 1 2/2 1.8 (1.7 - 1.9) 0.005 (0.001 - 0.009)
a) Trend, Protein abundance is either significantly increased or decreased in MScl as compared to 
monophasic ADS.
b) Sig. Number of differentially identified peptides p<0.01 / Total, is the total number of identified 
peptides for same protein.
c) Fold change, i.e. fold expression difference calculated based on median abundance from 18 MScl 
and 21 ADS patients, Shown is average of fold difference for all peptides of the same protein. Mini-
mum and maximum range for the same is indicated.
d) p-value was calculated by Wilcoxon test. Given in the table is the average p-value and range for 
all differentially abundant peptides of the same protein.
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children with MScl (table 2)as compared with monophasic ADS. Peptides with increased 
abundance (n=53) in the MScl group corresponded with 14 proteins and peptides with 
decreased abundance (n=35) corresponded with 7 proteins. An inventory of these 21 
proteins is given in table 2. Moreover, fold expression difference between MScl and 
monophasic ADS groups groups and statistical significance are plotted simultaneously 
for our entire data set (n=2260 peptides) as a Volcano plot (figure 1). This permutation 
analysis resulted in 20 ± 41 (median 9) false positive peptide markers, which indicated 
that our observations are not due to chance alone, because more than 90% of the 
permutations yielded 0-4 significant hits i.e. in 900. Only 4 times out of 1000 more 
than 88 hits with low p-value were detected (FDR: 0.4%). Whereas, contrasting to this 
mere background chance, from the actual data set (true hits) 88 peptides were identi-
fied. Therefore, comparison of permutated data with the real data indicated that the 
occurrence of differentially abundant peptides related to MScl or monophasic ADS was 
highly significant (p<0.001).
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Volcano plot: p-value versus fold change
p-value =0.01
      
Peptides with increased
abundance in MScl group
Peptides with decreased
abundance in MScl group
Not significant (p>0.01)
Peptides have significant p-value <0.01  
and high fold difference
(a)
(b)
Figure 1. Volcano plot: p-value versus fold change. Peptides (n=2260) showing distribution of fold 
change and statistical significance. In plot each point represents a peptide, and shows the ratio 
between MScl (n=18) and monophasic ADS samples (n=21) plotted against the level of statistical 
significance. Y-axis shows p-values, obtained (plotted at log10) from a Wilcoxon test performed 
between abundances of peptides. X axis shows ratio of median between MScl and monophasic ADS 
(plotted on log 2).
(a) Above the dashed horizontal line, red points (n=53 peptides) were found with increased in abun-
dance (right side of the vertical line), green points (n=35 peptides) decreased in abundance (at left 
side of the vertical dashed line) in the MScl group (compared to monophasic ADS).
(b) Peptides shown in gray colour, below the dashed horizontal line did not pass stringent statistical 
criteria for identification of candidate peptide.
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Identified proteins with increased abundance (n=14) in MScl (table 2) were: amyloid-
like protein 2 (2/2, 2 significant peptides for a total of 2 peptides), neurofascin (3/3), 
carboxypeptidase E (2/3), neuronal growth regulator 1 (2/3), contactin-2 (4/9), amyloid 
beta A4 (6/11), brevican core protein (5/7), disintegrin and metalloproteinase domain-
containing protein 22 (2/2), tyrosine-protein phosphatase non-receptor type substrate 
1 (3/4), dickkopf-related protein 3 (6/11), neuronal cell adhesion molecule (9/18), 
Ig kappa chain V-III region (2/2), Ig gamma-1 chain C region (5/11) and kallikrein-6 
(4/7). Proteins identified with decreased abundance in MScl (n=7) were: apolipoprotein 
B-100 (7/17), c4b-binding protein alpha chain (2/4), haptoglobin (18/29), haptoglobin-
related protein (2/4), leucine-rich alpha-2-glycoprotein (2/3), monocyte differentiation 
antigen CD14 (3/3), and protein diaphanous homolog 1 (2/2). The function of these 14 
proteins and overlap with previous studies are summarized in table 3. Among the 14 
proteins with increased abundance in the MScl, 12 were associated with CNS structure 
and functions (86%), especially to the grey matter (table 3), compared to 17% of the 
total identified proteins related to CNS structure and functions. Seven proteins identi-
fied with decreased abundance in the MScl (relative to monophasic ADS group) were 
components of the innate immune system and inflammation (table 3B).
Proteins identified in the current study did not exhibit any myelin related proteins, 
for instance; myelin oligodendrocyte glycoprotein and myelin basic protein.
We examined for the influence of age of onset on the 88 candidate peptides abun-
dances for children with MScl and monophasic ADS by correlation analysis. We found a 
mean coefficient of determination (± SD) for MScl 0.04 ± 0.06, and for monophasic ADS 
0.05 ± 0.05. Thus, by correlation analysis no significant correlation was found between 
age and peptide abundance for children with MScl and monophasic ADS for all 88 
peptides.
dIScUSSIOn
In the current study, we have used LC-MS proteomic approach to search for differences 
in CSF proteome between children with MScl and monophasic ADS in children. Benefit 
of this Orbitrap technique is the possibility to identify relatively vast amounts of dif-
ferent peptides and at the same assess their abundances, in a small sample volume. 
We observed a striking difference between the two groups, using stringent statistical 
criteria. We searched for the known functions of the 88 peptides corresponding to 21 
distinctive proteins (14 proteins increased and 7 decreased in abundance in MScl), mak-
ing use of available/biological databases (www.geneontology.org and www.nextprot.
org) and the literature. Among the 14 proteins with increased abundance in MScl, 12 
were associated with CNS structure and functions, especially to the gray matter. Three 
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table 3. table summarizes function of differentially abundant markers and overlap with previous 
studies. Most of the proteins were assigned as either neuronal or immune related molecules based 
on previous reports and database searches. First column shows name of the protein and Uniprot 
accession number (given in the bracket, it denotes protein ID). Second column shows function of 
proteins. Third column shows comparison with a previous study on children MScl (Dhaunchak and 
colleagues) using ADS-MScl (n=8, mean age 12 yrs.) vs. monophasic ADS (n=11, age 10 yrs.). The 
fourth column shows overlap with the work of Schutzer and colleagues, they used CIS-MScl n=9, age 
18-42 yrs. and established MScl & controls (n=6, 31-54 yrs.)
3A. Function of proteins identified with increased abundance in MScl
differential proteins
(Accession number)
Functions and expressions dhaunchak et 
al. (8)
Schutzer et al. (9)
Amyloid-like protein 
2 (Q06481)
Relative of amyloid precursor protein 
family, memory processes(36), 
concentrated in synapses(37), regulates 
neuronal stem cell differentiation during 
cortical development(38)
× ** Variant
neurofascin 
(O94856)
Cell adhesion, synapse formation(39), 
located at CNS paranodal domain and 
expressed by oligodendrocytes, target for 
autoantibody-mediated axonal injury in 
MScl (21)
No sig. diff. ×
contactin-2 (Q02246) Axon connection, majorly expressed on 
CNS juxta-paranodal domain
No sig. diff. ***
Amyloid beta A4 
protein (P05067)
Component of amyloid plaques (Alzheimer 
brains), neurite growth, neuronal adhesion 
and axonogenesis
× ×
Brevican core protein 
(Q96gw7)
Major proteoglycan in perisynaptic 
extracellular matrix of brain(40), inhibit 
neurite outgrowth from cerebellar granule 
neurons(24)
No sig. diff. Decreased in 
first-attack CIS-
MScl relative to 
established RR-
MScl and controls
carboxypeptidase E 
(P16870)
Found in brain and throughout 
neuroendocrine system, synthesis of most 
neuropeptide(41)
Same trend (4 
sig./21 total, 
p=0.004)
×
neuronal growth 
regulator 1 (Q7z3B1)
Trans-neural growth-promoting factor, 
promotes outgrowth and expressed on 
reactive astrocytes after entorhinal cortex 
lesion (in mice)(42)
No sig. diff. ×
tyrosine-protein 
phosphatase 
non-receptor type 
substrate 1 (P78324)
Supports adhesion of cerebellar 
neurons, neurite outgrowth and glial cell 
attachment(29)
× ×
neuronal cell 
adhesion molecule 
(Q92823)
Paranodal region of CNS, axo-glial 
contact(43)
No sig. diff. **
disintegrin and 
metalloproteinase 
domain-containing 
protein 22 (Q9P0k1)
Expressed in the juxta-paranodal complex 
(43).
Not same trend 
(2 sig./10; 
p=0.01, 0.02)
×
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3A. Function of proteins identified with increased abundance in MScl (continued)
differential proteins
(Accession number)
Functions and expressions dhaunchak et 
al. (8)
Schutzer et al. (9)
dickkopf-related 
protein 3 (Q9UBP4)
Highly expressed in the brain and spinal 
cord, influences synapse formation(9),
× **
kallikrein-6 
(Q92876)
Brain-related serine protease, elevated 
in active MScl, regulate early CNS 
demyelination in a viral (mouse) model of 
MScl (27).
× **
Ig gamma-1 chain c 
region (P01857)
Immune response, elevated in adult MScl 
and CIS as compared to non-inflammatory 
neurological diseases(16)
× ×
Ig kappa chain V-III 
region POM (P01624)
Immune response, elevated in adult MScl 
as compared to non-inflammatory and 
inflammatory neurological diseases(16)
× ×
3 B. Function of proteins identified with decreased abundance in MScl
differential proteins Functions dhaunchak 
et al (8)
Schutzer et 
al. (9)
Apolipoprotein B-100 
(P04114)
Innate immune related, not produced in CNS(44), 
observed in CSF and can cross a dysfunctional 
blood-CSF barrier(44)
× ×
c4b-binding protein 
alpha chain (P04003)
Innate immune defense, involved in complement 
activity(45)
× ×
Haptoglobin (P00738) Innate immune defense(30) × ×
Haptoglobin-related 
protein (P00739)
Innate immune defense(46) × ×
leucine-rich alpha-2-
glycoprotein (P02750)
Induced by inflammation, cell adhesion, high 
expression in the deep cerebral cortex(26), novel 
marker of granulocytic differentiation (30))
× ×
Monocyte 
differentiation antigen 
cd14 (P08571)
Main modulator of innate immune system(32) × ×
Protein diaphanous 
homolog 1 (O60610)
Coordinates cellular dynamics by regulating 
microfilament and microtubule function(34), role 
in cell–matrix adhesions, variant related to innate 
immune function (35)
× ×
Abbreviations and definitions: ×, Protein was not identified; **, Increased expression in first-attack 
CIS MScl group compared to established RR-MScl and controls; ** Variant, Variant of same protein 
was found with increased expression in first-attack CIS MScl group compared to established RR-
MScl and controls; ***, Protein was found with increased expression in first attack CIS-MScl relative 
to RR-MScl but decreased in first attack CIS-MScl vs. controls; ****, Decreased expression in first-
attack CIS-MScl vs. established RR-MScl and controls; no sig. diff., Protein was identified in pediatric 
CSF samples but there was no statistical difference in abundance was found between MScl and 
monophasic ADS group comparison; Same trend, when protein abundance was compared between 
two group (for ex MScl and monophasic ADS), expression (either increased or decreased in MScl) 
of identified protein showed overlap with our study; not same trend, When abundance of protein 
was compared they did not show expression in the same direction (either increased or decreased 
expression in MScl) relative to our study.
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of these 12 proteins were CNS related proteases, and other two proteins were related 
to immune functions. The functions of these 14 proteins are summarized in table 3 A. 
Seven proteins identified with decreased abundance in MScl relative to monophasic 
ADS were components of the innate immune system and inflammation (see table 3 B). 
Thus, in the MScl group, there was a clear over-representation of neuronal and axoglial 
proteins (table 3 A). Whereas in the monophasic ADS group, proteins associated with 
innate immunity were over-represented (table 3 B).
Recently, two research group demonstrated the identification of axoglial and grey 
matter proteins using mass spectrometry in CSF of MScl patients (8, 9). Similar to our 
study, Dhaunchak and his colleges compared CSF of 8 pediatric MScl patients with 11 
monophasic ADS (8). The overlap of some proteins in the MScl group is noticeable (e.g. 
carboxypeptidase E), despite clear differences in sample handling such as depletion of 
abundant proteins with possible carrier function for other proteins, and exclusion of 
proteins with less than 5 kDa weight.
Our results show also overlap with molecules identified in the CSF of adult acute 
onset MScl cases, Schutzer and colleagues performed the mass spectrometry analysis 
in the CSF on CIS cases versus established relapsing remitting MScl (RR-MScl) and 
controls(9). They showed proteins that distinguished these CIS patients from both 
established RR-MScl and controls. For example, they showed significant increase of 
kallikrein 6, dickkopf-3 in first attack MScl in comparison to established RR-MScl and 
Controls. They also showed a significant increase in contactin-2 (neuronal membrane 
protein) in first-attack MScl patients relative to established RR-MScl whereas decrease 
in CIS compared to controls (9) (table 3 B).
Our findings stipulate the neurodegenerative arm of MScl neuropathology, also in 
children, and already present at the earliest stage of clinical disease. In analogy with 
the findings of others (8, 9) and ourselves in previous studies (16-19) we also observed 
a striking lack of myelin proteins in these clear-cut cases of acute demyelination. 
We assume this may not directly imply absence of such free proteins in this type of 
pathology, but rather it may reflect the specific physicochemical properties of the 
hydrophobic myelin components, and perhaps different pathways of elimination from 
the CSF, e.g. via draining macrophages (20). In any case we have to be cautious in using 
the dominant presence of gray matter over white matter proteins as suggestive proof 
that neurodegeneration is a primary event in MScl, and would precede demyelination.
The presence of CNS grey matter may simply represent damage by inflammation, 
and the molecules identified may provide leads to a better understanding of this 
presumed inflammation induced neurodegeneration. It should be stressed that not all 
differential proteins were over-represented in MScl. Some were under-represented, 
pointing at more complex mechanisms such as a perturbation in the physiology of the 
axoglial apparatus (8).
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A disturbing factor in our study could be the fact that, due to the skewed occurrence 
of monophasic disease at younger age, both groups were not matched according to 
age. We doubt however whether this has influenced the results, as we did not see an 
age effect in any of the two groups (MScl and monophasic ADS) on abundance of the 
21 identified proteins.
From the 21 proteins identified here, 14 showed increased abundance in MScl, and 
their known functional roles are summarized in table 3 A. Two proteins were associ-
ated with the amyloid beta A4 protein family. Amyloid-like protein 2 is concentrated 
at neuronal synapses and has a role in memory processes. Amyloid beta A4 protein is 
associated with neurite growth, neuronal adhesion and axonogenesis.
Four (of 21) proteins: contactin-2, neurofascin, neuronal growth regulator 1 and 
brevican core protein were shown to be located at the paranodal, juxta-paranodal 
region of the CNS of myelinated axons in the CNS. Myelinated axon can be divided into 
axon initial segments, nodes, paranodes, juxtaparanodes (begins at the innermost axo-
glia junction of paranode) and internodes. Contactin-2 is axonal glycoprotein which 
is shown at juxta-paranode domain of myelinated axons (9). Neurofascin plays a role 
in the assembly of nodes of Ranvier in the CNS (21). Two isoforms of neurofascin are 
shown to interact with contactin-associated protein and contactin-1 to form paranodal 
junction that attaches the myelin loop to the axon; and helps to separate voltage gated 
sodium channel at node and potassium channel at juxtparanode region (22). Disruption 
of neurofascin localization shows early changes preceding demyelination and remy-
elination in MScl (23). Interestingly, contactin-2 and neurofascin have are autoimmune 
targets in MScl (22). Neuronal growth regulator 1 is shown to be located at paranodal 
region of CNS and play a role in axo-glia contact at the node of Ranvier. Identification of 
contactin-2 and neurofascin in CSF of children with MScl is consistent with a previous 
study (8) however, they did not find significant difference in CSF of children with MScl 
and monophasic ADS (table 2 and 3). Among the 4, brevican core protein is known as 
CNS specific proteoglycan at the surface of neuroglial sheaths, where it is enriched in 
perisynaptic extracellular matrix (24).
Among the proteins with increased abundance in MScl (of 14), the proteases/pep-
tidases protein named as, carboxypeptidase E plays a role in synthesis of most neuro-
peptides (25). Next, disintegrin and metalloproteinase domain-containing protein 22 
are highly expressed in brain and localized at juxta-paranode. This molecule presumed 
to be work as a major neuronal receptor (26). An other brain related protease was 
kallikrein-6, which is a secreted serine protease, and it is described to regulate early 
CNS demyelination in a viral model (expression in the brain and spinal cord of mice) 
of MScl (27). Additionally CSF kallikrein-6 elevated level is reported in MScl (adults) as 
compared to neurological controls (28) (table 3A).
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Among other proteins with increased abundance in MScl (of 14), tyrosine-protein 
phosphatase non-receptor type substrate 1, is implicated in the neurite outgrowth and 
glia-cell attachment and shown to support adhesions of cerebellar neurons (29). Next 
the highest expression of dickkopf related protein 3 is reported in the brain and spinal 
cord (table 3A). Thus the majority of proteins with increased abundance in our MScl 
group (compared to monophasic ADS) were neuronal related with the exception of two 
immune function related proteins Ig gamma-1 chain C region and Ig kappa chain V-III 
region POM (table 3 A).
Our study reports seven proteins with decreased abundance in pediatric onset-MScl 
as compared to the monophasic ADS (table 2) group. Six of these seven proteins have 
previously been reported as specific component of innate immune functions (table 3 
B). Haptoglobin an acute phase protein (30) was identified as most distinctive one 
(18/29, 18 significant peptides for a total of 29 peptides) from those which were 
elevated in monophasic ADS group (compared to children with MScl). Another study 
in adults showed increased haptoglobin concentration in NMO comparison to adult 
MScl patients (31). C4b-binding protein alpha chain which is a crucial component 
of complement cascade inhibits function of complement component. Interestingly, 
we also found monocyte differentiation antigen CD14, which is shown to be mainly 
expressed on cells of monocytic lineage (macrophages and monocytes) (32). Higher 
CD14 levels might be linked with increased levels of cytokines triggering inflammatory 
processes in ADS children. Monocytic cells secrets soluble sCD14 (activation product 
of activated monocytes) so this may affect the enormous macrophase activation during 
acute monophasic ADS (33).
Among seven identified proteins protein diaphanous homolog is a member of the 
formin family (34), it is expressed in brain and, their variants are shown to be required 
for innate immune response to gram-negative bacterial Infection (35).
Overall in MScl group we found a significant over-representation of proteins associ-
ated with changes in CNS gray matter, axons, synaptic regulation, node of Ranvier and 
brain protease (table 3 A). Several of these proteins are part the axoglial apparatus 
and may relate to disturbances in axo-glia interaction (8) (table 3 A). Two of them 
(contactin-2 and neurofascin) have been identified as possible axo-glial auto-antigens 
in MScl (22).
The overlap of proteins observed in previous studies (8,9) (table 3 A) as part of the 
axo-glia apparatus, and grey matter provides validation for these proteins. Further 
insight into the role of these proteins in early-onset MScl can be useful for disease 
process understanding and might be useful as a future tool to differentiate MScl from 
monophasic ADS in children. These pathologically relevant proteins (mostly CNS grey 
matter related), elevated in CSF of early-onset MScl in children might be involved in 
early disease mechanisms. Further insight into the role of these proteins can be useful 
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for disease process understanding. Moreover, such proteins might be useful as a future 
tool to differentiate children MScl from children with monophasic ADS. In addition, 
knowing the start of MScl could immediate an earlier treatment with disease modify-
ing therapies. However, the current research is designated as discovery phase study, 
which serves as a base for the follow-up on verification and validation phase studies 
which can provide in clinically valuable biomarkers. In future, it would be interesting to 
further validate our findings with an independent technology more importantly in an 
independent sample group.
In conclusion our data indicate that monophasic ADS can be differentiated from 
MScl in children primarily by CNS grey matter proteins and immune related proteins. 
Our findings point to perturbed axoglial physiology as a hallmark of the earliest events 
of MScl pathogenesis.
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ABStRAct
B lymphocytes play a pivotal role in multiple sclerosis pathology, possibly via both an-
tibody dependent and independent pathways. Intrathecal immunoglobulin G produc-
tion in multiple sclerosis is produced by clonally expanded B cell populations. Recent 
studies indicate that the complementarity determining regions of immunoglobulins 
specific for certain antigens are frequently shared between different individuals. In 
this study, our main objective was to identify specific proteomic profiles of mutated 
complementarity determining regions of immunoglobulin G present in multiple scle-
rosis patients but absent in healthy controls. To achieve the above objective, from 
cerebrospinal fluid of 29 multiple sclerosis patients and 30 healthy controls we 
purified immunoglobulin G and separated the corresponding heavy and light chains 
by SDS - PAGE. Subsequently, bands were excised, trypsinized and measured with 
high - resolution mass spectrometry. We sequenced 841 heavy and 771 light chain 
variable region peptides. We observed 24 heavy and 26 light chain complementarity 
determining regions that were solely present in a number of multiple sclerosis indi-
viduals. Using stringent criteria for the identification of common peptides, we found 
five complementarity determining regions shared in three or more patients and not in 
controls. Interestingly, one complementarity determining region with a single mutation 
was found to be in common in six patients. Additionally, one other patient carrying a 
similar complementarity determining region with another mutation was observed. In 
addition, we found a skew in kappa to lambda ratio and in the usage of certain variable 
heavy region which was previously being observed at the transcriptome level. At the 
protein level, cerebrospinal fluid immunoglobulin G share common characteristics in 
the antigen binding region between different multiple sclerosis patients. The indica-
tion of a shared fingerprint may indicate common antigens for B cell activation.
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IntROdUctIOn
Autoimmune mechanisms play a central role in the pathogenesis of multiple sclerosis 
(MScl). Recent trials indicate that B - lymphocyte depletion therapy can substantially 
reduce disease activity in relapsing remitting (RR) MScl patients (1). Clinical amelio-
ration after depletion seems to precede reduction in autoantibody levels, possibly 
because this treatment rapidly affects the antigen-presenting cell functions of B cells 
(2). This finding has boosted interest in studies on the pathogenic role of auto - reac-
tive B - cells. Despite the success of inhibiting antibody - independent functions of B 
cells, arguments remain for an additional chronic pathogenic role for auto - antibodies 
within the central nervous system (CNS). This includes: a) the presence of antibodies in 
cerebrospinal fluid (CSF) and brain tissue (3); b) depositions of antibody within areas of 
demyelination along with local complement activation (3); c) myelin oligodendrocyte 
glycoprotein (MOG) specific antibodies in some subpopulations of MScl patients (4, 5). 
Additionally, KIR 4.1 was recently identified as a target of autoantibody response in 
subgroup of person with MScl (6).
It has been shown that the distribution of genes used to generate antibodies in B 
cells from CSF and lesions of MScl patients are skewed from naturally expected distri-
butions. Several groups described clonal B cell populations within the CNS, sometimes 
even skewed to certain families of variable heavy (VH) regions (7, 8). No common 
motifs have yet been found to be shared between different MScl patients. This would 
be in line with classical immunological insight that suggests that it is extremely rare 
to find common sequences in the immunoglobulin G (Ig) variable regions amongst dif-
ferent individuals. However, this view has recently been challenged (9-11). Both after 
vaccination and in paraneoplastic syndromes like anti - Hu, strikingly identical shared 
complementary determining region (CDR) motifs between patients were observed 
(12). Of note is also a surprising study in which it was observed that malignant chronic 
lymphocytic leukemia B cells in different patients all recognized a single fungal antigen 
and showed shared use of CDR3 sequences between different individuals (13).
A novel approach to study Ig gene usage in biofluids of MScl is the use of proteomic 
sequencing. Obermeier and colleagues described overlap between Ig B cell (CSF) 
transcriptomes and proteomes in four individual MScl cases, without inter - individual 
overlapping sequences (14). However, this elegant proof of principle study was limited 
to four MScl patients and there was no comparison between patients and controls. The 
possibility to sequence CSF Ig at the protein level (10, 14, 15) may bring along some 
advantages. The genetic approaches used so far share the benefit that complete se-
quences can be identified at a single cell level, still Ig derived from such clones do not 
necessarily represent the actual Ig repertoire found in CSF. Furthermore, where genomic 
studies are restricted to CSF cells, humoral CSF studies also include Ig proteins from 
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other anatomical brain areas, such as parenchyma, meninges and Virchow Robin spaces. 
Finding common characteristics of the antigen binding sites of Ig between patients may 
provide leads into the question whether common antigenic stimuli are responsible for 
recruitment of intrathecal B cells in MScl. We previously described a new approach by 
using advanced nano - scale liquid chromatography coupled online to a high resolution 
mass spectrometer (LC - MS) (10, 16, 17), a reliable and powerful method for sensitive 
detection of CDR peptides (18). Moreover it can also be used to compare CDR peptide 
profiles between a relatively large number of patients and controls.
Our main question was if we could detect specific proteomic profiles of CDR present 
in MScl patients, but absent in controls. Here, we report a number of common CDR 
sequences in Ig of a group of MScl patients that were not observed in healthy controls. 
In addition we showed disturbed kappa (κ)/lambda (λ) chain ratios in CSF Ig of MScl 
patients and VH family usage in patients compared to controls.
MAtERIAlS And MEtHOdS
clinical Samples: MScl patients and non - neurological controls
CSF samples were collected from untreated MScl patients, which were selected by 
an experienced neurologist (RQH) and were followed prospectively by the Rotterdam 
Multiple Sclerosis Center ErasMS at the Department of Neurology at the Erasmus Medi-
cal Center (Rotterdam, the Netherlands). The procedure for CSF sample collection was 
as described previously (19). All MScl patients had defined relapsing remitting MScl 
or a clinically isolated syndrome according to the 2005 McDonald criteria for MScl 
(20). The control individuals were free of any neurological disorders. They underwent 
minor, non - neurologically indicated, surgeries. CSF was taken prior to the administra-
tion of sedatives as part of the anaesthesia procedure. Therefore this group is further 
referred to as healthy controls. Immediately after collection, the CSF samples were 
centrifuged (10 minute at 3000 rpm) to discard cells and cellular elements, and the 
supernatant was aliquoted and stored at −80°C, until further use for this study. Blood 
contaminated CSF samples were excluded based on the presence of erythrocytes 
detected by microscopic examination immediately after sampling. One aliquot of a 
sample was used for routine CSF diagnostics in the Clinical Chemistry department of 
Erasmus MC. This diagnostic procedure for the MScl patients included quantification 
of total protein, albumin, assessment of the number of Oligoclonal bands (OBs), and Ig 
index. Moreover, these samples taken from another aliquot were previously studied to 
determine intra - individual variations in CSF protein abundances (Stoop et al., 2010). 
This study was approved by the institutional ethical committee of the Erasmus MC and 
written informed consent was obtained from all participants.
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Ig Quantification Assay
An ELISA assay using 96 well plates (Immuno 96 Micro Well TM Solid Plate, Thermo 
Fisher, Bremen, Germany) was used to determine Ig concentrations in CSF samples. 
In this assay affiniPure F(ab’)2 Fragment Goat Anti-Human IgG (H+L) (Jackson Immu-
noResearch laboratories, Suffolk, United Kingdom) at a concentration of 1.3 mg / ml, 
was used to coat the wells as a capture antibody. As a detection antibody, horse radish 
peroxidase conjugated polyclonal secondary antibody, antihuman Fc Goat (Anti human 
IgG HRP Sigma-Aldrich, Saint Louis, MO) was used. Samples were incubated with anti-
bodies for five minutes and gently shaken (400rpm) at 4°C on a thermo-cycler shaker 
(Eppendorf). 3,3′,5,5′,- tetramethylbenzidine (TMB, Sigma-Aldrich, Saint Louis, MO) 
(100µL per well) was used as a substrate for horseradish peroxidase that developed 
a soluble blue reaction product. Reaction was stopped with 100µL 1M hydrochloric 
acid. Ig concentration was determined photometrically by absorbance at 450nm and 
quantified using an eight point’s calibration curve ranging from 1.0×10−5 to 0.5 µg/µl.
Ig Purification
Ig was purified from CSF samples by Melon Gel IgG Spin Purification kit (Pierce, Rock-
ford, IL) according to the manufacturers’ protocol for serum with slight modifications. 
All CSF samples were diluted at a ratio of one to three with purification buffer. We used 
100 µL CSF from patients and 200 µl from controls based on the Ig concentration assay 
(two times more CSF volume for controls were used in comparison to the patients to 
normalize for Ig concentration). Subsequently, the diluted CSF was added to a spin col-
umn containing Melon Gel resin. After 15 minutes of incubation, the spin column was 
centrifuged at 5000 g and the flow through was collected that contained the purified 
Ig. Ig concentrations were determined in the flow through fractions after purification 
(with above described Ig ELISA). Equal amount of Ig across all patients and controls 
were then taken and subsequently lyophilized (Sublimator 400, Zirbus Technology, 
Tiel, the Netherlands) for six hours. The lyophilized Ig fractions were then stored at 
−20°C for one day before proceeding to separation by SDS - PAGE.
For SDS - PAGE separation loading buffer was added to each lyophilized sample and 
heated at 90°C for 10 minutes. Purified Ig antibodies were resolved into heavy (IgH) 
and light chain (IgL) by reducing one - dimensional SDS - PAGE using Bio - Rad Mini - 
Protean electrophoresis system gels (10% polyacrylamide gels of 0.75 mm thickness). 
The gels were stained with Novex® Colloidal Blue Staining (Invitrogen, Carlsbad, CA) 
according to the manufacturers’ instructions. Overnight destaining was performed for 
visualization of IgH and IgL chain protein bands and subsequently gels were scanned.
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In - gel trypsin digestion
We excised gel bands manually in a laminar flow cabinet as a preventive measure 
to minimize environmental keratin and other contaminating protein - like materials. 
Protein bands were cut into plugs and transferred into Eppendorf tubes. We performed 
reduction by dithiothreitol and alkylation with iodoacetamide. Subsequently in-gel 
digestion was performed overnight at 37°C and further peptide extraction procedures 
were performed (18). After peptide extraction, samples were dried for three hours in a 
vacuum centrifuge (SPD 1010, Thermo Savant, Holbrook, NY), and afterwards stored at 
−80°C until LC - MS measurements.
chromatography Separation and Mass spectrometric Measurement
Before LC - MS measurements, the dried peptide samples were dissolved in 40 µL of 
an aqueous solution of 0.1% TFA and sonified. The samples were measured with a 
nano LC system (Ultimate 3000, Thermo Fisher Scientific, Amsterdam, the Netherlands) 
coupled on - line to a hybrid linear ion trap/Orbitrap mass spectrometer (LTQ-Orbitrap-
XL, Thermo Fisher Scientific, Bremen, Germany).
Samples were loaded onto a trap column (PepMap C18, 300 µm ID x 5 mm length, 
5 µm particle size, 100 Å pore size; Thermo Fisher Scientific) and washed and desalted 
for 10 minutes using 0.1% TFA (in water) as loading solvent. Then the trap column was 
switched online with the analytical column (PepMap C18, 75 µm ID x 250 mm, 3 µm 
particle and 100 Å pore size; Thermo Fisher Scientific) and peptides were eluted with 
the following binary gradient: starting with 100 % solvent A, then from 0 % to 25 % 
solvent B in 60 min and from 25 % to 50% solvent B in further 30 min, where solvent 
A consisted of 2% acetonitrile and 0.1% formic acid in HPLC grade water, and solvent 
B consisted of 80 % acetonitrile and 0.08% formic acid in HPLC grade water. All LC 
solvents were purchased from Biosolve, Valkenswaard, the Netherlands. Column flow 
rate was set to 300 nL/min, and eluting peptides were measured first by a UV detector 
(at a wavelength of 214 nm in a 3 nL nano flow cell; Thermo Fisher Scientific) and 
consecutively introduced into the MS. For electro - spray ionization (ESI), metal - coated 
nano ESI emitters (New Objective, Woburn, MA, USA) were used and a spray voltage 
of 1.5 kV was applied. For MS detection, a data - dependent acquisition method was 
used: high-resolution survey scan from 400–1800 Th. was detected in the Orbitrap 
(target of automatic gain control=106, resolution=30,000 at 400 m/z, lock mass set to 
445.120025 Th. (protonated [Si (CH3)2O]6 (21)).
On the basis of this full scan the five most intensive ions were consecutively isolated 
(AGC target set to 104 ions) and fragmented by collision activated dissociation (CAD, ap-
plying 35 % normalized collision energy), and detected in the ion trap. Precursor masses 
within a tolerance range of +/− 5 ppm that were selected once for MS/MS were excluded 
for MS/MS fragmentation for three minutes or until the precursor intensity fell below a 
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S/N of 1.5 for more than 5 scans. Samples were prepared and measured in a randomized 
order. Internal quality control sample was measured once in every five measurements. 
Before each run, a blank run was performed to monitor background of the system.
dAtA AnAlySIS And PEPtIdE IdEntIFIcAtIOn
Peptide identification by Mass and Fragmentation
Acquired LC - MS profiles for the separate purified IgH chain and the IgL chain datasets 
were analyzed separately using the Progenesis LC - MS software package (version 2.6, 
Nonlinear Dynamics Ltd, Newcastle - upon - Tyne, United Kingdom). In this software 
package individual runs were aligned with each other to compensate for variations 
of retention times (samples which could not be aligned by at least 200 vectors using 
the automated alignment option were excluded for further analysis as recommended 
by the manufacturer). Before peak - selection, integration of the area of the peaks was 
performed. The resulting peaks could then be associated with the amino acid sequence 
information if corresponding fragmentation spectra were available. From raw data files, 
MS/MS spectra were extracted and converted into mgf files using extract_msn (part 
of Xcalibur version 2.0.7, Thermo Fisher Scientific Inc.). Sequencing of the fragmen-
tation spectra was conducted by a Mascot MS/MS database search (version 2.3.01, 
Matrix Science Inc., London, UK) against the human subset of the NCBInr sequence 
database (National Center for Biotechnology Information database for non - redundant 
sequences; version 15th August 2010, Homo sapiens taxonomy; 232854 sequences). 
The following settings were used for the database search: a maximum of two missed 
cleavages, tryptic cleavage, oxidation as a variable modification of methionine (+ 
15.995 u) and carbamidomethylation as a fixed modification of cysteine (+ 57.021 
u). Further peptide mass tolerance was set to 10 ppm and fragment mass tolerance to 
0.5 Da. For peptide identification minimum ion score of 25 was required. The resulting 
peptide identifications were filtered using Scaffold (version 3.2.0, Proteome Software 
Inc., Portland, OR). Peptide false discovery rates (FDRs) were calculated by Scaffold on 
the basis of FDR= (false positive)/(false positive + true positives)). On average FDRs 
was determined always lower then 0.1%. Filter criteria for the generated identification 
result table were set to greater than 95 % peptide probability (and greater than 95 % 
protein probability. At this stage all non - Ig proteins (examples: albumin, transferrin, 
keratin etc.) were filtered out on basis of their protein names to focus solely on the 
Ig proteins. Subsequently, the identified peptides and proteins were imported into 
the Progenesis software package and linked to their corresponding peptide peak. The 
Progenesis analysis matrix contained mass, charge, intensity, abundance and MS/MS 
fragmentation spectra of detected peptides.
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The abundance listed for all peaks can be defined as background or signal. To re-
move background from real peak signals we used the following procedure: First around 
30 randomly chosen peaks in all samples with low intensity region were reviewed in 
regards of their isotopic pattern. Peaks with more than two isotopes were classified as 
valid peaks, and peaks with no isotope or just one or two isotopes were classified as 
background. We performed manual checks on all peptides of interest to confirm back-
ground level and the detection of exact location and overlap of peaks among samples 
in the above mentioned Progenesis software package. The specific aim of this work was 
to find CDR peptide fragments which were present in common in MScl patients and not 
in the control group. Therefore we filtered the datasets for candidates that were found 
in at least three MScl patients and were absent in control patients.
Manual confirmation of Peptide Identifications
For further confirmation of identification of peptides as depicted above, we assessed 
the MS / MS fragmentation spectra. If an identical peptide was shared among patients, 
for each individual sample one should expect similar spectral patterns (in terms of 
mass fragmentation and retention time window) to be present in different samples. 
Additionally, we evaluated the isotopic patterns in the mass spectrometry spectra 
in terms of number and appearance of isotopes. Using the method described above, 
those marker peptides that did not pass our filter were not qualified as marker.
cdRs Identification (assigning location in Ig structure)
All identified amino acid sequence were aligned to a variable (V), Diverse (D), Joining 
(J), constant (C) – region Ig germ line sequences of human (Homo sapiens) derived 
from the IMGT database (ImMunoGeneTics information system® http://www.imgt.org; 
Montpellier, France (22). As described previously (16, 17, 23), we used the BLASTp 
search algorithm (BLASTp algorithm; NCBI Blast version 2.2.22) to align the identified 
peptide sequences to the corresponding Ig.
All peptide alignments with bit scores greater than 12.5 were selected for further 
analysis. Peptides aligned to the variable domain germ line were further submitted 
to the IMGT/domain gap alignment tool (http://www.imgt.org), which positions the 
peptide to the germ line sequence in the IMGT unique numbering residue system. The 
alignment with the most homologous germ line allele was provided by the IMGT tool 
and included in the data if the identity score was at least 70%. By this approach we 
were able to locate a peptide to CDRs or frame work region. A CDR peptide was defined 
as a peptide containing minimum three amino acids in the CDR part, irrespective of 
framework length. Moreover, the methodology overview is described in the form of 
flow chart (figure 1).
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Statistical Analysis
We determined a set of CDR peptides that were exclusively present in at least three 
MScl samples but not in any control samples (true result). To determine the probabil-
ity that this finding is not due to chance alone, we performed permutation tests. We 
permutated (randomized) the sample group assignment (patient or control group) and 
rerun the determination of exclusively present CDR peptides 5000 times (false hits). 
Relative frequency of occurrence of exclusive CDR peptides in a randomized sample 
set was calculated by dividing the false hits exceeding the true result by the numbers 
of randomization trials. For these computations we used the statistics package R (R 
version 2.15.2, www.r-project.org). Other statistical analysis of data and graphical 
presentations were performed using GraphPad Prism (GraphPad Software version 5.00, 
www.graphpad.com) or by Excel 2010 function.
RESUltS
In total 59 samples were included for analysis of the IgH comparison set (n = 29 MScl 
versus n = 30 controls). IgL comparison set included 55 samples (n = 29 MScl versus 
n = 26 controls). Four IgH samples (2 MScl and 2 controls) and six IgL samples (1 MScl 
and 5 controls) were excluded after label - free analysis because of weak alignment 
and UV information.
Patient characteristics
All patient characteristics are shown in table 1. Significant differences in the gender 
and age (Mann - Whitney test, p < 0.0001) were observed between MScl patients and 
controls. All other parameters did not show any differences (Mann - Whitney test, p > 
0.05) between the groups. MScl patients have slightly increased Ig concentrations in 
CSF. Therefore we normalized CSF Ig concentration. After normalization, UV quantified 
area (peptide abundance) obtained during LC - MS measurements did not show any 
significant difference (Mann - Whitney test, p = 0.80 IgH and p = 0.18 IgL) in concentra-
tion of digested peptides between groups.
VH and Vk family distribution in MScl patients and controls
The peptide spectral count (MS / MS identification based) information (Scaffold based) 
acquired at the individual level (method figure 1) was used to analyze Ig VH family 
distribution between MScl patients and controls. An alignment match score of 70 % 
was used as a cut off value and a mean score of 90 % ± 8.5 % was observed. The mean 
sequence length was 10 ± 2.1 amino acids (mean ± SD). Peptide counts were normal-
ized at the individual patient level to the total number of peptides found for the given 
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Figure 1. Schematic illustration of the proteomics based methodology used to assign shared cdR 
exclusive presence in cSF Ig of MScl patients.
(A) Ig was purified from CSF of MScl patients (100 µL) and non - neurological controls (200 µl) based 
on the Ig concentration assay. Purification was performed by Melon gel IgG Spin Purification kit. Puri-
fied Ig was separated into IgH and IgL chain by reducing one - dimensional SDS - PAGE gels. (B) After 
In - Gel trypsin digestion of excised IgH and IgL bands, the mixture of peptides was measured by 
Nano LC - LTQ Orbitrap MS. Mass spectra were analyzed by Progenesis software and peptide search 
was performed by Mascot. Identified peptides were used for CDR identification using IMGT database 
and BLASTp search algorithm to find MScl specific CDRs.
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(B.1) Detail of part B: (1) Nano LC - LTQ Orbitrap MS generated, LC - MS profiles (raw MS run data) for 
the IgH and IgL datasets. They were analyzed separately using Progenesis LC - MS software package 
(label free quantification). Sequencing of the MS / MS spectra was executed by a Mascot MS / MS 
database search against the human subset of the NCBInr sequence database. Afterwards, the identi-
fied peptides were imported into the Progenesis and linked to their corresponding peak. The peak 
abundance (UV area under curve) information was used for CDRs presence or absence analysis. (2) 
Identified peptides were extracted and converted into FASTA format. They were aligned to a V, D, J 
and C element of Ig (Homo sapiens) germ line sequences derived from the IMGT database. We used 
the BLASTp search algorithm to align the identified peptide sequences to the corresponding Ig frag-
ments. Next, they were submitted to the IMGT / domain gap alignment tool. This analysis provided 
alignment details of CSF Ig peptides in comparison to Ig germ line that included: gene name, homol-
ogy match score, mutation/mismatch and start and end position. (3) Peptide identification details 
were uploaded in Scaffold program. The Scaffold file contains a peptide identification view report 
based on the spectral counts (at MS / MS level). Peptide counts were obtained at the individual 
level for each sample and were exported to a spreadsheet containing detailed information about 
the protein and peptide hits. On basis of the resulting combined peptide set, alignment summary 
in comparison to the germ line were assigned at the individual level (using a BLASTp algorithm and 
IMGT database). This information was used for VH and VK family distribution analysis.
Abbreviations used: BLAST, basic local alignment search tool; BLASTp, basic local alignment search 
tool for protein; IMGT, ImMunoGeneTics information system; Feature (or Peak), object of defined mass 
with an identified charge state, retention time and isotopes characterized by the analysis software.
table 1. clinical characteristics of MScl patients and non-neurological controls. Clinical charac-
teristics are presented as median (25th and 75th percentiles). The differences were identified by 
Mann-Whitney test. Statistical Significance considered at p <0.05.
IgH IgL
control (n=30) MScl (n=29) p value control (n=26) MScl (n=29) p value
Age (yrs) at 
sampling
52 (39 - 68) 31 (26-41) <0.0001 53 (41-67) 33 (27-42) <0.0001
gender 13 ♂ 17 ♀ 2 ♂ 27 ♀ <0.0001 13 ♂ 13 ♀ 2 ♂ 27 ♀ <0.0001
total protein (g/l) 0.39
(0.33-0.50)
0.37
(0.260.46)
0.07 0.39
(0.33-0.51)
0.36
(0.26-.45)
0.05
Albumin (g/l)a) 0.19
(0.17-0.35)
0.19
(0.140.24)
0.61 0.18
(0.10-0.36)
0.19
(0.15-0.24)
0.87
Abnormal cSF
Ig indexb) (OBs)c)
N/A 21 (23) N/A N/A 21 (23) N/A
time from cIS to 
cSF samplingd)
N/A 5 (2- 38) N/A N/A 5 (2-40) N/A
Abbreviations used: IgH: Heavy chain IgL; Light chain: N / A; Not applicable; OBs: Oligoclonal bands; 
♀: Female; ♂: Male
a) Albumin concentration, (g/ l) is reported for n = 11 IgH and n = 8 for IgL. b) Ig index, (CSF / serum 
Ig): (CSF / serum albumin), was denoted as increased if greater than 0.67. c) OBs, Presence of CSF - 
specific OBs. d) Time from CIS to CSF sampling, Time from first attack to CSF sampling in months and 
defined as first neurological episode caused by inflammation of demyelination.
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IgH chain family. Usage of peptides assigned to each family was compared between 
both groups. Log transformed data was not normally distributed (by D’ Agostino and 
Pearson omnibus normality test), therefore a non -parametric statistical test was used 
to determine statistical significance using raw data. In comparison to controls, VH 4 was 
found to be slightly but statistically significant (p = 0.03) and trend towards increased 
VH 3 in MScl was observed (p = 0.05) (Figure 2). No significant differences were found 
for the other six VH (p > 0.05) families. Family usage of the VK chains between MScl 
patients and controls was also performed in the similar way like VH. We found peptide 
alignment match mean score 86 % ± 11 %. The mean amino acid sequence length was 
10 ± 2.6 (mean ± SD). Analysis did not show significant difference in between groups.
disturbed κ/λ ratio in MScl patients
The κ/λ ratio was analyzed between controls (n = 26) and MScl patients (n = 29). The 
ratio of κ and λ light chains was determined from the abundance data for representa-
tive peptides from the LC - MS dataset (Progenesis). The peptides used were C region 
peptides (n = 10) having an alignment match score of 100 % ± 0 % (mean ± SD) for 
κ (n = 6) and 97 % ± 3 % (n = 4) for λ peptides. The κ to λ mean ratio in control was 
2.52 ± 1.71 and in MScl 4.06 ± 2.76. A two tailed t - test was applied since on log scale 
transformed data normal distribution was found by means of normality testing. The 
ratio showed significant elevation in MScl group (p = 0.03) (Figure 3).
Figure 2. the family usage of VH3 and VH4 peptides in MScl in comparison to controls. The family 
usage of IgH repertoire expressed in CSF of MScl and controls is shown. Horizontal lines represent 
median value. Peptide counts were normalized at the individual patient level to the total number 
of peptides in given family. Frequencies (percent) of peptides are plotted at the Y axis. Usage of 
peptides assigned to each family was compared between both groups. Slight over representation of 
VH4 family (Mann-Whitney test, p = 0.03) was observed in MScl patient group (N = 29) in compari-
son to the control group (N = 30).
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As a result of nano – LC - LTQ Orbitrap MS measurements of tryptically digested Ig 
bands, we found 54,057 MS peaks totally in the IgH chain and 56,664 in the IgL chain 
comparison set by Progenesis. The database (NCBInr) analysis by Mascot identified 
1086 peptides for IgH samples. Similarly (by NCBInr) we identified 920 peptides for 
IgL samples. Next, the BLASTp algorithm aligned our peptide (experimental) sequences 
to a database (IMGT) of germline sequences that were present in naive B-cells (as de-
scribed in method). The best matching germline allele was selected from the database. 
Comparison of the peptide with the best matching germline allele also revealed which 
amino acids were most likely mutated during rearrangement and affinity maturation. In 
this way, from the 1086 IgH peptides, 809 sequences were assigned to the V region, 32 
sequences to the J region and 99 sequences to the C region. Similarly (by IMGT), from 
the 920 IgL peptides, 722 peptides were assigned to the V region, 49 sequences to the 
J region and 99 to the C region. Next, within the IgH variable domain, we could assign 
41 peptides to the CDR1, 128 to the CDR2 and 171 to the CDR3. Within the IgL vari-
able domain, we could assign 78 peptides to the CDR1, 233 to CDR2 and 51 to CDR3. 
Moreover, a summary of identification is shown as a flowchart. Many of the IgH and IgL 
peptides in our dataset were unassigned. Possible reason for this could be rearranged 
CDR3 sequences having too little similarity to the germline sequence to allow for 
alignment. We were interested in peptides that were observed only in the MScl group. 
Therefore, based on the presence or absence of these peptides in the MScl group we 
found 24 IgH and 26 IgL peptides in the MScl group that could only be identified in 
the MScl group and not in controls. In contrast as expected peptides derived from the 
Ig C region were equally distributed in both patients and controls (data not shown). 
Figure 3. the κ to λ ratio in cSF Ig of MScl patients (n = 29) and controls (n = 26). The κ to λ ratio 
in CSF Ig of MScl and controls is expressed on a logarithmic (ln) scale and shown as means with SD. 
Ratios showed elevation in MScl group (unpaired t - test, p = 0.03).
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We searched for those CDR related peptides in the MScl group that shared among mul-
tiple MScl individuals. Next, we zoomed into the CDR regions to assess for peptides that 
were shared in at least three MScl patients and absent in the controls. We found nine 
IgH peptides and six IgL peptides. At lower threshold (i.e. shared in at least two MScl) we 
observed 14 IgH peptides and 13 IgL peptides (data not shown).The elucidated results 
here emphasized the fact that CDR peptides were from MScl patients, and were not 
from three or more controls. As a confirmation step, a second round of assessment was 
performed by means of 2-D view analysis in the Progenesis software package. To check 
whether the fragmentation spectra of a peptide were similar in all patients in whom 
it was identified, we critically scrutinized and assessed the fragmentation spectra of 
peptides. At this point, we found five peptides that were proven to be shared between 
three or more MScl patients. The exact characteristics are shown in table 2.
To determine the probability, that exclusive presence of CDR in MScl is not due to 
chance alone we permutated the entire dataset repeatedly 5,000 times for CDR marker 
category. Analysis showed that CDR exclusive presence in MScl is not due to chance in IgH 
(P = 0.0005) and also in IgL (P = 0.0007). Five peptides were found to be specific to three 
or more patients in the MScl group. Interestingly, one of the mutated CDR2 commonly 
used was seen in seven different MScl patients. IMGT Alignment analysis showed that 
this CDR peptide had different mutations (T, E, and N) or insertion (F) at the same spot. 
The QDGSEtYYVDSVK (amino acid given in bold, mismatch/mutation from Ig germline) 
peptide was quantified in six MScl patients and not in 30 controls (Figure 4). Further, 
four out of the six MScl patients were identified by MS/MS (and not in controls), giving 
additional support for proper sequence identification (Figure 4). Sequence alignment 
with the human germ line sequences (derived from IMGT database) showed homology 
to the IGHV 3-7 and threonine (T) amino was found mutated/mismatched from the lysine 
(K) of the germ line. A similar peptide, QDGSEEYYVDSVK was identified in three MScl 
patients. Alignment showed the mutation of a glutamic acid (E) at the same spot. In ad-
dition to the peptide described above, two CDR resembling mutations QDGSEtFYVDSVK 
(bold italic, insertion) and QDGSEnYYVDSVK were also exclusively observed solely in 
one MScl patient. Next, the IDWDDDKYYSTSLK peptide was quantified exclusively in four 
MScl patients. For two of these MScl patients fragmentation spectra were obtained that 
showed identical peptide MS/MS, supporting robustness of the peptide identification. 
Alignment analysis showed homology to the IGHV 2-70*01 (CDR2) for these peptides, 
another identical CDR, IDWDDDKYYtTSLK with mutation was observed solely in one MScl 
patient. Next, the YNSAPLTFGGGTK peptide was identified exclusively in three patients. 
Homology search showed alignment to the CDR3 of gene IGKV 1-27 *01 and IGKJ 4 *01. 
Finally, the LLIHGASnR peptide was identified solely in three MScl patients. Alignment 
showed homology to the IGKV 3-20 *02 CDR2 and histidine (H) and asparagine (N) were 
found mutated from the tyrosine (Y) and serine (S) compared to the germ line.
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Figure 4. QdgSEtyyVdSVk mutated cdR2 identification in six MScl patients and not in 30 con-
trols. Peptides were analyzed by Progenesis LC-MS and comparison between MScl and control was 
performed. After alignment of the chromatograms in the Progenesis software, 2D profiles were com-
pared to find expression profile between both groups. (a) Precursor mass of the peptide not found 
in any of the 30 controls. (b) Precursor mass of the peptide identified in six out of 29 MScl patients. 
The region covered in a) and b) by red box/isotope boundaries indicates area of interest and shows 
precursor mass isotopic pattern, peptide abundance was calculated as the sum of the peak areas 
within these isotope boundaries. (c) Example of identical MS/MS fragmentation spectra in different 
MScl samples. Red circle (at left) in the figure indicates location of retention time and mass (m/z) 
where MS / MS scan was triggered. Almost identical MS/MS fragmentation spectra were observed 
in different patients. (d) A MS/MS spectra containing the m/z values and abundances of peptide ion 
products. Longer series of contiguous y and b ions shows a higher probability of correct identifica-
tion. The sequence proposes a mutated CDR2 peptide. Red circle shows mutated (T) amino acid from 
germ line that was found during alignment using IMGT database. A CDR peptide was defined as a 
peptide containing a minimum of three amino acids in the CDR part irrespective of framework length.
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dIScUSSIOn
The main observation of this study was the shared use of identical mutated sequences 
in CDR of purified Ig from CSF of different MScl patients. In contrast, in a set of 30 
healthy controls no overlap in the tryptic peptide sequences of CDR regions existed. 
To the best of our knowledge, this is the first study that uses a proteomics approach 
to analyse and compare the sequences of purified Ig from CSF of a significant large 
set of MScl patients and controls. Most studies until now have investigated clonality 
at the transcriptome level (8, 27-29). In these previous studies no common sequences 
between distinct individuals had been reported. These studies used FACS based cell 
sorting method or CSF cell isolation and ended up with limited number of CD19+ 
B cells repertoire or/and CD138+ plasma cells (8, 28). Further they used cloning at 
nucleic acids level by means of PCR based technologies. Apart from the larger number 
of patients investigated, here we have targeted the CSF Ig at the protein level and did 
not investigate CSF B cells.
Although, all MScl CSF samples tested here had signs of elevated intrathecal Ig 
production we cannot claim that the public sequences shared here between distinct in-
dividuals are responsible for the OBs seen in immunoelectric focussing used in routine 
hospital chemistry. It should be realised that the sophisticated MS technique applied 
here makes it possible to detect peptide sequences at concentrations far below the 
threshold for routine immunoelectric focussing (18).
The current paradigm in Immunology is that antigen specificity of B cells is deter-
mined via random mechanisms, and therefore one would expect different sequences 
of the antigen binding CDR between different individuals. This has recently been 
challenged by a number of observations. First, Scheid et al. cloned 576 new Human 
immunodeficiency virus (HIV) antibodies from four unrelated individuals and found 
that despite extensive hypermutation, these antibodies shared consensus sequences 
in both framework and CDR V - regions of IgH chains (9). In another study in Sjögren’s 
syndrome, secreted human Ro52 antibody from different patients were found to share 
public V region sequences in unrelated patients (30). Finally, our group observed 28 
common Ig - derived sequences in the paraneoplastic anti Hu - syndrome that were 
specific for auto-antigen and were found exclusively in samples from a single autoan-
tibody defined clinical neurological entities (12).
Our study in MScl patients appears to follow the same paradigm challenging pattern. 
A considerable set of 24 IgH and 26 IgL CDR peptides were exclusively present in 
MScl patients. We found nine peptides in the IgH set and six peptides to be shared 
among at least three MScl patients. These numbers were somewhat higher with a lower 
threshold for sharing Ig in at least two MScl patients. At lower threshold (shared in two 
MScl patients), we observed 14 CDR peptides in IgH and 13 in IgL exclusively in MScl 
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patients. This indicates that under (auto) antigenic pressure there may be common se-
lection mechanisms for the production of intrathecal Ig production by B lymphocytes. 
The suggestion of shared sequences within different MScl individuals is reminiscent to 
what has been reported on recruited T lymphocytes in this disease (31).
Although the reason remains unproven it would not be farfetched to speculate that 
some CDR sequences may better survive the clonal selection process than others, 
perhaps due to a stronger binding of the 3 D structure of the CDR to the antigen. Better 
insight in common selection mechanisms for (auto) antibodies in MScl and identifica-
tion of inter-individually shared specific CDR sequences might even deliver markers for 
subgroup identification.
Apart from focusing on the CDR regions, we also investigated possible use of com-
mon VH and lgL chain families. VH repertoires can be divided into seven families based 
on sequence similarity (22). Previous studies at the genomic level indicated a skewed 
use of VH4 in MScl (8, 32). Although it is hard to draw firm conclusions here, it was 
striking to see over-representation of peptide sequences (p = 0.03) of the VH4 fam-
ily in MScl patients compared to controls. In addition, we observed a trend towards 
increased VH3 family usage in MScl (p = 0.05). No significant difference was observed 
for the use of VK chain between both groups.
An additional observation here has been the increased κ/λ ratios in the MScl group. 
This observation is in agreement with previous studies (33) using conventional assays 
for IgL detection.
Compared to the other studies, a limitation of our study was that we do not know the 
antigen specificity of the V-regions identified here. In fact we do not show complete 
Ig sequences, due to the fact that trypsin digestion is needed for this approach. In 
light of the shared sequences observed in known antigen-specific antibodies in HIV 
infection, anti-Hu paraneoplastic disease and Ro52 autoimmunity it would be of future 
relevance to investigate possible use of public V - region sequences in purified specific 
antibodies against MScl candidate antigens such as anti MOG, anti neurofascin and anti 
KIR 4.1 (6, 34, 35).
In the available previous studies no attempts were shown to match the identified 
sequences with those available in public data bases such as BLAST (NCBI). We here 
performed such a cross-check and were surprised to notice that similar sequences 
were found in other studies investigating B cells from CSF of MScl patients.
Although the used technique makes it impossible to show the sequence of complete 
Ig proteins, it is striking that these peptides have also been identified in other MScl 
studies. For example our study showed a common CDR usage in seven different patients. 
This QDGSEKYYVDSVK peptide which is part of the CDR2 belongs to the IGHV 3-7 germ 
line. We found different amino acid mutations (T, E or N) and insertion (F) at the same 
spot (K) of when compared with the germ line. QDGSEtYYVDSVK and QDGSEtFYVDSVK 
107
Shared IgG CDRs in Different MScl Patients
ch
ap
te
r 4
sequences were published in the database from the study assessing intrathecal CSF 
B cells sequences on two MScl patients using RT - PCR approach (24). The peptide 
QDGSEtFYVDSVK was also shown by a different study that sequenced CSF OBs in four 
MScl patients using proteomics approach (14). Furthermore gene IGHV 3-7 associ-
ated with same has also been shown in previous studies performed on CSF B–cells 
of MScl patients (14, 24, 25). Next, gene IGHV2-70 related to IDWDDDKYYSTSLK and 
IDWDDDKYYtTSLK has also been described in different previous studies performed on 
CSF B cells of MScl patients (25, 26). The peptide IDWDDDKYYSTSLK has no mutation, 
while it is plausible that this peptide may be found in a larger healthy population, we 
presume that this peptide is enriched in the MScl population. Certain V-genes may be 
preferentially selected in the antibody response against certain antigens (Repertoire 
bias) (7). Thus, such peptides, especially as a part of a larger panel of peptides, help in 
the identification of patient populations even if they are not unique to that population. 
Next, peptide YNSAPLTFGGGTK does not contain amino acids introduced by somatic 
hypermutation but it was generated by V(D)J - recombination. Nevertheless it is unique 
because of its particular deletion of two nucleotides of the V-region in conjunction 
with one nucleotide of the J-region plus the lack of any additional N-nucleotides. In all, 
three of the CDRs observed in three or more MScl patients have been linked to MScl 
in the past.
In MScl patient’s the phenomenon of repertoire bias (7, 8, 32, 36) has been described, 
whereby specific genes from the germline repertoire are favoured in the panel of anti-
bodies that is produced during the immune process. These pressures drive antibodies 
in convergent directions. Indeed one might expect many CDR3 sequences as they are 
important for the specificity of an antibody. However, two aspects may favour CDR 1/2 
instead. First, CDR3 are generally highly mutated on the border of V, D and J germline 
alleles. As such they are difficult to identify by homology to the germline sequences, 
and may remain unidentified. Second, it may be that the highly mutated CDR3 are in 
fact mostly unique to an individual, and that motifs shared between individuals are 
instead found in the moderately mutated CDR1/2 regions.
To conclude, this proteomic study shows for the first time CDR peptides shared 
between individual MScl patients and not in controls. There was a striking overlap with 
a few CDR peptides identified in other studies that assessed B cell clonality in MS CSF 
at the nucleic acid levels. Whether such common B cell responses are indeed driven 
by auto-antigens remains to be determined. It will be of interest to study common 
V-region use in known autoreactive Ig’s that appear to play a role in MScl (6).
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ABStRAct
Natalizumab is a very effective, relatively new drug for the treatment of relapsing 
remitting multiple sclerosis. Inflammatory and neurodegenerative processes in the 
central nervous system are presumed to cause adverse effects during the course of 
this disease. To monitor the effects of Natalizumab treatment on the cerebrospinal fluid 
(CSF) proteome of patients, CSF samples were taken from patients before commenc-
ing treatment as well as after one year of treatment. Profiling proteomics experiments 
using electrospray Orbitrap mass spectrometry and pair wise comparison of patients 
before and after one year of Natalizumab treatment revealed a number of candidate 
biomarkers that were significantly differentially abundant between the before- and 
after treatment groups. Three proteins were subsequently validated using selected 
reaction monitoring (SRM) in a new, independent sample set. All three proteins, Ig mu 
chain C region and haptoglobin, both known inflammation-related proteins, as well as 
chitinase-3-like protein 1, were confirmed by SRM to be significantly lower abundant in 
CSF of multiple sclerosis patients after one year of Natalizumab treatment. The findings 
for chitinase-3-like protein 1, a presumed biomarker for more rapid progression from 
a first clinically isolated syndrome to clinically definite multiple sclerosis, was further 
confirmed by ELISA measurements.
Multiple sclerosis 
patients
Multiple sclerosis 
patients
Before natalizumab
treatment
After natalizumab
treatment
Before natalizumab
treatment
After natalizumab
treatment
List of differentially
abundant proteins (n=5)
Positively validated
-Chitinase-3-like protein 1
-Ig mu chain C region
-Haptoglobin
CSF discovery sample set CSF validation sample set
LC-MS and statistical analysis for
differential abundant peptides and proteins
SRM and ELISA validation of three proteins
identified in the discovery samples set
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IntROdUctIOn
Multiple sclerosis (MScl) is a common cause of neurological disability in young adults. 
The cause of the severe neurological disability is the interruption of myelinated tracts 
in the central nervous system (CNS) (1). Most pathogenesis models for the disease 
support the existence of two connected processes that occur in patients with MScl; in-
flammation and neurodegeneration (2). These processes are not uniformly represented 
across patient populations but can predominate selectively in individual patients, con-
tributing to the heterogeneity of phenotypic expression of the disease (3). The majority 
(approximately 85%) of MScl patients have the relapsing remitting (RR) MScl subtype 
of the disease (4). RR MScl is characterized by relapses with increased disease activity, 
which occur at irregular intervals, followed by periods of remission. It is believed that 
the disease process starts with increased migration of auto-reactive lymphocytes across 
the blood-brain barrier (5). Treatment for RR MScl is focused on the reduction of the 
number of relapses. These therapeutic agents, such as interferon beta and glatiramer 
acetate, are moderately effective and reduce the annualized relapse rate by about a 
third (6, 7). The monoclonal antibody Natalizumab (brand name: Tysabri) is an effective 
agent for relapsing remitting multiple sclerosis patients shown by a 68% reduction of 
relapse rate plus a strong effect on MRI lesion parameters (8).
The therapeutic effect of Natalizumab is mediated by suppression of leukocyte mi-
gration into the central nervous system by blocking the Very-Late Activation Antigen 4 
ligand on immune cells(9). As a consequence, a reduction of inflammation and inflam-
matory mediators might be observable in the central nervous system of Natalizumab 
treated patients. There are indications that also neurodegeneration-related proteins 
can be influenced by Natalizumab treatment (10).
We anticipated that the strong effects of Natalizumab on MS disease activity plus 
the possibility to study CSF samples before and after treatment provides a unique 
model to study potential CSF markers that are relevant for CNS pathology, and may 
eventually even serve as markers for effects of therapy. Therefore we here employed 
state-of-the-art quantitative proteomics techniques to differentiate between cerebro-
spinal fluid (CSF) samples of multiple sclerosis patients before and after treatment with 
Natalizumab.
MEtHOdS
CSF samples were taken from relapsing remitting MScl patients before Natalizumab 
treatment commenced at the University Medical Center Eppendorf (Hamburg, Ger-
many). The post-treatment samples were taken at the same hospital one year after the 
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start of Tysabri treatment. The Tysabri treatment consisted of a year-long treatment of 
monthly Natalizumab infusion (300 mg intravenously, infused over approximately one 
hour, every four weeks). All patients gave their consent for the repeated CSF sampling. 
Immediately after sampling, the CSF samples were centrifuged for 10 min at 3000 
rpm to discard cells and cellular elements. The samples were subsequently used for 
routine CSF diagnostics, which included quantification of total protein concentration 
(table 1). The remaining volume of the samples was aliquoted and stored at −80°C, 
where they remained until sample preparation for this study. The sample details are 
listed in table 1 (discovery sample set column).
From each CSF sample, 20 µL was added to 20 µL of 0.2% Rapigest (Waters, Milford, 
MA) in 50 mM ammonium bicarbonate buffer. After 30 min incubation periods with 
1,4-dithiothreitol (60°C) and, subsequently, iodoacetamide (37°C), 4 µL of 0.1 µg/µL 
gold-grade trypsin (Promega, Madison, WI)/3 mM Tris-HCl (pH 8.0) was added to each 
sample. The samples were incubated overnight at 37°C. To adjust the pH of the digest 
to pH < 2, trifluoroacetic acid (TFA) was added to the mixture prior to the final incuba-
tion step at 37°C for a duration of 45 minutes to stop the enzymatic digestion reaction.
Mass spectrometry measurements were carried out on a Ultimate 3000 nano LC sys-
tem (Dionex, Germering, Germany) online coupled to a hybrid linear ion trap/Orbitrap 
MS (LTQ Orbitrap XL; Thermo Fisher Scientific, Germany). Five µL digest (i.e. 2 µL CSF) 
were loaded on to a C18 trap column (C18 PepMap, 300 µm ID ×5 mm, 5 µm particle 
size, 100 Å pore size; Dionex, The Netherlands) and desalted for 10 minutes using a 
flow rate of 20 µL/min 0.1% TFA. Then the trap column was switched online with the 
analytical column (PepMap C18, 75 µm ID ×150 mm, 3 µm particle and 100 Å pore size; 
Dionex, The Netherlands) and peptides were eluted with following binary gradient: 
0%–25% solvent B in 120 min and 25%–50% solvent B in further 60 minutes, where 
table 1. details of all patients and related samples included in this study (discovery and valida-
tion sample sets). The values for age, disease duration, EDSS score (Expanded Disability Status 
Scale) and protein concentrations are averages (with standard deviation in brackets). In both sample 
sets the change in EDSS, as well as the protein concentration in the discovery sample set, from be-
fore treatment to after treatment is not significant (p>0.01).
discovery set samples
(germany)
Validation set samples
(Sweden)
gender distribution (M/F) 4/13 5/15
Age (years) 37.1 (8.1) 41.4 (9.8)
disease duration (years) 8.4 (5.8) 11.2 (6.6)
EdSS before treatment 3.7 (1.3) 4.3 (1.9)
EdSS after treatment 3.6 (1.4) 4.2 (1.9)
Protein concentration before treatment (mg/l) 381.7 (75.1) -
Protein concentration after treatment (mg/l) 318.8 (87.3) -
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solvent A consist of 2% acetonitrile and 0.1% formic in water and solvent B consists of 
80% acetonitrile and 0.08% formic acid in water.
Column flow rate was set to 300 nL/min. For MS detection a data dependent acquisi-
tion method was used: high resolution survey scan from 400–1800 Th. was performed 
in the Orbitrap (value of target of automatic gain control AGC 106, resolution 30,000 at 
400 m/z; lock mass was set to 445.120025 u (protonated (Si(CH3)2O)6(11)). Based on 
this survey scan the 5 most intensive ions were consecutively isolated (AGC target set 
to 104 ions) and fragmented by collision-activated dissociation (CAD) applying 35% 
normalized collision energy in the linear ion trap. After precursors were selected for 
MS/MS, they were excluded for further MS/MS spectra for 3 minutes.
The raw data was pre-processed using the Progenesis LC-MS software package (ver-
sion 2.6, Nonlinear Dynamics, Newcastle-upon-Tyne, United Kingdom). Peptides were 
identified and assigned to proteins by exporting features, for which MS/MS spectra were 
recorded, using the Bioworks software package (version 3.2; Thermo Fisher Scientific, 
Germany; peak picking by Extract_msn, default settings). The resulting .mgf file was 
submitted to Mascot (version 2, Matrix Science, London, United Kingdom) for identifica-
tion to interrogate the UniProt-database (release 2010_04; taxonomy: Homo sapiens, 
containing 77399 sequences). Only ions with charge states between +2 and +7 were 
considered and only proteins with at least two unique peptides (Mascot ions sore > 
25, (i.e. a peptide probability cut off value of 0.01)) assigned to them were accepted as 
true identifications. Modifications: carbamidomethylation of cysteine was set as fixed 
and oxidation of methionine as variable modification, allowing a maximum of 2 missed 
cleavages. Mass tolerance for precursor ions was set to 10 ppm and for fragment ions at 
0.5 Da. The Mascot search results were imported back into the Progenesis software to 
link the identified peptides to the detected abundances of these peptides. The peptide 
abundances were normalized to the total ion current to compensate for experimental 
variations using an algorithm available in the analysis software. Subsequently the data 
were exported in Excel format.
The abundances of all identified peptides were compared between the groups of 
samples (before and after treatment with Natalizumab) by performing a paired t-test 
on all individual peptides. Proteins of which 50% or more of the peptides had a low 
p-value in this t-test (p<0.01) were deemed to be significantly differentially abundant 
between the two groups.
Validation by Selected Reaction Monitoring
To validate the found differentially abundant proteins a validation sample set of CSF 
samples of Natalizumab treated relapsing remitting multiple sclerosis patients was col-
lected at the Karolinska Institute in Stockholm, Sweden. The CSF samples, which were 
Chapter 5
118
taken from 20 patients both before and after treatment were stored at −80°C before 
shipping on dry ice to the analysis laboratory (Table 1). Subsequently these samples 
were enzymatically digested following the exact same protocol as used for the original 
samples. The digested CSF samples were spiked (at 20 fmol/µL, corrected for peptide 
purity (99%)) with known concentrations of stable isotope-labelled peptide standards 
corresponding to sequences 100-112 (NVPLPVIAELPPK) and 113-120 (VSVFVPPR) of 
Ig mu chain C region (P01871), sequences 119-131 (TEGDGVYTLNNEK) and 162-170 
(ILGGHLDAK) of haptoglobin (P00738), and sequences 322-335 (GNQWVGYDDQESVK) 
and 370-377 (FPLTNAIK) of chitinase-3-like protein 1 (P36222) for quantification by 
selected reaction monitoring (SRM).
Peptides in spiked CSF digests were separated by reversed-phase chromatography 
on an Ultimate 3000 nano LC system (Dionex). Spiked CSF digest (1 µL) was loaded 
onto a C18 trap column (PepMap C18, 300 µm ID by 5 mm length, 5 µm particle size 
and 100 Å pore size; Dionex) and washed for 5 min at a flow rate of 20 µL/min with 
0.1% TFA in H2O. Next, the trap column was switched in line with the analytical column 
(PepMap C18, 75 µm ID by 150 mm length, 3 µm particle size and 100 Å pore size; 
Dionex). Peptides were eluted at a flow rate of 300 nL/min with the following gradient: 
0%–45% solvent B in 30 min, where solvent A is H2O/acetonitrile (ACN) 98%/2% 
(vol/vol), 0.1% formic acid (FA) and solvent B is H2O/ACN 20%/80% (vol/vol), 0.1% FA. 
Separation of the peptides was monitored with a UV detector (absorption at 214 nm).
SRM analysis was performed on a 4000 QTRAP (AB Sciex, Concord, Canada) in the 
positive ion mode. Three transitions were attempted for quantification for all peptides 
(NVPLPVIAELPPK, transitions y3, y9, and y11; VSVFVPPR, transitions y3, y4 and y5; 
ILGGHLDAK, transitions b6, b7 and y7; GNQWVGYDDQESVK, transitions y7, y8 and 
y9; and FPLTNAIK, transitions y5, y6 and y7). No transitions could be quantified for 
the TEGDGVYTLNNEK peptide of haptoglobin, as this peptide could not be detected 
on the ESI-QqQ. Hence haptoglobin was quantified on the values obtained for the 
ILGGHLDAK peptide only. All transitions of the FPLTNAIK peptide of chitinase-3-like 
protein 1 proved to be lacking sensitivity for quantification, so these were subse-
quently excluded from the quantitative analysis. The y7 transition of NVPLPVIAELPPK 
of chitinase-3-like protein 1 was excluded from the calculations due to interference, 
hence this peptide was quantified by two transitions, whereas the remaining three 
quantified peptides were quantified by three transitions. The linearity of the SRM assay 
was determined in the range of 100 amol/µL to 100 fmol/µL, and peak heights proved 
to be linearly well correlated to spiked peptide concentrations (R2 > 0.9947 for all 11 
quantified transitions. The instrument was optimized for collision energy en decluster-
ing potential per individual peptide, and the cycle time was set to 0.9850 seconds 
for a total of 2132 cycles per sample. Limits of detection and quantification were not 
determined, however, all quantified transitions had acceptable S/N ratios (S/N > 4). We 
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performed data analysis using the SRM data analysis program Skyline (version 1.1). 
Peak areas were checked for interference with other peaks in the biological samples 
and if necessary adjusted to eliminate interference, prior to exportation of the heavy/
light peptide ratio values. Concentrations of the analyte peptides were determined 
based on the ratio between the peak area of the analyte peptide to the peak area of 
the spiked isotope-labelled internal peptide standard, which was added at a known 
concentration, using the average value calculated per peptide based on all quantifi-
able transitions. Hence the concentration of the GNQWVGYDDQESVK peptide is based 
on two transitions, whereas the concentrations of the NVPLPVIAELPPK, VSVFVPPR and 
ILGGHLDAK peptides are based on three transitions.
Validation of chitinase-3-like protein 1 by ElISA
To further confirm the differential abundance of chitinase-3-like protein 1 between 
untreated and Natalizumab treated multiple sclerosis patients, an ELISA for this protein 
was purchased, and performed according to the manufacturers (R&D Systems, Abing-
don, United Kingdom) instructions.
RESUltS
Using ESI-Orbitrap mass spectrometry a total of 3289 peptides were identified during 
the measurements of the “before treatment” and “after treatment” CSF samples of the 
seventeen relapsing remitting multiple sclerosis patients in the discovery sample set. 
These peptides relate to 578 unique proteins, of which 301 were identified by 2 or 
more peptides. Using a paired t-test to compare the CSF samples from before treatment 
to the samples from after treatment, 122 peptides had a p-value below 0.01 (statistical 
background determined by permutation: 33+/− 21). Five proteins identified by two or 
more peptides were identified as having at least 50% of the peptides with p-values 
below 0.01 in the comparison between the samples before and after treatment. These 
proteins, namely haptoglobin, Ig mu chain C region, Ig mu heavy chain disease protein, 
serine protease inhibitor and scavenger receptor cysteine-rich type 1 protein M130, 
are listed in Table 2. Additionally, chitinase-3-like protein 1, a potential CSF marker for 
conversion of clinically isolated syndrome of demyelination (CIS) to clinically definite 
MScl (12), was identified by eleven unique peptides. One of these peptides had a 
significant p-value in the statistical analysis, and an additional five peptides showed 
low, nearly significant p-values (between 0.016 and 0.071). All peptides of chitinase-3-
like protein 1 were decreased in the Orbitrap measurements of the CSF samples after 
treatment. Hence, although not statistically significant according to the predetermined 
criteria, this protein did show a trend towards statistical significance.
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Because this protein has been previously implicated as a conversion factor for CIS to 
MScl, we decided to include chitinase-3-like protein 1 in the validation stage of the 
study. The majority of proteins related to the inflammatory response, including previ-
ously reported potential markers for multiple sclerosis complement C3, complement 
C4 and clusterin(13), were lower abundant after Natalizumab treatment, although this 
did not reach statistical significance, with the exception of haptoglobin and the immu-
noglobulin proteins listed in table 2. Previously reported markers of neurodegenera-
tive processes, chromogranin A and contactin-1(14), were not significantly changed 
after treatment, although both proteins were higher abundant after treatment. None 
of the four proteins reported to be decreased in abundance after six months of 
Natalizumab treatment by Ottervald et al.(10) was statistically significantly changed 
after six months of Natalizumab treatment. Alpha-1 antichymotrypsin was slightly 
less abundant after treatment and the other three proteins, contactin-1, neuronal cell 
adhesion molecule and neural cell adhesion molecule 1, were slightly more abundant 
after treatment. Three proteins, haptoglobin, Ig my chain C region and chitinase-3-like 
protein 1, were selected for validation using SRM. The other three proteins listed in 
table 2 were not selected for validation because they were identified by two peptides, 
table 2. The fourteen peptides identified as differentially abundant between the “before treatment” 
and “after treatment” groups.
Primary 
accession 
number
Protein number of peptides with 
p<0.01 / total number of 
peptides
Higher abundant 
in group
P00738 Haptoglobin 15/26 Before treatment
P01871 Ig mu chain C region 7/12 Before treatment
P04220 Ig mu heavy chain disease protein 1/2 Before treatment
P05154 Serine protease inhibitor 1/2 Before treatment
Q86VB7 Scavenger receptor cysteine-rich type 1 
protein M130
1/2 Before treatment
table 3. SRM results for the three proteins selected for validation. The listed concentrations for the 
proteins are averages (with standard deviations in brackets). The p-values indicate that all three 
proteins (chitinase-3-like protein 1, Ig mu chain C region and haptoglobin) are significantly lower in 
concentration in CSF of multiple sclerosis patients after Natalizumab treatment.
Protein Peptide cSF concentration 
before natalizumab 
treatment (mg/l)
cSF concentration 
after natalizumab 
treatment (mg/l)
p-value
Chitinase-3-like protein 1 GNQWVGYDDQESVK 0.153 (0.101) 0.100 (0.065) 0.038
Ig mu chain C region NVPLPVIAELPPK 1.061 (1.142) 0.538 (0.522) 0.024
Ig mu chain C region VSVFVPPK 0.179 (0.175) 0.072 (0.080) 0.026
Haptoglobin IGGHLDAK 0.803 (0.610) 0.433 (0.339) 0.002
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and only one of these was significantly different between the sample groups. This 
validation procedure showed that the peptides of these proteins were significantly 
lower in concentration in CSF of MScl patients after treatment with Natalizumab in a 
new, independent sample set (p = 0.038 for chitinase-3-like protein 1, p = 0.024 and 
p = 0.026 for Ig mu chain C region, and p = 0.002 for haptoglobin, Table 3), confirming 
the results obtained by the ESI-Orbitrap. The concentrations of these peptides (and 
related proteins) in individual patients were decreased in CSF after treatment with 
Natalizumab in nearly all patients. Additionally, an ELISA for chitinase-3-like protein 
1 was performed for further confirmation, which showed a significant decrease in 
abundance of this protein after treatment (p =0.004) in CSF of MScl patients in the 
validation sample set (Figure 1).
dIScUSSIOn
In this study, we analyzed the CSF proteome of MScl patients treated with Natali-
zumab to assess the effects of the drug on the proteins in the CSF by comparing paired 
samples from patients before treatment and twelve months after treatment. Overall the 
changes in the CSF proteome after twelve months treatment with Natalizumab were 
limited, but we were able to make a number of interesting observations. The applied 
label free LC-MS strategy of this study allowed for the semi-quantitative analysis of 
Figure 1. Concentrations of chitinase 3-like protein 1 in CSF of MScl patients before (red) and after 
(blue) treatment with Natalizumab as determined by ELISA. The concentration of this protein in CSF 
is significantly lower after treatment (p = 0.004).
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over 300 proteins, which, although surely do not entail the entire CSF proteome, al-
lows analysis of the CSF proteome beyond merely the high abundant proteins. The 
three-hour chromatography gradient is capable of separating the digested peptides 
of the CSF proteome sufficiently to enable an in-depth analysis of the CSF proteome, 
although fractionation or depletion of the samples would potentially allow for even a 
more in-depth analysis.
The observation that the proteins related to inflammation are less abundant in 
CSF after Natalizumab treatment is in line with the proposed mechanism of action 
of the drug (15). Natalizumab, a humanized monoclonal IgG4κ antibody, selectively 
binds to the α4-integrin component of adhesion molecules found on lymphocytes and 
monocytes. This binding inhibits interaction with cells expressing the ligand of VLA-
4, vascular cell adhesion molecule-1 (VCAM-1), consequently blocking adherence of 
activated leukocytes to endothelial cells, which is a required step of the extravasation 
into inflamed tissue (16). Hence inflammation is inhibited in MScl patients due to the 
fact that Natalizumab prevents the migration of autoreactive leukocytes out of blood 
vessels into target organs, such as the CNS, by blocking the adhesion molecules of the 
α4-integrin component of adhesion molecules on leukocytes.
Also in line with the proposed mechanism of Natalizumab is the lack of signifi-
cantly differentially abundant neurodegenerative proteins after treatment. As the drug 
mechanism firmly points towards an effect on the inflammatory part of the disease 
processes, an effect on neurodegeneration was not directly expected to be observed 
here. Although a previous study shows that axonal damage in MScl is reduced by Natali-
zumab treatment, it is anticipated that a highly effective anti-inflammatory treatment 
reduces axonal loss, as inflammatory activity is associated with axonal damage (17). 
Consequently, these neurodegenerative effects are likely secondary to inflammatory 
processes. In contrast to the study by Ottervald and co-workers, in the presented study 
CSF samples from 6 months after the start of Natalizumab treatment were not included 
(10). The neurodegeneration-related proteins, alpha-1 antichymotrypsin, contactin-1, 
neuronal cell adhesion molecule and neural cell adhesion molecule 1, which Ottervald 
et al. described as significantly less abundant after six months of treatment, but not 
after twelve months treatment, were not significantly differentially abundant after 
twelve months of Natalizumab treatment in our study. Since no CSF samples were 
taken after six months of Natalizumab treatment and analysed in this study, as well as 
the fact that the experimental procedures differed substantially between the studies, 
it is difficult to compare them. Three of the four proteins reported as lower abundant 
by Ottervald and co-workers (10) were even slightly higher abundant after treatment, 
although these values did not reach significant levels. Hence, no proteins that had 
previously been related to neurodegenerative effects in MScl could be observed in CSF 
to be affected by Natalizumab treatment in this study.
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A number of the differentially abundant proteins found to be less abundant after 
Natalizumab treatment (Table 2) is related to the inflammatory response, which is in 
the pathogenetic hallmark of MScl. Consequently, the observation that inflammatory 
response-related proteins with a known higher abundance in CSF of MScl patients such 
as immunoglobulins and haptoglobin (18) are downregulated after treatment with a 
drug that blocks the entry of inflammatory cells into the CNS and the subsequent 
inflammatory effects stands to reason. All proteins identified as significantly higher 
abundant after treatment were only identified by a single peptide, which is less reliable 
than identification by multiple peptides. Two of the differentially abundant proteins, 
haptoglobin and Ig mu chain C region (both lower abundant after treatment), were 
subsequently validated by a different, quantitative mass spectrometry method in an 
independent data set. The validation experiment confirmed the Orbitrap profiling 
results for both proteins even though one of the peptides of haptoglobin could not be 
quantified for technical reasons.
Both IgM and haptoglobin are related to the inflammatory response and have been 
previously implicated in multiple sclerosis (19, 20). The proposed mechanism of action 
of Natalizumab includes inhibition of leukocyte infiltration into the CNS, therewith 
dampening the local inflammatory reaction. In light of this the lower abundance of 
Ig mu chain C region and haptoglobin in CSF of multiple sclerosis patients after Na-
talizumab treatment may not be surprising. Still, it is of note that a previous study has 
linked intrathecal IgM production with MS disease activity (19).
The third and final protein that was quantified in the SRM validation experiment, 
chitinase 3-like protein 1, was not significantly differentially abundant according to 
the stringent criteria set for the Orbitrap profiling experiments (p < 0.01 for 50% 
of the peptides of a protein). However the fact that a clear trend towards statistical 
significance could be observed, coupled with a report that chitinase 3-like protein 1 
is a potential marker for conversion of CIS to clinically definite MScl (12), prompted 
the inclusion of this protein in the validation experiment. Both the validation by SRM 
(p = 0.038) as well as by ELISA (p = 0.004) confirmed the Orbitrap profiling experi-
ment. The difference in p-values between the validation (statistically significant) and 
profiling (not statistically significant) experiments is most likely due to the selectivity 
of the validation method, as accurate quantification is more reliable using targeted 
methods such as SRM and ELISA, compared to untargeted methods like full scan label 
free Orbitrap measurements. The values measured for the differentially abundant pro-
teins in the individual patients were, in the vast majority of the cases, lower abundant 
after Natalizumab treatment. Two patients were exceptions to this observation, but for 
which we could not identify an obvious clarification. Nevertherless, the observed trend 
in the remaining individuals is a clear illustration of the differential abundance of the 
proteins in these Natalizumab treated multiple sclerosis patients.
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Some caution is needed about the interpretation of our data, as this study (because 
of medical ethical reasons) did not include a control group of patients followed over 
time without receiving Natalizumab treatment. The possibility of a placebo effect 
on biomarkers or other unknown factors theoretically remains. Despite this note of 
caution, the treatment associated differences in this study group were striking, the sta-
tistical thresholds for relevance were relatively high and the findings have a biological 
rationale.
Chitinase 3-like protein 1, which is also known as YKL40, is a chitin-binding, but chi-
tinase activity-lacking member of the glycoside hydrolase 18 chitinase family (21). One 
of the main cell types that secretes this protein are macrophages, linking the protein 
to the inflammatory response. Increased abundance of this protein in all likelihood is 
not specific for conversion of CIS to MScl or response to Natalizumab treatment in MScl 
patients, but rather a marker for inflammatory activity in the affected compartment, 
which is supported by the observation of increased levels in serum of several types of 
cancers and diseases such as rheumatoid arthritis (22-24). Additionally, the role of the 
chitinase family in the pathogenesis of MScl is further exemplified by the observation 
of increased plasma levels of chitotriodase in MScl patients compared to controls (25, 
26).
In conclusion, in this hypothesis-free proteomic approach we observed that Natali-
zumab treatment of MScl patients resulted in a decrease in the levels of inflammation-
related proteins in the CSF, which is in line with the proposed mode of action of natali-
zumab. CSF proteins related to neurodegeneration were not affected by Natalizumab 
treatment; although statistical power may have been insufficient to detect this most 
interesting was a decrease in the CSF levels of chitinase 3-like protein 1 after twelve 
months treatment with Natalizumab. The relevance of this marker for MScl activity has 
recently been indicated because this molecule is a potential marker for conversion of 
CIS to clinically definite MScl.
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ABStRAct
Multiple sclerosis (MScl) disease frequently remits during the third trimester of preg-
nancy but exacerbates in the first postpartum period. In this context, we investigated 
protein identification, its abundance and its change related to these two periods in 
urine. Using mass spectrometry (LTQ Orbitrap), we identified 1699 tryptic peptides 
(relates to 402 proteins) in urine from 31 MScl and 8 control at these two periods. 
Pregnancy related peptideswere significantly elevated (p<0.01) in MScl patients as 
compared with controls (Analysis 1; 531 peptides in MScl and 36 peptides in controls 
higher abundance in the third trimester compared to postpartum). When comparing 
the longitudinal differences (Analysis 2), we identified 43 (related to 35 proteins) MScl 
associated peptides (p<0.01) with increased or decreased difference ratio in MScl 
compared with controls. The most discriminating peptides identified were trefoil fac-
tor 3 and lysosomal associated membrane protein-2. Both proteins have a role in the 
innate immune system. Three peptides with a significant decreased ratio were plasma 
glutamate carboxypeptidase, Ig mu chain C region, osteoclast associated immune 
like receptor. Our results indicate that the protein expression pattern in urine of MScl 
patients contain information about a remote CNS and brain disease processes.
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IntROdUctIOn
Multiple sclerosis (MScl) is a chronic demyelinating disorder of the central nervous 
system (CNS) (1). During pregnancy, it is described that disease activity is at the low-
est level. Compared to a period of one year before pregnancy, a 70% decline in MScl 
disease activity is noted during the third trimester of pregnancy (2, 3). This decline is 
followed by an increased annualized relapse rate in disease activity at first postpartum 
period most clearly in the first three months after delivery, which even goes up to 
~70% above the pre-pregnancy rate (4, 5). Most of our knowledge regarding pregnan-
cy-related remission in MScl disease activity is derived from conventional studies that 
focused on individual components, such as estrogen (6-10). Others have focused on 
anti-inflammatory thymus cell antigen 1 (Thy1) to thymus cell antigen 2 (Thy2) shifts in 
peripheral blood (11) and T-cell subset fluctuations during pregnancy (12). In the above 
context, recently, Gilli and colleagues (13) studied pregnancy-related remission in MScl 
disease activity on RNA microarray platform using immune cell population of blood/
peripheral blood mononuclear cells (PBMCs) and noticed a decrease in inflammation 
related genes during MScl pregnancy. Brynedal et al. (14) also showed that the disease 
bouts in MScl primarily depend on events outside of the CNS, which highlights the 
importance to study changes in urine and other bio-fluids. It can be assumed that the 
biological mechanisms of this declined disease activity in pregnant women with MScl 
will involve in altering the protein level in urine. The biological mechanisms or this 
decreased activity of disease during pregnancy has not been investigated yet neither 
at protein nor at the DNA/RNA level. Therefore, large-scale identification of proteins 
and comparison at protein levels in tissues and body fluids compared to genomics data 
of PBMCs is still needed to get information to understand these phenomena. Our main 
aim was to identify MScl specific proteins that are potentially related to the changed 
frequency of relapses and remissions during pregnancy (5), in order to find proteins 
that are related to the protective effect that pregnancy has on the central nervous 
system in MScl. These pathologically relevant proteins might be potential treatment 
targets for MScl or merely be of interest with regards to their function or location in the 
biological pathways involved in MScl, pregnancy or the disease modifying effects of 
pregnancy in MScl. We used high resolution nano-scale liquid chromatography online 
coupled to a high resolution mass spectrometer (LC-MS) to investigate if MScl associ-
ated peptides exist in urine. We used urine, longitudinally obtained during pregnancy. 
In the current study, we quantified and identified the urinary proteome during third 
trimester (28-30 weeks) of pregnancy, and at the first postpartum period (within 4-8 
weeks after delivery) in pregnant women with and without MScl. We emphasized and 
discussed the tryptic peptides and proteins that are related to pregnancy and proteins 
that change significantly different in MScl compared to normal pregnancy.
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ExPERIMEntAl SEctIOn
Patients
The described study was approved by the Clinical Research Ethics Board of Erasmus 
University Medical Center, and all patients provided written informed consent. The 
exclusion criteria for both patients and controls were recurrent abortion, hypertension, 
diabetes mellitus or, other systemic diseases. Women with full term pregnancy were 
included in the study. Normal pregnant controls (n=8) were recruited from the out-
patient clinic of Obstetrics, Erasmus MC. The study included 31 MScl patients during 
their pregnancy at third trimester (28–30 weeks), and the first postpartum (4–8 weeks) 
visit. MScl patients and controls were matched for age. Patient data collected were: 
maternal age, disease duration, gestational age at delivery, pre-eclampsia, birth weight, 
breast feeding, data related to relapse rate before pregnancy, during the third trimes-
ters of pregnancy, and in three months after delivery. The study was designed in such 
a way that the absence of clinical infection was determined by medical history and 
questionnaires. MScl patients did not receive any disease modifying therapies during 
the course of the study. MScl patients and controls had no pregnancy related disorders 
and no urinary tract infections. The time of sample collection was remained consistent 
(between 10 am and noon) throughout the study. After collection, urine samples were 
centrifuged (3000 g) to remove cell debris, and the supernatant was stored at −80°C 
for subsequent proteomics analysis. Urine creatinine concentrations were determined 
by routine analysis of the Clinical Chemistry department of the Erasmus MC.
Urine protein purification and in-solution trypsin digestion
Protein was purified as previously described (15), with the exception of a molecular 
weight cut-off (MWCO) filter, which was not used in the present study. Briefly, samples 
were taken from the –80°C freezer and thawed at room temperature (RT). Urine (1.2 ml) 
was mixed with 0.6 ml of 3 M urea, 15 mM NH4OH, 0.03% SDS and kept at RT for 30 
min. Next, 1.5 ml of the mixture was desalting using PD-10 columns (GE Healthcare, 
Uppsala, Sweden). Columns were equilibrated with 25 ml 0.01% NH4OH, and subse-
quently samples were loaded on to these columns. A volume of 2 ml of equilibration 
buffer was applied to the column, the flow-through was collected and lyophilized (Sub-
limator 400, Zirbus Technology, Tiel, The Netherlands), and stored at −20°C. Next, these 
samples were subjected to trypsin digestion. Lyophilized samples were re-suspended 
in 35 µL LC water. To 25 µL of each sample 25 µL 0.2% Rapigest (Waters Corporation, 
Milford, MA) 100 mM ammonium bicarbonate was added. The reduction was performed 
at 5 mM DTT for 30 min heating at 60°C. Thereafter samples were cooled down to 
RT (approximately 25 min), and subsequently alkylated with at 15 mM for 30 min in 
darkness and at RT. Afterwards, 500 ng of trypsin (Promega, Madison, WI, USA) was 
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added (yielding an estimated protease to protein ratio of 1:20). The samples were then 
incubated overnight at 37°C. The digestion was stopped by adding 5% TFA to obtain a 
final concentration of 0.5% TFA (pH<2) followed by incubation at 37°C (at 450 rpm) for 
30 min. Prior LC-MS analysis, 1 µL of each sample were loaded onto a nano LC system 
(Thermo Fisher Scientific, Germering, Germany), peptides were eluted by a short 15 
min gradient (3.2% to 40% acetonitrile), and abundance of eluting peptides was mea-
sured by UV absorbance at 214 nm. Total UV absorbance of all eluting peptides was 
used to normalize overall abundance differences between various samples and adjust 
injection volumes for subsequent LC-MS analysis.
lc-MS measurements and database search
Tryptic digested samples were measured on a nano-LC system (Thermo Fisher Scien-
tific, Germering, Germany) coupled in-line to a hybrid linear ion trap/Orbitrap mass 
spectrometer (LTQ-Orbitrap-XL Thermo Fisher Scientific, Bremen, Germany). Samples 
were loaded on to a trap column (PepMap C18, 300 mm ID 5 mm length, 5 mm particle 
size, 100 Å pore size; Thermo Fisher Scientific), washed and desalted for 10 min, using 
0.1 % trifluoroacetic acid (TFA) (in water) as loading solvent. Next, the trap column was 
switched in-line with the analytical column (PepMap C18, 75 mm ID x 500 mm, 2 µm 
particle and 100 Å pore size (Thermo Fisher Scientific). Peptides were eluted with the 
following binary gradient (starting with 3% solvent B, then from 3% to 25% solvent 
B in 60 min and from 25% to 50% solvent B in 30 min, where solvent A consisted of 
0.1% formic acid (restituted with HPLC grade water), and solvent B consisted of 80% 
acetonitrile and 0.08% formic acid (restituted with HPLC grade water). The column 
flow rate was set to 250 nL/min, and eluting peptides were measured first by a UV 
detector at a wavelength of 214 nm in a 3 nL nano flow cell (Thermo Fisher Scientific), 
and subsequently introduced into the MS. All LC solvents were purchased at Biosolve, 
Valkenswaard, the Netherlands.
For electro-spray ionization nano ESI emitters (New Objective, Woburn, MA, USA) 
were used and a spray voltage of 1.5 kV was applied. For MS detection, we used a 
data-dependent acquisition method: high resolution survey scan from 400–1800 Th. 
was detected in the Orbitrap (target of automatic gain control = 1 E7, resolution = 
30,000 at 400 m/z, lock mass was set to 445.120025 Th (protonated (Si (CH3)2O)) 6). 
On the basis of this full scan the five most intensive ions were consecutively isolated 
(AGC target set to 10,000 ions), and fragmented by collisional activated dissociation 
(applying 35% normalized collision energy), and detected in the ion trap. Precursor 
masses within a tolerance range of ±5 ppm that were selected once for MS/MS were 
excluded for MS/MS fragmentation for the next 3 min, or until the precursor intensity 
drop below an S/N of 1.5 for more than five scans. Orbitrap full scan spectra and ion 
trap MS/MS fragmentation spectra were acquired partially simultaneously. All urine 
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samples were prepared and measured in random order. In order to monitor the back-
ground of the LC-MS system each run was preceded by a blank run. Also, to check the 
system performance at optimum, a pooled urine sample (10 µl from each) was used 
as an internal quality control, and was measured once in every five measurements for 
assessing the quality of the measurements in time (where the quality control check was 
based on a check for number of identifications and retention time shift with regards to 
potential retention time alignment).
MS/MS spectra (Orbitrap) from the raw data files of each sample were converted into 
mgf files using Extract-MSN (part of Xcalibur version 2.2, Thermo Fisher Scientific Inc.), 
and used to perform database searches using Mascot (version 2.3.01; Matrix Science 
Inc., London, UK), against the human subset of the Uniprot KB/Swissprot database (ver-
sion 2011_10, human taxonomy, 20,257 entries). Therefore, following settings were 
used carbamidomethylation of cysteine (+57.021 u) as fixed and oxidation of methio-
nine (+15.996 u) as a variable modification, tryptic enzyme specificity was allowed a 
maximal of 2 miss-cleavages. The mass tolerance for precursor ions was 10 ppm, and 
the mass tolerance for fragment ions was 0.5 Da. Database search results were further 
processed by Scaffold (version 3.6.3, Proteome Software Inc., Portland, OR) to merge 
the individual search results, compute protein grouping and calculate peptide and 
protein probabilities. The resulting peptide identifications were filtered using scaffold. 
Peptide false discovery rate (FDRs), related to peptide identification, was calculated by 
Scaffold on the basis of FDR = (false positive) / (false positive + true positives)). The 
average protein FDR was determined always lower than 0.16 % for proteins and 1 % 
for peptides. The FDR was determined by a decoy database.
Progenesis label-free quantification
The LC-MS measured data files were imported into Progenesis LC-MS software pack-
age (Version 3.1; Nonlinear Dynamics Ltd, Newcastle-upon-Tyne, UK). Samples were 
aligned to a reference run (selected objectively by the software) for their retention 
time using an automated LC-MS algorithm option. Peptide abundances (abundance is 
defined as area under the peak) were calculated as the sum of the peak areas within 
the isotope boundaries obtained from the mass spectrometry scan. Only peaks with 
a charge state ranging from +2 to +8, with two or more isotopes were included for 
further analyses. LC-MS quantified peptides were further normalized to the total ion 
current to compensate for experimental variations utilizing an algorithm available in 
the Progenesis analysis software. Database search results subsequently imported into 
Progenesis, and assigned to their corresponding peptide peaks. Finally, a spreadsheet 
that contained for each feature the abundance in the individual samples and, if avail-
able, the corresponding peptide identification (feature report). For following statistical 
calculations, we used normalized and logarithmized (²log) abundances.
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Statistical analysis
Statistical comparison was performed using an unpaired two tailed Wilcoxon test. A 
p-value of <0.01 indicated statistical significance. Two types of analysis were carried 
out designated as Analysis 1 and Analysis 2. In the first analysis (Analysis 1), pregnancy 
associated longitudinal changes from third trimester of pregnancy to first postpartum 
period (ratio between abundances) were determined for 8 controls and for 31 MScl 
patients separately.
In the second analysis (Analysis 2), disease associated peptides were determined 
by comparing the longitudinal change from third trimester of pregnancy, and first post-
partum period between 31 MScl patients, and 8 controls. First, we determined to what 
extend and significance, peptides abundance levels change during (third trimester), 
and after the end of pregnancy (delivery). For this, we calculated the protein abun-
dance ratios (third trimester/postpartum) for each individual and subsequently the 
mean ratio per group and the difference (significant or not-significant) of the proteins 
identified (third trimester vs. postpartum). To determine the level of false discovery, 
sample groups were permutated in a repetitive way for 1000 times. Here, the false 
discovery was related to statistical significance in the comparison between the groups 
and the background determined by permutation was analyzed by scrambling/random-
izing all samples. We permutated the complete set of 1699 observations (peptides) 
between four sample groups (MScl: third trimester of pregnancy; MScl: postpartum 
period; controls: third trimester of pregnancy and controls: postpartum period). This 
permutation test allowed for determining a background mean value including a stan-
dard deviation (SD) for the 1000 experiments performed. For these computations and 
to generate figures of the obtained data the R statistics package (R version 3.0.2, http://
www.R-project.org) (16) was used. For other statistical tests and graphics, Microsoft 
Excel (version 2010), GraphPad Prism (version 5.00, www.graphpad.com) and SPSS 
were used.
RESUltS
clinical characteristics
The main characteristics of the 31 MScl and 8 normal women included in the study 
are summarized in Table 1. Maternal age (at onset), duration of gestation, number of 
total pregnancies, deliveries in the past, birth weight, and gender of the baby did not 
show significant differences (p>0.01) between the two groups (Table 1). Six (out of 31) 
patients had experienced relapse at the first postpartum period i.e. in first 3 months. 
One of these 6 had relapse also during the third trimester. Urine creatinine levels did 
not show any significant differences (p>0.01) between groups. During measurement, 
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no significant difference (p>0.01) was observed between groups in LC-MS quantified 
peptide area (UV at 214 nm) and also, at the individual level in MS/MS spectral counts. 
In conclusion, no significant clinical chemistry differences were found in the two 
groups related to the parameters investigated (creatinine and protein concentration). 
table 1. Patient characteristics. Table illustrates the pregnancy and delivery characteristics of preg-
nant women with MScl and controls. Data is shown as median with the range between brackets; 
mean ± SD is also indicated. The patient and controls characteristics were compared using a Wil-
coxon test. Table shows no significant difference (p>0.01) between controls and MScl women.
Controls (n=8) MScl patients (n=31) p value
Mean ± SD Median
(Range)
Mean ± SD Median
(Range)
Control
vs. MScl
Age at onset (Years) 32 ± 5 34 (25 – 37) 32 ± 4 31 (25 – 39) 0.63 (ns)
Caesarean section 2 N/A 5 N/A N/A
Duration of gestation
(in weeks)
37 ± 3 38 (32 - 40) 39 ± 1 39 (37 – 42) 0.02 (ns)
Time to 1st symptom (weeks) N/A N/A 7 ± 5 6 (1 – 17) N/A
Time to diagnosis (weeks)a) N/A N/A 4 ± 3 3 (1 – 10) N/A
Relapse during 3rd trimesterb) N/A N/A 2 N/A N/A
Relapse in first three months after 
deliveryb’)
N/A N/A 6 N/A N/A
Number of total pregnancies 2 ± 1 2 (1 – 5) 2 ± 1 1 (1 – 5) 0.04 (ns)
Deliveries/abortions in pastc) 0.87 ± 0.99 1 (0 – 3) 0.40± 0.72 0 (0 – 3) 0.06 (ns)
Vacuum 0 N/A 5 N/A N/A
Birth weight of baby (in gram) 3269 ± 673 3280
(2050 – 4050)
3424 ± 394 3400
(2610 – 4490)
1 (ns)
Gender of babyd) 3 M, 6 F N/A 18 M, 13 F N/A 0.17 (ns)
Creatinine concentration
Mean ± SD
8.89 ± 5.57 9.2
(2.1 - 21.2)
9.34 ± 5.87 8.3
(0.9-29)
0.06 (ns)
Definition: A relapse was described as an episode of neurological disorder for which causative le-
sions are possibly to be inflammatory and demyelinating in nature and remain for more than 24 hour.
a) Time to diagnosis was available for 8 patients only. b) Only one MScl patient had a relapse during 
the third trimester of pregnancy; b’) Out of 31 MScl patients, 6 had relapse at the first-post-partum 
period. From these 6 MScl patients, one also had relapse at the third trimester.
c) Out of 31 MScl women; 17 MScl women had first pregnancy (no delivery in past), seven had sec-
ond pregnancy (one delivery in past), four had second pregnancy (no delivery and one abortion in 
past), one had third pregnancy (no delivery and two abortions in past), one had fourth pregnancy 
(two delivery and one abortion in past), and one had fifth pregnancy (three delivery and one abor-
tion in past).
Out of 8 control women; one control women had first pregnancy (no delivery in past), four had sec-
ond pregnancy (one delivery in past), two had second pregnancy (no delivery and one abortion in 
past), and one had fifth pregnancy (three delivery and one abortion in past).
d) One control women had twins (one male and one female).
Abbreviations: F, female; M, male; MScl, multiple sclerosis; N/A, not applicable; ns, not significant; SD, 
standard deviation; Data was analyzed using the Mann Whitney test.
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Technical variability was estimated from data coming from the quality control samples 
(as indicated in method section). These quality control samples were randomly divided 
into two parts. The mean (±SD) number of proteins identified in all quality control 
samples was 247±26, in the first group of quality control samples 258±25, and in the 
second group was 237±22. We did not observe a significant difference between first 
and second group of the quality control samples (p=0.16) i.e. technical variation in time 
is not changing significantly.
lc-MS AnAlySIS
Combining results from label-free LC-MS quantifications and peptide identifications 
yielded a set of 1699 unique peptides that relate to 409 proteins present in all samples 
of MScl patients and controls.
Analysis 1
Investigation of pregnancy association (i.e. longitudinal changes between third trimes-
ter of pregnancy and postpartum period) in controls (n=8), resulted in 36 differentially 
expressed tryptic peptides (p<0.01) with a mean (±SD) background of 12±12 obtained 
after 1000 permutations which is far less than the combinations that exist and large 
enough to exclude only outliers. The number of 36 is significantly different from the 
value obtained by permutations using a t-test. From the 36 peptides, 32 peptides were 
increased (related to 22 proteins) and 4 (related to 4 proteins) were decreased more 
than 2 fold during the third trimester of pregnancy compared to postpartum (Analysis 1) 
(Figure 1, Panel A). Of these 32 peptides, the top 5 (based on fold expression difference) 
was: pregnancy-specific beta-1-glycoprotein 1, pregnancy-specific beta-1-glycoprotein 
11, poliovirus receptor-related protein 3, pregnancy-specific beta-1-glycoprotein 9 and 
angiotensinogen. Examples of proteins that decreased at third trimester compared to 
postpartum in control subjects were: annexin A1, periplakin and protein HEG homolog.
Analog to this, analysis in the set of 31 MScl patients, resulted in total, of 531 dif-
ferentially expressed peptides (p<0.01) with the mean (± SD) rate of permutation 16 ± 
19. Of these 531, 468 peptides (relates to 188 proteins) were identified with p<0.01 
and at least 25% of the significance of peptides identified per protein.
Of these 468 peptides, 343 were observed with > 2 fold intensity difference. Among 
them (from 343) 218 peptides (related to 107 proteins) showed increased and 125 
(related to 61 proteins) decreased in abundance during the third trimester relative to 
the postpartum period in MScl patients (Figure 1, Panel A).
The most striking peptides elevated at third trimester pregnancy-specific beta-1-
glycoprotein 1, pregnancy-specific beta-1-glycoprotein 11, pregnancy-specific beta-
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Figure 1. (A) Summary of pregnancy and diseases associated peptide identification. The flowchart 
shows a summary of univariate analysis results.We tested 1699 peptides. First, we identified preg-
nancy associated peptides by compared abundance of peptide measured during 3rd trimester with 
the abundance of peptide measured at first postpartum in the same healthy women (n = 8) (ratio 
controls). The analysis resulted into 36 significant peptides. Then, we performed a similar compari-
son in 31 women with MScl (ratio patients) that resulted into 531 peptides. Next, to identify disease 
associated peptides, we compared difference in abundance ratio between controls and MScl pa-
tients that resulted into 43 peptides.
(B) Pregnancy dependent peptides in MScl patients and controls. All peptides plotted were associ-
ated with pregnancy in controls and MScl patients (p < 0.01). On the Y axis, the ratio of 3rd trimester 
of pregnancy/postpartum period for 8 controls is monitored. On the X axis, the ratio of 3rd trimes-
ter of pregnancy/postpartum period in 31 MScl patients is indicated. The diagonal line coincides 
or corresponds when the pregnancy association between controls and patients correlates ideally. 
Filled data points in red indicate peptides with significantly increased and those in green indicate a 
decrease in abundance identified during the 3rd trimester of pregnancy compared with the postpar-
tum period. Filled circles in gray represent pregnancyassociated increased or decreased abundant 
peptides in MScl patients and controls.
(c) Volcano plot of all peptide difference ratios, displaying the relationship between significance 
(p value) versus fold change between MScl patients and controls. A volcano plot of peptides (n 
= 1699) showing the distribution of fold change and significance simultaneously, from this pro-
teomics analysis. Each point represents a peptide and the difference in abundance ratio between 
MScl patients and controls plotted against the level of significance. The Y axis represents p values 
log 10 transformed from the Wilcoxon test between control ratios n = 8 (3rd trimester versus post-
partum) and patient ratios n = 31 (3rd trimester versus postpartum). The X axis shows the difference 
in abundance ratio (MScl patients/controls log 2 transformed) between MScl patients and controls. 
The dashed horizontal line is drawn at p = 0.01. Below the dashed horizontal line: All data points 
show a nonsignificant difference in abundance ratio compared between MScl patients and controls. 
Here red labeled circles were found with increased abundance at the 3rd trimester as compared 
with postpartum in controls and green were found with decreased abundance at the 3rd trimester 
of pregnancy compared with the postpartum period. Such pregnancy associated peptides were not 
found to be associated with the disease when difference in abundance ratio between MScl pa-
tients and controls were compared. Above dashed horizontal line: Data points shows significantly 
increased or decreased abundance ratio (p<0.01) in patients. Toward right side of vertical dashed 
line: Blue filled circles show peptides found with increased delta ratio in MScl patients (right side 
of the vertical dashed line) compared with controls. Blue filled circles with label show peptides 
identified with 25% of significance per protein. Toward left side of vertical dashed line: Orange 
filled circles shows peptides identified with decreased delta ratio in MScl patients compared with 
controls; labeling is shown for those who were identified with 25% of significance per protein. Red 
circles were pregnancy-associated as well as disease-associated. Labeled circles are those that had 
25% of significance of peptides per protein: (1) trefoil factor 3, (7) eukaryotic translation initiation 
factor 6, (12) lysosome-associated membrane glycoprotein 2, (13) hemoglobin subunit alpha, (2) 
collagen alpha-1(XII) chain, (3) plasma glutamate carboxypeptidase, (4) G-protein coupled receptor 
family C group 5 member B, (5) Ig mu chain C region, (6) desmoglein-3, (8) fibrillin-2, (9) receptor-
type tyrosine-protein phosphatase, (10) 14−3−3 protein sigma, (11) Ig kappa chain V−III region, 
(14) osteoclast-associated immunoglobulin-like receptor, (15) dermokine, and (16) phosphatidyl-
ethanolamine-binding protein 1. Abbreviations: ↑, with increased abundance; ↓, with decreased 
abundance; 3rd, third trimester during pregnancy; PP, first postpartum period. Numbering between 
brackets in legend is numbering in the figure (panel B and C).
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1-glycoprotein 2, and choriogonadotropin subunit beta variant 1. Also, glutaminyl-
peptide cyclotransferase, trefoil factor 3 and poliovirus receptor-related protein 3 
were observed to be elevated in the third trimester. Examples of top-listed peptides 
observed with decrease abundance at MScl third trimester compared to MScl post-
partum were: Ig gamma-1 chain C region, matrix metalloproteinase-9, tyrosine-protein 
kinase receptor, Ig gamma-3 chain C region.
Resampling and permutation
Proteins associated with pregnancy were overwhelmingly found in MScl patients com-
pared to controls. Another permutation test was carried out to determine the effect of 
sample size difference between control and MScl patients. We compared random 8 MScl 
	  Panel	A
Difference in abundance rao
Paents/Controls, log 2
Rao 3rdrd /PP Paents, log 2
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patients at third trimester (n=8) with postpartum (n=8) samples. We took repetitively 
8 MScl patients from the 31 and determined the mean and SD for pregnancy related 
peptides. Thereafter, we determined if pregnancy related peptides in controls (36) are 
significantly different as compared to MScl from the found mean using the SD obtained 
by iterative analysis. The first time we took 8 patients from the 31 MScl, determined 
59 (permutated mean ± SD, 12±14) different peptides (p<0.01) (third trimester versus 
postpartum), the second time taking at random another 8 from the 31 MScl patients 
resulted in 143 (12±15) peptides differentially expressed. Next, we repeated this for 
a third time, here we found 157 (11±13) and a fourth time 240 (11±14) differentially 
expressed peptides. This way, mean number of pregnancy related peptides obtained 
in MScl was 150 (11±7). Although the variation in the number of differentially abun-
dant peptides appears large, this is a representation of the biological variation due to 
the heterogeneous character of MScl. Technical variation was assessed based on the 
identical quality control samples measured repetitively during the same measurement 
sequence and was not statistically significant (p=0.16).
In comparison with controls, significantly more pregnancy related peptides were 
found in MScl (p<0.01). Therefore, analysis showed that by taking the same sample 
size in MScl and controls, the number of pregnancy related peptides were highly el-
evated in MScl as compared to the control group. Thus, the large number of pregnancy-
associated peptides found in MScl patients is not only because of the larger number of 
MScl samples analyzed.
Analysis 2
Comparison of longitudinal differences between third trimester of pregnancy and 
the postpartum period between MScl (n=31) and controls (n=8), resulted in 43 MScl 
associated peptides (related to 35 proteins) with a change in abundance during the 
third trimester and postpartum compared to controls. From these 35 proteins, two (pro-
epidermal growth factor and serum albumin) had 50% differentially abundant peptides 
expressed in the same direction) and for the rest, all differentially abundant peptides 
for same protein followed the same trend of expression (increased or decreased). Of 
these 43 tryptic peptides with >2 fold difference in abundance ratio, 12 peptides were 
increased during pregnancy and 28 were stronger decreased in MScl patients compared 
to controls. Peptides with increased (out of 12) ratio in MScl patients compared to 
controls were: Lysosome-associated membrane glycoprotein 2, eukaryotic translation 
initiation factor 6, inter-alpha-trypsin inhibitor heavy chain H4, serum albumin, trefoil 
factor 3, hemoglobin subunit alpha, keratin, type II cytoskeletal 6A, pro-epidermal 
growth factor, keratin, type I cytoskeletal 19, cubilin and involucrin IV.
Examples of differentially abundant peptides (28) with a decreased difference in the 
abundance ratio in MScl patients relative to controls were: Ig mu chain C region, plasma 
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glutamate carboxypeptidase, uromodulin, fibrillin-2, glutaminyl-peptide cyclotransfer-
ase, hemopexin, phosphatidylethanolamine-binding protein 1, collagen alpha-1(XII) 
chain, beta-2-microglobulin, Ig kappa chain V-III region.
Sixteen disease associated peptides (out of these 43) which were identified with 
p<0.01 and at least 25% of the significance of peptides identified per protein are 
listed in Table 2 A and Table 2 B. Furthermore, the peptides per differentially expressed 
proteins followed the same trend of expression either, increased or decreased. Four 
(of 16) peptides had an elevated level in MScl (trefoil factor 3), whereas 12 peptides 
had a decreased ratio in MScl (Ig mu chain C, plasma glutamate carboxypeptidase, 
phosphatidylethanolamine-binding protein and Ig kappa chain V-III region etc.). 
Moreover, in Figure 1, Panel C, delta fold expression difference between MScl patients 
and controls and statistical significance are plotted simultaneously for illustration in 
a volcano plot. When, we determined the FDR (related to statistical significance) by 
permutation the complete set of 1699 observations (peptides) between four sample 
groups (MScl: third trimester of pregnancy; MScl: postpartum period; controls: third 
trimester of pregnancy and controls: postpartum period), analysis indicated identifica-
tion of 43 disease specific peptides significant. The mean (±SD) rate of permutation 
was 16±11 (median 11), whereas the true hits, i.e. MScl associated identified peptides 
were significantly elevated to 43.
table 2. MScl disease-Associated Peptides: (A) 4 Peptides for Which Longitudinal Difference Ratios 
between 3rd and Postpartum Were Significantly Increased in Patients (n = 31) in Comparison with 
Controls (n = 8) and (B) 12 Peptides that had Significantly Decreased Abundance Ratios in Patients 
As Compared with Controlsa).
2 A.
Protein Sequence description p-value Fold change
(log 2)
Identified
p<0.01/total
Q07654 IPGVPWCFKPLQEAECTF Trefoil factor 3 0.0005 2.38 1/4
P56537 TSIEDQDELSSLLQVPLVAGTVNR Eukaryotic translation 
initiation factor 6
0.004 2.75 1/1
P13473 GILTVDELLAIR Lysosome-associated 
membrane glycoprotein 
2
0.005 2.93 1/2
P69905 TYFPHFDLSHGSAQVK Hemoglobin subunit 
alpha
0.007 2.03 1/4
2 B.
Protein Sequence description p-value Fold change 
(log 2)
Identified 
p<0.01/total
Q99715 WDPAPGPVLQYR Collagen alpha-1(XII) 
chain
0.0005 −2.25 1/2
Q9Y646 VGALASLIR Plasma glutamate 
carboxypeptidase
0.001 −5.36 1/2
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dIScUSSIOn
To our knowledge, this is the first LC-MS proteomics based work of MScl in pregnant 
women. We identified and quantified 1699 unique peptides in longitudinal urine 
samples from 31 MScl patients and 8 controls. In the current investigation, we have 
used urine as a sample because of its ease of availability during pregnancy. In ad-
dition, it is relatively less complex in protein content than serum (17), and relatively 
stable in protein content if stored in a protocolized way (18,19). Also, the peripheral 
pathological and physiological processes that occur outside the CNS, and triggers the 
MScl relapses (14) are likely to be reflected in body fluids. Such peripheral inflam-
matory and demyelination related factors might result in a systematic change in the 
abundances of specific proteins. The demyelination involves several types of immune 
cells (e.g., T cells, B cells, and macrophages/monocytes) and inflammatory mediators 
(e.g., cytokines and chemokines). The LC-MS method determines levels of peptide 
abundance, and can provide insight into the activity state of relevant proteins under 
different physiological/disease conditions in the sample chosen. Most of the previous 
studies have reconsidered those proteins which are already known to be increased 
during pregnancy for example, estrogen and progesterone (7). Complementary to 
2 B. (continued)
Protein Sequence description p-value Fold change 
(log 2)
Identified 
p<0.01/total
Q9NZH0 ETAFEEDVQLPR G-protein coupled 
receptor family C group 
5 member B
0.001 −0.78 1/1
P01871 GVALHRPDVYLLPPAR Ig mu chain C region 0.001 −6.28 1/4
P35556 SATAGSEGGFLAPEYREEGAAVASR Fibrillin-2 0.004 −3.09 1/2
P32926 VPDFNDNCPTAVLEK Desmoglein-3 0.004 −1.36 1/3
Q12913 TPSSTGPSPVFDIK Receptor-type tyrosine-
protein phosphatase eta
0.005 −1.30 1/3
P01620 LLIYGASSR Ig kappa chain V-III 
region
0.005 −1.79 1/3
P31947 SNEEGSEEKGPEVR 14-3-3 protein sigma 0.005 −1.79 1/2
Q8IYS5 EGVAAPLQYR Osteoclast-associated 
immunoglobulin-like 
receptor
0.007 −2.34 1/3
Q6E0U4 VSEALGQGTR Dermokine 0.008 −0.80 1/2
P30086 NRPTSISWDGLDSGK Phosphatidylethanol-
amine-binding protein 1
0.009 −1.74 1/4
aThe Table shows a total 16 peptides identified with significant (p < 0.01) increased or decreased 
abundance ratio in MScl patients (n = 31) in comparison with controls (n = 8). Proteins had at least 
25% significant (p = 0.01) differentially abundant peptides.
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previously performed longitudinal studies to analyze PBMCs immune molecules/
monocytes (13, 20) at the RNA level (in blood) using microarray approaches, we directly 
investigated at the protein level using proteomics method. The transcriptomics based 
study on immune cells (13) is not directly comparable to the current study in terms of 
clinical parameters (see Table 1), because of differences in gestational age, and a time 
window at sampling (13). In the context of above, Gilli and colleagues found 347 dif-
ferentially expressed genes in non-pregnant MScl patients compared to non-pregnant 
controls (13). We did not observe any overlap with this study, probably also because 
differentially regulated genes at the mRNA level often cannot directly be translated 
into protein abundance (21). Also, Neuteboom and colleagues analyzing, monocyte 
transcriptomics during pregnancy on six patients showed an increase of CD64 during 
the third trimester compared with baseline (20). This study indicates that enhanced 
innate immune functions can be in effect in MScl. This observation is in agreement with 
the current study.
Pregnancy association
First, we determined just the pregnancy association in controls and MScl patients 
(Analysis 1). We observed an altered expression of a large number of 531 peptides 
(Figure 1, Panel A) during the third trimester of pregnancy, as compared to the postpar-
tum period. In agreement with a previous study in serum (22), we have also found an 
order of magnitude increase in abundance of placenta derived pregnancy-associated 
immunoregulatory proteins (pregnancy specific beta-1-glycoprotein 1, 9 and 11) at 
MScl third trimester compared to postpartum period compared to controls. Pregnancy 
specific glycoproteins are known to modulate the innate immune system by inducing 
secretion of anti-inflammatory cytokines by human monocytes (23), and also suggest-
ed as one of the most important immunosuppressive substances (23). Interestingly, 
in our study, we also observed increased abundance of choriogonadotropin subunit 
beta variant 1, which was previously described at transcript level only. It is essential 
for normal implantation and placental development (24, 25). This particular protein is 
known to be noncoding beta subunit of human chorionic gonadotropin (25), which is 
considered as an immunosuppressive. On the other hand, notable peptides with high 
fold decreased abundance at MScl third trimester as compared to postpartum period 
was linked with inflammation related molecules, such as Ig gamma-1 chain C region, Ig 
gamma-3 chain C region and matrix metalloproteinase-9. The highest activity of matrix 
metalloproteinase-9 in serum was observed to correlate with short duration relapsing 
and active forms of MScl (26). In another study, the high level of metalloproteinase-9 
was found to be associated with MScl pathogenesis and contributes to blood–brain 
barrier disruption and entry of T-lymphocyte into the CNS (27). Here the findings of the 
above studies in serum and CNS were in agreement with our results in urine.
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In both MScl and control, the most discriminating peptides with increased abun-
dance at third trimester (compared with postpartum) were pregnancy related glyco-
proteins (Figure 1 A). In control subjects, only 4 peptides were found with decreased 
abundance at third trimester as compared to postpartum (Figure 1A). From the previ-
ously described pregnancy association result, it can be concluded that the pregnancy 
derived proteins with immunomodulatory function are abundant at third trimester (p 
<0.01) relative to the postpartum period in MScl, and that these pregnancy related 
proteins are more abundant than in control subjects. Most likely, these proteins have 
functions during pregnancy third trimester, and contribute to a significant reduction 
of 70% in MScl relapse rate which is described previously (2, 5). Previous studies in 
serum also suggest that the increased levels of pregnancy derived factors might be 
responsible for suppression of disease state via T cell regulations (28). On the other 
side, peptides with decreased abundance at third trimester (compared to postpartum 
period), i.e. molecule elevated at postpartum might be explained by altering most likely 
diminished immunomodulatory responses due to disease aggravation.
The increased number of pregnancy associated peptides in MScl as observed in 
Analysis 1 is not due to a larger sample size as compared to control group. The result of 
permutation analysis showed a decreased permutated mean of 16 ± 19 as compared 
to the original observation of 531 pregnancy associated peptides, which indicated an 
expected difference related to pregnancy. The increased number of pregnancies asso-
ciated peptides identified in both MScl and control during third trimester (as compared 
to postpartum) is probably the result of different physiological states due to pregnancy 
(Figure 1A). The observed elevation of pregnancy related proteins in MScl as compared 
to control group could reflect involvement in the reduction of MScl disease activity.
disease association
Altered protein expression during third trimester compared to postpartum can be 
associated with MScl, but it can also be due to pregnancy or even a combination of 
both. Therefore, we compared longitudinally MScl and controls (Figure 1A). Peptides 
observed with increased abundance ratio in MScl compared to control were 12. The 
data were scrutinizing by using a filter of 25% of significant peptides identified per 
protein. We ended up with four peptides (related to 4 proteins,
Table 2 A), two related to immunomodulatory proteins: trefoil factor 3 and lysosome 
associated membrane glycoprotein 2 (LAMP 2), the other two (eukaryotic translation 
initiation factor 6 and hemoglobin subunit alpha) have no relation with immunomodu-
latory response during the third trimester of pregnancy. Trefoil factor 3 was signifi-
cantly elevated (p <0.01) at third trimester compared to postpartum, and this was on 
average three times higher in MScl than in control (higher fold difference). This protein 
is known to be significantly elevated (up to 47 times higher abundant) in serum during 
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gestation (29). Trefoil factor 3 has been shown to induce peptides related to innate 
immune defense such as defensins in breast milk, indicating a possible relation to both 
pregnancy (30) as well as MScl (31). This is in agreement with the data observed in this 
study.The direct evidence of LAMP 2 in relation to immune defense is not yet described 
in literature. However, a variant of LAMP 2 (LAMP 1) is linked to immune response (32), 
therefore it is worthwhile to investigate the role of trefoil factor 3 and LAMP 2 associ-
ated with MScl.
decreased abundance ratio in MScl compared to controls
Peptides observed with decreased abundance ratio in MScl compared to control sub-
jects were in number 31. The data were further filtered (by using the same parameter 
as described in the above section) and 12 peptides remained (Figure 1, Panel A and 
C). Among these 12, the Ig mu chain C region plays an important role in primary de-
fense. Its decreased abundance in CSF of MScl patients is described after 1 year of 
Natalizumab treatment (33). The inhibition of glutamate carboxypeptidase II activity is 
known for the treatment of cognitive impairment in MScl (34), which is a homolog of 
plasma glutamate carboxypeptidase (carboxypeptidase Q). Another protein named as 
phosphatidylethanolamine-binding protein, inhibits nuclear factor kappa-light-chain-
enhancer of activated B cells (NF-κB) activation, NF-κB plays a critical role in the regula-
tion of immune and inflammatory responses and has been shown in MScl pathogenesis 
(35), it is considered as a potential therapeutic target for the treatment of MScl. Next, 
immune molecules, for example, Ig kappa chain V-III region, and osteoclast-associated 
immunoglobulin-like receptor have been linked to inflammation.
We also observed that beta-2 microglobulin passed the criteria for significance 
p<0.01 but not for 25% of the significance of the peptides identified per protein (1 
peptide identified at <0.01 out of 5), which has been previously described as a MScl 
related marker (36) in the urine of non-pregnant MScl patients. In addition, increased 
(as compared to controls) urinary free light chains kappa in MScl have been previously 
described for the activity of immunological processes (18).
Altogether, by using the high throughput and sensitive proteomics platform (LC-MS 
based proteomics), we have identified tryptic peptides with an increased abundance 
ratio that was related to the innate immune system. Peptides with a decreased abun-
dance ratio were related to disease relapse. Also the accompanying biological function 
of differentially expressed pregnancy related proteins found in the current investiga-
tion in MScl pregnant women might have an advantageous effect on the reduction of 
disease activity in MScl disease.
Chapter 6
144
cOnclUSIOn
Pregnancy is the only known natural modifier of disease course in MScl (1, 2). In the 
current study, we identified proteins that are particularly expressed during this most 
inactive disease period of a MScl patient. Moreover, we have compared MScl and control 
during and after pregnancy and found disease associated peptides. The LC-MS based 
proteomic profiling of urine samples during MScl pregnancy revealed a significant 
number of disease associated peptides. In addition, peptides that relate strongly to 
pregnancy, are linked with or involved in innate and adaptive immune response either 
directly or indirectly or were immunosuppressive. Apparently, the pregnancy associ-
ated proteins and their accompanying biological function might have an advantageous 
effect on MScl disease suppression. It is surprising that a disease primarily occurring in 
the CNS can be detected in body fluids as remote as urine. The finding of our current 
investigation may open a new window for further manipulation of identified peptide 
related to MScl disease association. It may also help to give more insight to understand 
further the pathogenesis, prognosis and treatment of MScl disease.
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In this thesis we describe the mass spectrometry (MS) based proteomics investigations 
to identify the multiple sclerosis (MScl) associated potential biomarkers in body fluids. 
Developments in MS technology have made MS-based proteomics a promising tool for 
protein profiling and biomarker discovery. MScl is a complex disease whose pathogen-
esis is highly heterogeneous (1, 2) and due to heterogeneity it is doubtful that single 
biomarker will be found for pathological processes or to predict progression of the 
disease. We have applied unbiased discovery driven approach to screen body fluid 
proteome and measure expression of proteins using sensitive and high-throughput 
measuring platform. We have used a data dependent, label free quantitative method 
in a wide variety of samples (CSF, CSF IgG autoantibodies and urine) from a range of 
MScl patients. Differential expression analysis was performed and an effort was made 
to identify and evaluate potential MScl associated biomarkers involved in biological 
pathways.
The most important findings, and conclusions of chapter 2-6 are combined and 
discussed in this chapter. At the end of this chapter the challenges and future research 
prospects of MScl are highlighted.
PROtEOMIcS cOMPARISOn OF cEREBROSPInAl FlUId OF RElAPSIng 
REMIttIng And PRIMARy PROgRESSIVE MUltIPlE SclEROSIS
In chapter 2, we have described the difference between two commonly believed differ-
ent clinical subtypes (based on disease course) of MScl. We found that the proteome 
profiles of CSF in PP (n=10) and RR MScl (n=11) patients share many similarities. This 
is in agreement with the absence of clear-cut differences between the two main clini-
cal MScl sub-groups, at genetic, immunological, imaging and pathological levels (3). 
However, proteomics comparison between the PP and RR MScl group revealed seven 
differentially abundant proteins. In the same context, one other group (4) using pro-
teomics analysis (MALDI-TOF) on CSF showed 11 differentially regulated peptides in 
both serum and CSF between relapse-onset MScl (n=41) and PP MScl (n=13) patients, 
these peptides do not directly correlate with our data.
Next, two differential proteins were further validated by independent methods in 
validation cohort (containing of 10 RR MScl and 10 PP MScl samples), these were jag-
ged-1 (abundance decreased in PP MScl compared to RR) and vitamin D-binding protein 
(only detected in the RR MScl). Jagged-1 protein mediates Notch signaling (role during 
T cell development)5 and also previously shown to be associated with MScl (6) and have 
immunomodulatory properties, thus can be considered as a new therapeutic target for 
MScl (7). Vitamin D regulates the differentiation, activation of CD4+ T-lymphocytes (8) 
and can inhibit the development of autoimmune processes, therefore it might have 
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neuroprotective role in MScl. Proteins identified with differential abundance were also 
studied using Ingenuity Pathways Analysis in order to place them in biological context. 
As a result, six of the seven were found to be related with the neurological disease. 
Further, when level of these proteins were measured for sensitivity and specificity, it 
was not high, however when analysed together sensitivity increases to 0.8 and speci-
ficity increases to 0.75, still value remain low for confident separation between two 
MScl types. Though we analysed only a low number of samples, still our study is of 
importance from MScl pathological point of view. Moreover, the findings of our study 
might also be useful in terms of future characterization of MScl patients group.
Future research
For better understanding of function, these proteins should be individually evaluated 
in relevance to MScl. Future step should be to validate the disease protein targets: 
Jagged-1 protein and vitamin D-binding protein i.e. target’s relevance to MScl pathol-
ogy must be determined. This includes more details for functional characterization, 
additional evidence for pathway or network assignment and modulating the protein’s 
activity to determine its connection to the disease phenotype.
MAIn FIndIngS
v The proteome profile of CSF in primary-progressive (PP) and relapsing-remitting (RR) mul-
tiple sclerosis (MScl) patients overlap largely, still a low number of significant differences 
could be observed and validated. Protein jagged 1 (three times less abundant in PP compare 
to RR MScl) and vitamin D binding protein (detected in RR MScl only) were elevated in RR 
MScl. These two proteins deserve further study to be used as potential markers to differenti-
ate between PP and RR MScl.
v CSF of childhood onset MScl is associated with significantly increased abundance of CNS 
grey matter proteins (for example contactin-2 and neurofascin) and decreased abundance 
of innate immunity related proteins in comparison to children presenting with monophasic 
acquired demyelinating syndromes (ADS). Interestingly, contactin-2 and neurofascin are pre-
vious autoimmune targets in MScl.
v CSF immunoglobulin G proteins shares common characteristic in the antigen binding region 
among different RR MScl patients and not in controls. This may indicate a common antigen 
for B-cell activation. Right now these sequences cannot be used as a marker and more vali-
dation is required.
v Pregnancy-related proteins were significantly elevated in MScl patients compared with con-
trols (emerged from comparing third trimester with the postpartum period). When compar-
ing the longitudinal differences, we identified 43 MScl associated peptides with increased 
(example trefoil factor 3) or decreased (such as Ig mu chain C region and plasma glutamate 
carboxypeptidase) abundance ratio in MScl compared to controls.
v Monitoring the effect of Natalizumab therapy in MScl patients before and after one year of 
treatment revealed differentially abundant and validated proteins, for example, Ig mu chain 
C region, haptoglobin, and chitinase 3 like protein 1. All these three proteins were signifi-
cantly less abundant in CFS of MScl patients after one year of treatment.
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gRAy MAttER RElAtEd PROtEInS ARE ASSOcIAtEd wItH cHIldHOOd-OnSEt 
MUltIPlE SclEROSIS
In chapter 3 we studied the first event of CNS demyelination in CSF samples from 39 
children with initial acquired demyelinating syndromes (ADS), of them 18 were de-
tected with MS and 21 with monophasic disease course. Currently, an early adequate 
diagnosis of MScl in children with an initial acquired demyelinating syndrome is a 
challenge because combination of clinical features, CSF findings and MRI criteria (9-
11) are not enough to predict the disease course at first event. Protein markers that 
help to differentiate between children with monophasic ADS and those subsequently 
diagnosed with MScl are desirable.
In this chapter, using high resolution nano liquid chromatography online coupled 
to a high-resolution mass spectrometer (LC-MS) we observed a total of 2260 peptides 
(relates to 318 proteins). Statistical analysis showed striking difference between child-
hood onset MScl and monophasic ADS. Interestingly, 14 proteins were identified with 
increased and seven with decreased abundance in childhood onset MScl compared to 
monophasic ADS, which was later evaluated by permutation analysis as described in 
chapter 3. Among 14 proteins with increased abundance in MScl, 12 were CNS struc-
ture and functions related proteins especially to the grey matter. These proteins were 
amyloid-like protein 2, neurofascin, contactin-2, amyloid beta A4 protein, brevican 
core protein, carboxypeptidase E, neuronal growth regulator 1, tyrosine-protein phos-
phatase non-receptor type substrate 1, neuronal cell adhesion molecule, disintegrin 
and metalloproteinase domain-containing protein 22, dickkopf-related protein 3 and 
kallikrein-6. Localization for some of these proteins in CNS structure are shown in 
Figure 1. Similar to the previous findings, our study also showed absence of (12-15) 
compact myelin antigens (myelin forms a layer around the axon of a neuron). We found 
this particularly striking because according to the traditional way of thinking myelin is 
viewed as potential disease targets in MScl (white matter disease) (16). However, the 
lack of myelin in our data might be related to physiochemical property of the hydro-
phobic myelin components and probably different pathway of elimination (17). Grey 
matter presence may merely represent damage by inflammation, and thus identified 
molecules might provide better clue to understand presumed inflammation induced 
neurodegeneration.
A similar study involving 19 CSF samples from children has been previously report-
ed, however they had a different sample handling protocol (12) In the same context, 
we found some overlap for example carboxypeptidase E with increased abundance in 
childhood onset MScl group. Furthermore, our finding was also showed overlap with 
another previous study (18) which was performed on clinically isolated syndrome 
(CIS, individual’s first neurological episode) versus established RR MScl patients and 
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showed elevated levels of contactin-2, kallikrein-6 and dickkopf-related protein 3 in 
first attack MScl patients (compared to established RR MScl). In addition, compared to 
children with monophasic ADS, we found increased abundance of proteins (six of 14) 
that localize to the axoglial apparatus (the area of contact between the myelinating cell 
and the underlying axon) for example neurofascin, contactin-2, brevican core protein, 
disintegrin and metalloproteinase domain-containing protein 22, neuronal cell adhe-
sion molecule and neuronal growth regulator 1 (12, 19, 20).
In a previous study, neurofascin has been identified as a novel target for autoanti-
body-mediated axonal injury (21) whereas, contactin-2 was identified as an autoanti-
gen targeted by T-cells and autoantibodies in MScl patients (22).
On the other hand, six out of seven proteins detected with decreased abundance 
in MScl group included those related to innate immune function such as haptoglobin, 
C4b-binding protein and monocyte differentiation antigen CD14.
Presence of differentially expressed proteins with over as well as under-representa-
tion in MScl indicated disturbances in the physiology of axoglial apparatus. Some areas 
yet to be addressed in this study was the inclusion of an age matched cohort however, 
our analysis did not show any influence on the identified differentially abundant pro-
teins. In conclusion our study indicate that CNS grey matter proteins elevated in CSF 
of childhood onset MScl are pathologically relevant and might be part of the early 
mechanism of the disease.
Figure 1. Proteins located at the node of Ranvier, paranode and juxtaparanode are shown in the 
figure. Red box indicates example of proteins which were identified with increased abundance in 
childhood onset MScl patients as compared to monophasic ADS group in our study cohort. These 
domains are the location for neurofascin, contactin 2, contactin-associated protein (cell adhesion 
molecules), brevican and NrCAM protein (extracellular matrix proteins). (Reproduced with permission; 
Acta Neuropathol (2014) 128:161–175)
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Further clinical verification and validation may provide clinically valuable marker to 
differentiate children with monophasic ADS from children with MScl. Moreover, know-
ing the beginning of the disease could help to initiate an early treatment with disease 
modifying therapies.
Future research
In future, it would be interesting to further validate our findings with independent 
tools such as ELISA, SRM, Western blotting etc. and also in an independent group. 
Further insights into the role of these proteins could be useful for disease process 
understanding. In addition, correlation of serum antibodies against axoglial proteins 
such as contactin-2 and neurofascin might be important for understanding the disease 
pathology.
cEREBROSPInAl-FlUId-dERIVEd IMMUnOglOBUlIn g OF dIFFEREnt 
MUltIPlE SclEROSIS PAtIEntS SHARES MUtAtEd SEQUEncES In 
cOMPlEMEntARIty dEtERMInIng REgIOnS
In this part, the main findings and conclusions of the study to identify common mutated 
antigen binding regions of IgG exclusively present in MScl, described in chapter 4 is 
discussed.
B lymphocytes play a crucial role in MScl pathology (23), possibly via both antibody 
dependent and independent pathways. Intrathecal synthesis of Igs (OCBs) restricted to 
the CSF i.e. not present in serum is a hallmark of MScl (24) (however, OCB is not specific) 
and it is produced by clonally expanded B cell populations. In this study in order to in-
vestigate CSF IgG antibodies clonality, we performed proteomic analysis on purified CSF 
IgG antibodies from untreated RR MScl patients (n=29) and non-neurological controls 
(n=30). The study was performed without antigen panels. Using LC-MS measurements 
of tryptically digested Ig bands (heavy (IgH) and light chain (IgL)) and the database 
search we found 1086 peptides for IgH and 920 peptides for IgL. Subsequently, within 
the IgH variable domain we could assign 41 peptides to the CDR1, 128 to the CDR2 and 
171 to the CDR3. Within IgL variable domain, we assigned 78 peptides to the CDR1, 
233 to CDR2 and 51 to CDR3.
We found over-representation (p=0.03) of peptide sequences of the VH4 family in 
MScl patients compared to controls. In addition, we observed a trend towards increased 
VH3 family usage in MScl (p =0.05). We also found the increased κ/λ ratios in the MScl 
group, which was in line with previous study (25).
Further, we found five final CDR peptides that were shared between three or more 
MScl patients and not seen in any controls. The results were highly significant as shown 
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by permutation analysis. Moreover, at lower threshold i.e. shared in at least two MScl 
patients (and not in controls) we found 14 IgH and 13 IgL CDR peptides. None of the 
previous studies have made such an attempt for MScl, however one study described 
overlap between Ig B cell (CSF) transcriptomes and proteomes in four individual MScl 
cases, without interindividual overlapping sequences but without comparison between 
patients and controls (26).
Remarkably, one of the mutated CDR2 QDGSEtYYVDSVK (homologous to IGHV 
3 – 7 gene, mutation from germline is shown in bold,) shared use was observed in 
seven different MScl patients, interestingly this particular CDR peptide had different 
mutations (T, E, and N) or insertion (F) at the same spot. Next, the IDWDDDKYYSTSLK, 
a CDR2 peptide (homologous to IGHV 2-70 *01) was shared exclusively in five MScl 
patients. Next, the YNSAPLTFGGGTK, CDR3 peptide (homologous to IGKV 1-27 *01 and 
IGKJ 4 *01) was identified exclusively in three MScl patients. Finally, the LLIHGASNR 
peptide was identified solely in three MScl patients. We found overlap with a few CDR 
peptides identified in other studies that investigated B-cell clonality in the CSF of MScl 
patients at the nucleic-acid level (26-28). Whether, such common B-cell responses are 
indeed driven by autoantigens remains to be determined. It will be of interest to study 
common V-region use in known auto reactive IgGs that appear to play a role in MScl.
Usually, the antigen specificity of B cells is determined via random mechanisms, 
and so one would guess different sequences of the antigen binding CDR in different 
individuals. This notion has recently been challenged by different studies, that suggest 
that the development of IgGs are not a random process, but selection do occur during 
immune response and this selection is shared by different patients. Earlier studies that 
confirm shared sequences observed in known antigen-specific antibodies are: human 
immunodeficiency virus (HIV) infection (29), Ro52 autoimmunity in Sjogren syndrome 
(30), and anti-Hu paraneoplastic disease (31). In line with these, our study in MScl 
patients appears to follow the similar pattern.
Our study indicates that under (auto) antigenic pressure there may be common se-
lection mechanisms for the production of intrathecal Ig production by B lymphocytes. 
Although the reason remains uncertain, it would not be hard to assume that some CDR 
sequences might better survive the clonal selection process than others, possibly due 
to a stronger binding of the three-dimensional structure of the CDR to the antigen.
A better understanding of the common selection mechanisms for (auto) antibod-
ies in MScl and the identification of inter-individually shared specific CDR sequences 
might even deliver markers for subgroup identification.
Compared to the other studies, a drawback of our study was that we do not know the 
antigen specificity of the V - regions identified here. In fact we do not show complete Ig 
sequences, due to the fact that trypsin digestion is needed for this approach. In light of 
the shared sequences observed in known antigen-specific antibodies in HIV infection, 
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anti-Hu paraneoplastic disease and Ro52 autoimmunity it would be relevant to inves-
tigate the possible use of public V - region sequences in purified specific antibodies 
against MScl candidate antigens such as anti MOG (32), anti neurofascin (21) and anti 
KIR 4.1 (33).
This is the first study at protein level that showed that peptides generated from the 
variable part (CDR) of IgG antibodies are shared between MScl patients, which might 
be used to differentiate patients and control cohort.
Future research
The next step would be to confirm the sequence of the marker CDR peptides using syn-
thetic references by means of SRM method. Further, it might be interesting to examine 
the possible use of public V-region sequences in purified specific antibodies against 
MScl candidate antigens such as anti- MOG, anti-neurofascin, and anti- KIR 4.1 (exclu-
sively expressed by glial cells especially oligodendrocytes and astrocytes). In a recent 
study (33), serum IgG antibodies against KIR4.1 were observed in 47% MScl patients, 
1% other neurologic disease patients and 0% healthy donors. In addition, anti-KIR4.1 
autoantibodies were also detected in the CSF of 63% MScl patients. Similarly, axoglial 
proteins such as neurofascin and contactin-2 (autoantigen that is targeted by both T 
cells and autoantibodies), around the node of Ranvier, were identified as potential 
targets for autoantibodies in MScl. In addition, this approach can also be used for some 
other autoantibody targets in the MScl brain as shown in Figure 2.
Figure 2. Location of targets of autoantibody in the MScl brain. Autoantibodies (in MScl) target dif-
ferent antigens in myelin, neurons, oligodendrocytes, astrocytes and immune cells. The color of the 
target cells matches with the color of the text boxes with the identified antigens. Some ubiquitous 
antibody targets (*) present in virtually all cells are also shown. (Reproduced with permission; Autoim-
munity Reviews (2014) 13:1126–1137).
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In this chapter, bottom-up (peptide based) method was used to characterize IgG vari-
able region and CDR peptide (amino acid sequences) (34) using the highly effective 
and well studied liquid chromatography technique. MS method used in our study is 
highly sensitive (34) but it has some disadvantages as well, for example: a) it is hard 
to identify peptides from highly random CDR, and b) it is difficult to link a peptide 
back to the rest of the V-region it came from. In this way, digestion of protein into 
peptides increases complexity. Therefore, to address the above difficulty, it would be 
even better to use top-down (protein-based) proteomics (35), where we look at intact 
protein (or large fragments) using Fourier Transform Ion Cyclotron Resonance MS (a 
high resolution MS).
In chapter 4 we did not find many sequenced peptides recognized as CDR3. This 
is because the CDR3 is usually preceded by a conserved Lysine (K) or Arginine (R) 
amino acid and after tryptic cleavage, the ‘random’ CDR3 peptide is hard to align to 
a reference. Trypsin enzyme (cuts after K or R) is used as default because it has good 
specificity and compatibility with ionization in MS. To improve the CDR3 identification/
overcome this, an alternate enzyme that do not cleave at K and/or R can be used, this 
changes the products of protein digestion. As an example of an alternate enzyme: a) 
AspN can be used that cuts before Aspartic acid (D) but it is less specific (than trypsin) 
and may cleave additional amino acids from C-terminal end of peptides. b) LysN can 
be used that cuts before K; it may be useful in combination with Electron-transfer dis-
sociation (ETD) but with no added benefit.
The coverage of proteins in LC-MS experiments can be improved. The coverage 
of proteins is often incomplete because: a) More or less peptides do not ionize well 
and therefore are not seen at all. b) In IgG for identification of CDR3 peptides, some 
peptides cut at an unfortunate place c) few peptides are too large and some are too 
small to be observed. a, b and c might be addressed by using a different protease other 
than (or in addition to) trypsin (as described above). Furthermore, sequence coverage 
of CDRs can be improved by increasing the spectral quality and mass accuracy.
EFFEctS OF nAtAlIzUMAB tREAtMEnt On tHE cEREBROSPInAl FlUId 
PROtEOME OF MUltIPlE SclEROSIS PAtIEntS
In chapter 5 we examined the effects of Natalizumab therapy on the CSF proteome 
of RR MScl patients. Natalizumab is directed against the α 4 component of the α4β1 
integrin (CD49d;VLA4) expressed on the surface of lymphocyte and monocyte cells 
and by binding to α4β1 integrin (mediator of trans endothelial leukocyte migration) 
it blocks the migration of T-cells in to the CNS (36). The proposed mode of action 
of Natalizumab comprises inhibition of leukocyte infiltration into the CNS, hence re-
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ducing the local inflammatory response (37). Hence, we anticipated that this analysis 
might potentially provide CSF markers relevant for CNS pathology, and therapeutic 
efficacy. Accordingly, we investigated how biologically relevant markers change in 
response to Natalizumab therapy in RR MScl patient before and after 12 months of 
treatment. In this chapter we used hypothesis free proteomic approach and attempted 
to mine entire CSF proteome to explore the effects of Natalizumab treatment. Using 
label-free LC-MS analysis (semi quantitative analysis) 301 proteins were identified 
by two or more peptides and showed a number of biomarkers that were significantly 
differentially abundant between the before and after treatment groups. These three 
proteins were found in lower abundance in CSF of MScl patients after one year of the 
treatment. Remarkably, in a new independent sample set, differential expression of 
three proteins Ig mu chain C region, haptoglobin and Chitinase-3-like protein 1 (se-
creted by activated macrophages) were subsequently confirmed using SRM (a different 
quantitative mass spectrometry for absolute quantification). Chitinase-3-like protein 
1 was further confirmed by ELISA. Observation of decreased abundance of inflamma-
tion related proteins in CSF (after treatment), was in agreement with the proposed 
mechanism of action of the drug (37).
Also in agreement with the proposed mechanism of Natalizumab is the lack of signif-
icant differentially abundant neurodegenerative proteins after treatment however an 
effect on neurodegeneration was not directly expected to be observed here (according 
to drug mechanism). More interestingly, inflammatory response-related proteins with a 
known higher abundance in CSF of MScl patients such as Igs and haptoglobin (38) were 
found to be down regulated after treatment that inhibits the access of inflammatory 
cells into the CNS. As described in chapter 5 a similar study was performed by Ot-
tervald et al, where they had CSF samples from 6 months after the start of Natalizumab 
treatment (39). Due to ethical reasons, we could not follow up the control group of 
patients without the Natalizumab treatment. The possibility of a placebo effect on 
biomarkers or other unknown factors theoretically remains. In spite of this deficiency, 
the treatment-related differences in this study group were prominent, the statistical 
thresholds were relatively high, and the findings have a biological basis.
In conclusion, chapter 5 demonstrated that response to Natalizumab is associated 
with the down regulation of inflammation-related proteins in CSF.
Most interestingly, we observe a decrease in the CSF levels of Chitinase 3-like pro-
tein 1, which is a potential marker (have predictive capacity) for conversion of CIS to 
clinically definite MScl (40).
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Future research
Future research could be directed towards the detection and fractionation of low abun-
dance but potentially informative proteins by more in depth analysis or the depletion 
of high-abundance proteins such as albumin from the CSF samples.
PROtEOMIcS URInE AnAlySIS OF PREgnAnt wOMEn SUFFERIng FROM 
MUltIPlE SclEROSIS
In chapter 6 we performed LC-MS based proteomics to detect alteration of the urinary 
proteome during third trimester and after pregnancy at the first postpartum period. A 
longitudinal study on 31 MScl afflicted women (untreated RR MScl patients) and 8 con-
trols was carried out. We anticipated identifying MScl specific proteins that are poten-
tially related to the changed frequency of relapses and remissions during pregnancy. 
We hypothesized that the investigation of the natural protein modifiers (pregnancy) 
of the MScl could shed more light in understanding the biological mechanisms of this 
altered disease course.
We found that pregnancy related peptides were significantly increased in MScl 
patients compared to controls (531 peptides in MScl group and 36 in controls higher 
abundant in the third trimester compared to postpartum). Most discriminating proteins 
reported were different types of pregnancy-specific glycoproteins (PSGs), which are 
synthesized in the syncytiotrophoblast of the placenta (41,42) and these proteins are 
known to have the immunoregulatory properties. Presumably, these proteins might 
have functions during pregnancy, which contribute to a significant decline of relapse in 
MScl women patients, as shown by our analysis and previous reports.
Our finding was also in line with a previous study that indicated that PSGs regulate 
T-Cell function and inflammatory autoimmune (MScl) disease during pregnancy and 
thus they suppress MScl (43).
The modified peptide abundances during (compared to after) pregnancy could 
therefore be linked with MScl or even more likely a combination of both. For this rea-
son, we also compared the pregnancy related changes in a longitudinal way between 
MScl patients and controls. When comparing the longitudinal differences, we found 
43 (related to 35 proteins) disease associated peptides with increased or decreased 
ratio. This was further evaluated by permutation analysis. Four distinguished proteins 
were found (on applying restrictive criteria) with increased difference in abundance 
ratio, for example trefoil factor 3 and lysosome associated membrane glycoprotein 2, 
both of which have immunomodulatory properties. These proteins is are recognized to 
be significantly elevated (up to 47 times higher abundant) in serum during gestation 
(44), moreover it has been shown to induce peptides associated to innate immune 
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defense such as defensins (45). Further, we found 12 disease associated peptides with 
decreased abundance ratio in MScl (compared to controls). For example, Ig mu chain C 
region, which has a role in primary defense, was reported to have decreased abundance 
in the CSF of MScl patients after 1 year of Natalizumab treatment (46). Other examples 
were: a) glutamate carboxypeptidase II, whose activity inhibition is known for the 
treatment of cognitive impairment in MScl (47) b) phosphatidylethanolamine-binding 
protein, which inhibits the activation of nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), NF-κB plays a critical role in the regulation of immune and 
inflammatory responses. NF-κB was found to be important for MScl pathogenesis and 
is even considered as a potential therapeutic target for the treatment of MScl (48). 
Furthermore, we also found Ig kappa chain V-III region (49), osteoclast-associated 
immunoglobulin-like receptor (both linked to inflammation) and beta-2 microglobulin 
(50), all of which before has been previously described as MScl related marker in the 
urine of non-pregnant MScl patients.
We found that the peptides with an increased ratio were related to the innate immune 
system whereas the peptides with a decreased ratio related to the disease relapse. 
Further, the accompanying biological functions of differentially expressed pregnancy 
related proteins found in the current investigation in MScl pregnant women might have 
an advantageous effect on the reduction of disease activity in MScl patients.
In the present research, we worked with urine samples because it is readily acces-
sible (compared to CSF and brain tissue) for longitudinal sampling, and might be the 
ideal biofluid source for potential biomarkers of MScl (49). Another logical reason was 
that disease bouts in MScl primarily depend on events outside of the CNS without 
affecting the cells of CSF (51), which highlights the importance of studying the changes 
in serum and urine. In conclusion we identified tryptic peptides with increased abun-
dance ratio that was related to the innate immune system. Peptides with a decreased 
abundance ratio were related to disease relapse.
This is the first study where a high throughput and sensitive proteomics has been 
performed at the protein level in pregnancy associated MScl. We performed discovery 
driven research using high throughput and sensitive proteomics platform on a com-
partment that is remote from the site of its generation and has inherently undergone 
proteomics modification. Our results using proteomic research can help expand our 
understanding of MScl pathophysiology.
In this chapter, we showed that peptides which relate strongly to pregnancy are 
also linked either directly or indirectly with innate and adaptive immune responses 
or were immunosuppressive. Apparently, the pregnancy associated proteins and their 
accompanying biological functions might have a positive effect on MScl inflammation/
disease suppression. The outcome of our research is useful for future research directed 
towards the discovery of novel MScl treatments strategies.
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Future research
The next step of the study, would be the confirmation and absolute quantification of 
marker peptides using other independent methods (absolute quantification) such as 
ELISA or SRM using the same or another dataset. It would also be interesting to validate 
the identified disease associated proteins in patient’s serum (same or external).
cOnclUdIng REMARkS
The designated research work here emphasized the identification of biomarkers in 
MScl patients using a discovery driven proteomic approach. We have executed high 
throughput differential protein expression profiling, comparing MScl with control 
samples, to identify the biomarker proteins that are likely contributors to the MScl by 
their increased or-decreased (or no detection) abundance. Indeed, we have identified 
potential MScl related targets. By comparing the CSF proteins, we first made an effort 
to differentiate between the PP and RR subtypes of MScl. Next we discriminated child-
hood onset-MScl and monophasic ADS. We also made an attempt to identify markers 
for MScl modifying (Natalizumab) therapy. Further, we explored clonality of CSF IgG 
autoantibodies in RR MScl patients and showed that IgG share common characteristics 
in the antigen binding regions among different MScl patients. Finally, we investigated 
pregnancy MScl and detected proteins responsible for decreased (during pregnancy) 
and increased (postpartum period relapse) disease activity. We have validated some 
of our proteins using absolute quantification method as described in chapter 2 and 
5. At this point we are not claiming any therapeutic value to the above biomarkers, 
before we make further analytical and clinical verifications. However, the identified 
MScl related targets might assist with the diagnosis, prediction of the disease course, 
or identification of treatment response for Natalizumab. The findings of the current 
research would be critical for the detailed understanding of the biological pathways 
related to the neuropathology of the disease. These biomarkers may also help to 
identify interesting therapeutic values that and could be further investigated. Parts of 
these pathways might be suitable for new targeted therapies that might slow or stop 
the disease. In addition, these biomarkers may help to identify therapeutic values that 
new research can study. In future, the potential value of above identified biomark-
ers might serve as a curtain raiser the in depth understanding and treatment of MScl. 
Undoubtedly, the current findings adds a new chapter for further elucidation of MScl 
and provide valuable clues for increased understanding, treatment and cure for the 
MScl, and will help to tailor patient’s best care.
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Summary
Multiple sclerosis (MScl) is an inflammatory, autoimmune, demyelinating disease of 
the central nervous system (CNS). The disease occurs most commonly in young adults, 
it is increasingly being diagnosed in children. Unfortunately, there is no cure for MScl 
and diagnosis remains challenging because the disease is biologically very complex. 
Symptoms of the disease vary from patient to patient, different subtypes occur and 
other disease mimic mainly in the initial stages of disease progression, like Acute 
Disseminated Encephalomyelitis, Neuromyelitis Optica, Optic Neuritis and Sjogren’s 
syndrome (autoimmune diseases). Identification of biological markers in body fluids 
such as cerebrospinal fluid (CSF), and urine are of paramount. It helps with diagnosis, 
prediction of disease course, or identification of response outcome to treatments 
(such as Natalizumab) and to further understand the pathophysiology and therapeutic 
choices in various subtypes of MScl. Current advances in the field of proteomics allow 
large-scale, high-throughput, sensitive and accurate investigation for the detection, 
identification, and functional investigation of a proteome in a comparatively short 
period of time. Moreover progresses in protein fractionation and labeling techniques 
have improved protein identification including low abundant proteins. We used these 
approaches to find biomarkers of MScl from large numbers of well-characterized pa-
tient samples.
Thesis describes the identification of potential MScl biomarker research, with 
emphasis on distinguishing subtypes, first event of CNS demyelination in children, 
pathogenic IgG antibodies and pregnancy MScl.
chapter 1.1 summarizes the current knowledge about the proteomics technologies 
for biomarker discovery in MScl. In this chapter, we have discussed biological samples, 
available mass spectrometry based proteomics technologies, sample selection consid-
erations and future prospect of MScl research.
chapter 1.2 describes the general understanding of the disease pathology, the 
different subtypes, childhood-onset, CSF B cells and pathogenic IgG antibodies, preg-
nancy and the disease modifying therapy (Natalizumab).
chapter 2 highlights the differences and similarities of CSF proteome profile be-
tween primary-progressive (PP) (10–15% patients) and relapsing- remitting (RR) MScl 
(85–90% patients). Our research indicated that the proteome profiles of these two 
major subtypes of MScl overlap to a large extent. However, few differences were seen 
and confirmed by independent techniques for two proteins- Protein jagged-1 (more 
abundant in RR MScl as compared to PP MScl) and Vitamin D-binding protein (only 
detected in the RR MScl samples). Protein jagged-1 is related to remyelination of MScl 
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lesions. Vitamin D regulates the differentiation, activation of CD4+ T-lymphocytes and 
can prevent the development of autoimmune processes.
In chapter 3, study aimed at the identification of protein markers linked to diagnosis 
of MScl after the first demyelinating event. Twenty one proteins differentiated child-
hood-onset MScl and children presenting with monophasic acquired demyelinating 
syndromes (ADS). Proteomics analysis revealed that the CSF of childhood onset MScl is 
associated with the increased abundance of 14 CNS grey matter related proteins (for 
example neurofascin, contactin-2 and brevican core protein) as compared to the chil-
dren presenting with monophasic ADS. Whereas, seven proteins related to the innate 
immune system were abundant in children with monophasic ADS (such as haptoglobin 
and CD14). Further validation of differentially abundant protein is required.
In chapter 4, we focused on humoral immune responses in CSF of MScl patients. 
We hypothesized, that the antigen binding region of IgG specific for certain antigens, 
are frequently shared between different MScl individuals. This hypothesis was tested 
by proteomic method by sequencing antigen-binding regions (CDR) of heavy and light 
chain of IgG antibodies. In this study, our main objective was to identify specific pro-
teomic profiles of mutated complementarity determining regions (CDR) of IgG present 
in MScl patients but absent in controls. We found five CDR shared in three or more 
patients and not in controls. Interestingly, one CDR with a single mutation was found 
to be in common in six patients. In addition, as compared to controls, in CSF IgG of 
MScl patients, we showed a skew in kappa to lambda ratio (light chain of IgG) and in 
the usage of certain variable heavy region which was previously being detected at the 
transcriptome level. The result of the study provides leads concerning the question of 
whether common antigenic stimuli are accountable for the recruitment of intrathecal 
B cells in MScl.
In chapter 5, we performed a study to monitor the effect of Natalizumab treatment 
on MScl patients. This drug targets α4 integrins and leukocyte trafficking. We addressed 
its effects on CSF proteome before and after one year of the treatment. This study 
revealed a number of proteins that were significantly differentially abundant between 
the before and after treatment groups. Subsequently, three proteins (Ig mu chain C 
region, haptoglobin and chitinase-3-like protein 1) were validated in an independent 
sample set and by means of an independent method. Interestingly chitinase-3-like 
protein 1 is described as a presumed biomarker for more rapid progression from a first 
clinically isolated syndrome to clinically definite MScl. Our study showed significantly 
lower abundance of three inflammation-related proteins in CSF after one year of treat-
ment.
In chapter 6, we performed proteomics approach on alterations of the proteome of 
urine from MScl patients during third trimester of pregnancy and at first postpartum 
period. This study was motivated by the fact that pregnancy is the natural modifier of 
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MScl course. We found that pregnancy related peptides, were significantly elevated in 
MScl patients compared to controls. When comparing the pregnancy relate changes, 
we found 43 disease associated peptides identified with increased (such as trefoil fac-
tor 3 and lysosomal associated membrane protein-2) or decreased (for instance Ig mu 
chain C region and osteoclast associated immune like receptor) difference ratio in MScl 
compared to control. Our findings indicated that the peptides that relate strongly to 
pregnancy are linked with or involved in innate and adaptive immune response either 
directly or indirectly or were immunosuppressive. It seems that the pregnancy associ-
ated proteins and their accompanying biological function might have a beneficial ef-
fect on MScl suppression. Therefore, these promising urinary proteins deserve further 
investigation in the field of MScl.
Studies presented in this thesis have successfully applied modern mass spectrom-
etry based proteomics approaches to identify potential MScl biomarker. In CSF, we 
identified differentially abundant proteins that distinguished two clinical subtypes, 
showed therapy markers for Natalizumab treatment and distinguished childhood-
onset MScl from children presented with monophasic ADS. In addition, we applied this 
method and identified proteins in urine related to underlying biological mechanisms of 
MScl improvement during pregnancy. Furthermore, we successfully used this method 
to identify a panel of CDR peptides that discriminated samples of MScl patients from 
controls. This was a first indication that peptides generated from the variable part of 
IgG antibodies in CSF were shared between different MScl patients and such CDR were 
not detected in control groups. Our studies show that we add new information to MScl 
biomarker field and such biomarkers are of substantial interest with respect to the 
disease pathology, general understanding, diagnosis and for novel therapeutic targets. 
However these biomarkers need further validation for clinical use. Future develop-
ments in method will create new possibilities and will help to achieve this goal.
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list of abbreviations
2-DGE 2-dimensional gel electrophoresis
ACN acetonitrile
AGC automatic gain control
BBB blood brain barrier
BLAST basic local alignment search tool
BLASTp basic local alignment search tool for protein
C constant region
CAD collision activated dissociation
CDR complementarity determining regions
CNS central nervous system
CSF cerebrospinal fluid
D diversity element of immunoglobulin sequence
Da dalton
EAE experimental autoimmune encephalomyelitis
ESI electrospray ionization
FA formic acid
FT-ICR Fourier transform ion cyclotron resonance
FDRs false discovery rates
HIV human immunodeficiency virus
ICAT isotope coded affinity tags
ID internal diameter
Ig immunoglobulin
IgH heavy chain
IgL light chain
IMGT international ImMunoGeneTics information system
ITRAQ isobaric tags for relative abundance and quantitation
J joining element of immunoglobulin sequence
LC liquid chromatography
LC - MS liquid chromatography-mass spectrometry
MALDI Matrix-assisted laser desorption/ionization
MOG myelin oligodendrocyte glycoprotein
MS mass spectrometry
MS/MS tandem mass spectrometry
MScl multiple sclerosis
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OBs oligoclonal bands
ppm parts-per-million
RR relapsing remitting
SRM selective reaction monitoring
TFA trifluoroacetic acid
V variable element of immunoglobulin sequence
VH variable region of immunoglobulin heavy chain
VK variable region of immunoglobulin light chain kappa
κ immunoglobulin kappa light chain
λ immunoglobulin lambda light chain
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which is a Europe-wide network. She interacted with Prof. Dr. Rogier Q. Hintzen (Profes-
sor in neurology and immunology) and with Dr. Theo M. Luider (Head of Laboratory of 
Neuro-Oncology, Clinical & Cancer Proteomics), and started her PhD training in 2009 
on the “Identification of potential biomarkers in multiple sclerosis” under supervision 
of Prof. Dr. R. Q. Hintzen and Prof. Dr. Theo M. Luider at Erasmus Medical Centre, Rot-
terdam, The Netherlands. The results of her PhD research and published research work 
on multiple sclerosis biomarker are documented in the current thesis.

Stellingen bij het proefschrift van
Propositions associated with the thesis
Identification of Potential Biomarkers in Multiple Sclerosis
1) Complementarity determining regions of immunoglobulins in cerebrospinal fluid share 
sequences between individual multiple sclerosis patients and not with controls. This may 
reflect local intrathecal B cell responses that are driven by common (auto-) antigens in 
different multiple sclerosis patients.
2) The proteome profiles of cerebrospinal fluid in primary progressive and relapsing remit-
ting multiple sclerosis patients overlap to a large extent, but are not exactly the same. 
Differences can be observed in the presence jagged-1 and vitamin D-binding protein.
3) Natalizumab treatment of multiple sclerosis patients is associated with a decrease in the 
levels of inflammation-related proteins in the cerebrospinal fluid, such as chitinase 3-like 
protein 1.
4) Cerebrospinal fluid in pediatric multiple sclerosis contains significantly increased abun-
dance of grey matter proteins such as for example contactin-2 and neurofascin, compared 
with monophasic acquired demyelinating syndromes. This indicates that early axoglial 
damage is important in the neuropathology of multiple sclerosis.
5) The 3rd trimester versus postpartum differences of urine concentrations of several po-
tential disease modifying proteins were more exaggerated in multiple sclerosis patients 
versus healthy pregnant controls. Knowledge in such pregnancy-related physiological 
mechanisms to counter-act the disease will help to develop novel strategies to therapeu-
tically manipulate multiple sclerosis.
6) The effect of pregnancy on multiple sclerosis has fascinated researchers so much that 
there are more review articles available on this topic than original studies.
7) The verification of potential multiple sclerosis biomarkers is necessary for the develop-
ment of clinically applicable biomarkers.
8) Data do not speak for themselves - they need context, and require evaluation.
9) If the only tool you have is a hammer, you tend to see every problem as a nail. (Abraham 
Maslow)
10) Science is not about why… it’s about why not?
11) A signature always reveals a man’s character - and sometimes even his name. (Evan Esar)
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